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General introducti on and thesis outline 
CHAPTER 1





Colorectal cancer (CRC) is a major contributor to cancer-related morbidity and mortality, accounting 
for approximately one million new cases per year throughout the world, with more than half a million 
deaths annually [1]. Around 25% of these patients present with unresectable metastatic disease at 
the time of diagnosis, often in the liver, and around 30% of early stage patients develop recurrence or 
dissemination of the disease following surgery [2]. In order to reduce the risk of relapse and disease 
progression, (neo)adjuvant chemotherapy and radiotherapy are often considered in addition to 
surgical resection of the tumor. However, prevention of metastasis is not always achieved and a 
substantial price has to be paid in terms of treatment-associated morbidity and mortality [3]. In the 
scope of personalized medicine, it has become increasingly important that patients with a high risk 
for disease recurrence or progression, and patients who would benefit most from additional 
therapies, are identified. Biomarkers may play a major role in clinical decision making by providing 
information on the risk of metastasis development in patients, and prediction of therapy response.  
 
Biomarkers 
Oncological biomarkers can broadly be categorized into two groups: 1. Tumor-associated biomarkers 
and 2. Systemic biomarkers. In carcinomas, tumor-associated biomarkers are studied in tumor 
epithelium or stroma within the primary tumor or metastases. These tumor-associated biomarkers 
are usually studied at a fixed time point in tumor development, because they are evaluated in 
resection material, including tumor biopsies. Due to the invasive procedure, obtainment of tumor 
biopsies can pose risks to the patient, such as bleeding, perforation, and infection, and are therefore 
usually obtained only for diagnostic purposes. Analysis of hematoxylin-eosin (HE)-stained and 
immunohistochemical (IHC)-stained tissue sections are the standard diagnostic procedures. 
Importantly, assessment of primary tumor-associated biomarkers by HE and IHC relies on visual 
microscopic inspection, manual annotation procedures and inter-observer agreement. Therefore, 
these methods are prone to subjective criteria and will always be qualitative rather than quantitative. 
Since biomarker research is aimed at development and improvement of personalized cancer 
treatment in a clinical setting, objective and quantitative assessment of tumor biomarkers is crucial. 
Computer-assisted image analysis is a promising technique that might be used to overcome these 
problems and to justify treatment decisions based on biomarkers. 
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Systemic biomarkers are measured in the circulation of patients, for instance in peripheral 
blood, serum or plasma, and can, in contrast to biomarkers in primary and metastatic tumor tissue, 
rather easily be followed in patients over time. Many studies have focused on primary tumor-
associated biomarkers. Although it is important to study biomarkers and oncogenic processes in 
primary tumors, it must be realized that CRC patients die from the consequences of metastatic 
disease, and usually not due to primary tumor growth. The primary tumor is usually successfully 
removed during surgery, and, therefore, not present in patients when they develop metastases in the 
months or even years after surgery. Systemic biomarkers may provide insight in the dynamic process 
of metastases development since they can be monitored over time. In this thesis, we specifically 
focused on systemic biomarkers related to the immune system.  
 
Immunogenicity of colorectal cancer 
Over the past decades, the focus of cancer research has changed. Whereas tumor growth was 
previously studied in context of tumor cells only, especially for their ability to escape from cell cycle 
control mechanisms, the focus nowadays is on studying tumor growth in context of its tumor 
microenvironment (TME). The TME consists of different cell types and structures, including 
fibroblasts, signaling proteins, extracellular matrix, blood vessels, and, importantly, immune cells [4]. 
Due to their genetically unstable nature, tumor cells acquire mutations during tumor progression 
which generate possibly immunogenic antigens. Tumor cells may also acquire mutations which result 
in downregulation of proteins that are crucial for an immune response, for instance human leukocyte 
antigen (HLA) class I. Due to this process, also called “immunoediting”, tumor clones selectively grow 
out that are insensitive for immune control. Interestingly, up to 20% of sporadic CRC is observed to 
have DNA microsatellite instability (MSI) which results in high mutational load [5]. Patients with MSI 
CRC are observed to have numerous tumor-infiltrating lymphocytes [6], and showed reduced 
metastasis rate and significantly better clinical outcome compared to patients with microsatellite 
stable (MSS) CRC [7]. This suggests an important role for tumor-immune interactions in tumor 
development and progression of CRC. Different types of tumor-immune interactions can be identified 
in CRC patients, both in the primary tumor, the circulation, and in distant metastases [8].  
 
Tumor-immune interactions in the primary tumor 
In order to infiltrate into a primary tumor, immune cells have to navigate from blood vessels, located 
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chemokines secreted by cells in the TME. Hence, an effective primary tumor-immune response is 
heavily dependent on the ability of immune cells to infiltrate and migrate within the tumor. Over the 
last decade, a new scoring system based on T cell infiltration in the TME has been defined, also known 
as the “immunoscore” [9-11]. CRC patients with high density of intratumoral CD3+ and CD8+ T cells 
were observed to have a significantly better clinical outcome compared to patients with low density 
of intratumoral CD3+ and CD8+ T cells [9-11]. Recent studies suggested implementation of the 
immunoscore as biomarker as a new component in the classification of CRC in addition to the tumor-
node-metastases (TNM) classification [12, 13]. However, a significant number of CRC patients with 
tumors with high density of tumor-infiltrating T cells, and, therefore, with a relatively good prognosis, 
develop progression of their disease in clinical follow-up [9, 10, 12]. It is hypothesized that CRC tumors 
may escape immune recognition by cytotoxic CD8+ T cells via downregulation of HLA class I expression 
[14-18]. These tumors are potential targets for NK- and NKT cells, that are able to recognize and kill 
cells with downregulated HLA class I molecules through “missing-self” recognition [19-21]. Previous 
studies showed an association between NK- and NKT cell tumor infiltration and prolonged survival in 
patients with CRC [22-24]. However, NK- and NKT cells are generally scarcely infiltrated in CRC and 
might, therefore, only play a minor role in primary tumor-immune interactions [17, 24-26]. In addition 
to NK- and NKT cells, tumor-associated macrophages (TAMs) might also play important roles in the 
TME. Although TAMs have been reported as prognostic biomarkers in different epithelial cancer types 
[27-29], their role in CRC is still unclear as high TAM density has been reported to correlate with both 
unfavorable [30-32], and favorable clinical outcome [33-36]. In summary, different immune cell 
subsets play a role in tumor-immune interactions in primary CRC tumors. Aberrant HLA class I 
expression and other key proteins in T cell responses may be important immune escape strategies for 
primary CRC cells.  
 
Tumor-immune interactions in the circulation 
During the process of disease progression, CRC cells detach from the primary tumor and intravasate 
into the circulation. In contrast to the situation in the primary tumor, tumor cells in the circulation can 
directly interact with immune cells, not limited by the context of the TME of the primary tumor, which 
may result in a different tumor-immune response. For instance, whereas NK- and NKT cells scarcely 
infiltrate primary tumors, they are more abundantly present in the circulation [20]. The activation of 
NK- and NKT cells is dependent on a delicate balance between activating and inhibitory signals from 
cell surface receptors [37]. NK cell inhibitory receptors include natural killer group 2-A (NKG2A), and 
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killer cell immunoglobulin (Ig)-like receptors CD158a and CD158b that recognize HLA class I molecules. 
The activating signals are mediated by a wide array of receptors including natural killer group 2-C 
(NKG2C), natural killer group 2-D (NKG2D), DNAX accessory molecule-1 (DNAM-1), CD161, and natural 
cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46, that recognize a variety of stress-induced 
molecules that may be present on tumor cells. These molecules include galectin-3, recognized by the 
NKp30 receptor, which promotes epithelial to mesenchymal transition (EMT) of tumor cells. 
Additionally, NKT cells express a T cell receptor that recognizes glycolipids presented by the HLA-like 
molecule CD1d, which functions as an extra activating receptor [38]. Interestingly, CRC patients with 
downregulated HLA class I expression in their primary tumors developed fewer distant metastases in 
clinical follow-up [17]. This finding supports the hypothesis that NK- and NKT cells in the circulation 
play an active role in eliminating disseminated tumor cells in CRC patients [8]. Recently, studies 
showed reduced numbers of NK cells expressing activating receptors (e.g., NKG2D, NKp30, NKp46, 
and DNAM-1) in peripheral blood of patients with CRC [39]. Furthermore, these NK cells showed 
impaired IFN-γ secretion and degranulation upon activation, thereby implying impaired function [40]. 
This suggests impairment of NK cell activity in the circulation of CRC patients, which may facilitate the 
dissemination of tumor cells in the circulation, resulting in outgrowth of distant metastases. The 
number of NK- and NKT cells in the circulation, expression level of activating and inhibitory receptors, 
and presence of their ligands on tumor cells, might therefore be interesting biomarkers to predict the 
risk for development of metastases in CRC patients. Up till now, the underlying biology of these tumor-
immune interactions is poorly understood and remains to be further explored. In contrast to TAMs, 
the role of circulating monocytes, the precursor cells of macrophages, seems less ambiguous. Recent 
meta-analyses showed that a high lymphocyte-to-monocyte ratio in peripheral blood was a significant 
predictor of better overall survival, disease-free survival and cancer-specific survival in CRC patients 
[41, 42]. In summary, different immune cell subsets play critical roles during dissemination of tumor 
cells in the circulation of CRC patients. Especially circulating NK cells, NKT cells, and monocytes may 
play important roles during this process. It is crucial that underlying biology, concerning tumor-
immune system interactions in the circulation, is well understood for improvement of diagnostics, and 
design of efficient immune-based therapies for CRC patients. 
 
Tumor-immune interactions in metastases 
When tumor cells in the circulation escape from immune control, CRC cells mainly metastasize to the 
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different compared to tumor-immune interactions in the primary tumor or in the circulation. For 
instance, primary colorectal tumors that lost HLA class I expression were reported to rarely 
metastasize to the liver and were most often found in other organs [43]. This may be due to the 
abundancy of NK cells in the liver that may prevent establishment of liver metastasis by HLA class I-
negative tumor cell clones. As addressed above, NK cells are also abundantly present in the circulation, 
and should, therefore, have recognized and eliminated HLA class I-negative tumor cells from the 
circulation. This suggests that other mechanisms are involved in the survival of HLA class I-negative 
tumor cells in peripheral blood of CRC patients. Further research is required to determine why certain 
circulating tumor cells are able to survive in the peripheral blood. The focus of this thesis was 
therefore on tumor-immune interactions in the circulation of CRC patients since the balance between 
immune control and immune escape may determine whether circulating tumor cells are eliminated, 
or alternatively, escape from immune control, leading to the formation of distant metastasis in specific 
organs. NK cells, NKT cells, and monocytes might be key players in these interactions and expression 
of activation markers on these cell subsets may, therefore, have potential as biomarkers that identify 
CRC patients with a high risk for development of metastases.  
 
Outline of this thesis 
The aim of this thesis was to better understand the underlying biology of tumor-immune interactions, 
especially in the circulation of CRC patients.  
 
Chapter 2 describes a possible role of NKT cells in the TME and in the circulation of patients with 
cancer, by considering their phenotype and function. In Chapter 3, the immunophenotype of 
circulating T-, NK-, and NKT cell subsets was studied in patients with CRC and in healthy donors. 
Additionally, the clinical prognostic biomarker potential of circulating T-, NK-, and NKT cell subsets 
was studied in CRC patients. Chapter 4 describes the influence of tumor resection and adjuvant 
chemotherapy on the immunophenotype of circulating T-, NK-, and NKT cells in CRC patients. In 
Chapter 5, a method for semi-automated image analysis of HLA class I tumor epithelium expression 
in rectal cancer is presented. In Chapter 6, expression of NK cell receptor ligands in primary tumors is 
studied in relation to the expression of NK cell receptors on circulating NK- and NKT cells of CRC 
patients, and to clinical outcome, using the method as described in the previous chapter. Chapter 7 
explores the clinical relevance of the macrophage-associated molecule CD163 as biomarker in CRC. In 
this study, CD163 was studied on circulating monocytes, TAMs in the primary tumor, and as soluble 
General introduction and thesis outline 
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form in the circulation (sCD163). Finally, a summary and discussion on the results of this thesis is 
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Natural killer T (NKT) cells are a subset of CD1d-restricted T cells at the interface between the innate 
and adaptive immune system. NKT cells can be subdivided into functional subsets that respond rapidly 
to a wide variety of glycolipids and stress-related proteins using T- or NK cell-like effector mechanisms. 
Because of their major modulating effects on immune responses via secretion of cytokines, NKT cells 
are also considered important players in tumor immunosurveillance. During early tumor 
development, T helper (TH)1-like NKT cell subsets have the potential to rapidly stimulate tumor-
specific T cells and effector NK cells that can eliminate tumor cells. In case of tumor progression, NKT 
cells may become overstimulated and anergic leading to deletion of a part of the NKT cell population 
in patients via activation-induced cell death. Additionally, the remaining NKT cells become 
hyporesponsive, or switch to immunosuppressive TH2-/Treg-like NKT cell subsets, thereby facilitating 
tumor progression and immune escape. In this review, we discuss this important role of NKT cells in 
tumor development and we conclude that there should be three important focuses of future research 
in cancer patients in relation with NKT cells: (1) expansion of the NKT cell population, (2) prevention 








The immune system is a host defense mechanism that plays a pivotal role in the protection against 
pathogens and cancer [1]. It comprises multiple specialized subsets of cells that differentiate from a 
common pluripotent progenitor, the hematopoietic stem cell [2]. These subsets include natural killer 
T (NKT) cells that feature characteristics of both conventional T cells and natural killer (NK) cells. Upon 
activation, NKT cells are able to kill target cells either directly [3-5] or indirectly by influencing both 
myeloid- and lymphoid-derived immune cells [6]. Moreover, NKT cells are potent immune regulators 
since they can skew immune responses towards both inflammation and tolerance very quickly by 
secreting either T helper (TH)1-, TH2-, TH17-, T regulatory (Treg)- or follicular helper (TFH)- cell-associated 
cytokines [7]. Because of their major modulating effects on immune responses, NKT cells have also 
been considered important mediators of tumor immunosurveillance [8]. The role of NKT cells in 
relation to cancer has therefore been the focus of recent studies. In this review, we discuss the role 
of NKT cells in cancer in relation to their phenotype and function. We focus on non-haematological 
malignancies i.e. carcinomas, sarcomas, melanomas and neuroblastomas. First, the development and 
function of NKT cells are addressed in healthy individuals. Thereafter, the role of NKT cells is discussed 
in the development and progression of cancer. Finally, available NKT cell-based immunotherapies are 
presented and possibilities for future research are discussed. 
 
Development and localization of NKT cells 
NKT cells constitute a unique, but highly heterogeneous, subset of immune cells that arise in the 
thymus from CD4+CD8+ cortical thymocytes that have undergone T cell receptor (TCR) gene 
rearrangement, as is the case with conventional T cells [9]. TCRs are composed of an α- and a β-chain, 
each containing a variable and constant domain. The TCR α-chain is generated by recombination of 
the variable (V) and joining (J) segments, whereas the β-chain also requires diversity (D)-segment 
recombination. Based on their TCR repertoire, two NKT cell subsets have been described: type I and 
type II NKT cells. Type I NKT cells were first identified in mice in 1990 as a unique T cell population 
expressing the Vα14Jα18 invariant TCR α-chain. The type I NKT cell subset recognizes the 
glycosphingolipid α-galactosylceramide (α-GalCer) or its synthetic analogs when presented by major 
histocompatibility complex (MHC) class I-like CD1d molecules [10-12]. Four years after the 
identification of the invariant Vα14Jα18 TCR α-chain in mice, the human counterpart Vα24Jα18 was 
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cells, type II NKT cells are described with a more diverse and less well-defined TCR repertoire 
recognizing non-α-GalCer molecules (primarily sulfatide) presented by CD1d molecules [12,17-19]. 
 
Development of type I NKT cells in mice 
The development of type I NKT cells has been thoroughly studied in mice. During positive selection in 
the murine thymus, T cells expressing TCRs that are capable of binding to MHC class I or II molecules 
on cortical thymic epithelial cells are selected to undergo lineage commitment [9]. This process leads 
to maturation of CD4+ or CD8+ T cells that recognize MHC-presented peptides. Alternatively, type I 
NKT cells that express the randomly rearranged invariant Vα14Jα18 chain are positively selected upon 
binding to CD1d molecules expressed by cortical thymocytes [9,20-22]. As a result of this alternative 
positive selection, they recognize lipid-derived antigens presented by CD1d molecules [10]. During the 
maturation process, a part of the type I NKT cell population retains expression of the T cell-associated 
marker CD4, resulting in two major populations in mice: CD4+CD8- and CD4-CD8- (double negative, 
DN) type I NKT cells [23,24]. Additionally, Type I NKT cells acquire expression of the NK cell receptor 
(NKR) NK1.1 during maturation [9].  
 
Development of type I NKT cells in humans  
Whereas the thymic development of type I NKT cells is well-defined in mice, it has not as yet been 
studied in details in humans. It has been reported that NKT precursor cells can be identified in thymic 
tissue derived from human embryos and young children [25,26]. Similar to type I NKT cell 
development in mice, human type I NKT cells express cell surface markers that are usually associated 
with both T- and NK cells. For instance, a part of the human type I NKT cell population retains 
expression of the T cell-associated markers CD4 or CD8 during maturation, resulting in three major 
populations in humans: CD4+CD8-, CD4-CD8+ and DN type I NKT cells [27,28]. In addition, a part of the 
human type I NKT cells acquires expression of the NK cell-associated marker CD161 (the human 
counterpart of NK1.1 in mice), the classical NK cell marker in humans CD56 [27-29], and various other 
NK cell-associated receptors [27-31].  
 
Localization of type I NKT cells in humans 
After development and maturation in the thymus, NKT cells migrate to the periphery. In general, 
human type I NKT cells are present in small numbers (<0.1% of total T lymphocytes) in peripheral 
blood (PB), lymph nodes, spleen, thymus, lung, and bone marrow [32-34]. Whereas larger type I NKT 
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cell populations reside in the liver, colon, kidney (~1% of total T lymphocytes) [35-37], and omentum 
(~10% of total T lymphocytes) [38]. Importantly, it has to be taken into account that NKT cell numbers 
vary substantially among healthy individuals. For instance, circulating type I NKT cells have been 
reported to comprise more than 5% of the total T lymphocyte population in some individuals [39].  
 
Morphology of NKT cells 
Despite the fact that NKT cells are derived from the T cell lineage, their morphology resembles NK 
cells more closely. NK and NKT cells are both referred to as large granular lymphocytes, whereas T 
cells are described as small and non-granular [40-42]. In addition, NKT cells were reported to have a 
low nuclear-to-cytoplasmic ratio and their nucleus contained dispersed chromatin, similar to NK cells 
[41,43-45].  
 
Characterization and identification of human NKT cell subsets 
In addition to classification of NKT cells in type I and type II NKT cells based on their TCR repertoire, 
human NKT cells can also be classified into functional subsets based on their cytokine secretion 
pattern upon activation, using a similar approach as for TH-cell subsets [7].  
 
Functional type I NKT cell subsets 
At the moment, type I NKT cells can be divided into five different functional subsets (Figure 1). TH1-
like type I NKT cells have been identified in healthy individuals producing TH1-associated cytokines 
such as IFN-γ and TNF-α upon stimulation [7,30,46]. The majority of these type I NKT cells are DN and 
are thought to exert limited cytotoxic function [30,46]. They are able to induce an effective pro-
inflammatory immune cascade through cytokine signaling. Furthermore, a second TH2-like type I NKT 
cell subset with regulatory properties has been described secreting IL-4 and IL-13 upon activation 
[7,30,46]. This type I NKT cell subset mainly consists of CD4+CD8- cells which are able to suppress 
immune responses in various disease models [47-49]. Recently, three additional minor type I NKT cell 
subsets were identified. TH17-like type I NKT cells have been described, secreting the pro-
inflammatory cytokines IL-17, IL-21 and IL-22 when activated [50,51]. Additionally, FOXP3 expressing 
Treg-like type I NKT cells secreting the immunosuppressive cytokine IL-10 have been identified [52], as 
well as TFH-like type I NKT cells secreting IL-21 upon activation [46,53]. Interestingly, murine studies 
showed that functional type I NKT cell subsets (Figure 1) express unique transcription factors and the 




cells, type II NKT cells are described with a more diverse and less well-defined TCR repertoire 
recognizing non-α-GalCer molecules (primarily sulfatide) presented by CD1d molecules [12,17-19]. 
 
Development of type I NKT cells in mice 
The development of type I NKT cells has been thoroughly studied in mice. During positive selection in 
the murine thymus, T cells expressing TCRs that are capable of binding to MHC class I or II molecules 
on cortical thymic epithelial cells are selected to undergo lineage commitment [9]. This process leads 
to maturation of CD4+ or CD8+ T cells that recognize MHC-presented peptides. Alternatively, type I 
NKT cells that express the randomly rearranged invariant Vα14Jα18 chain are positively selected upon 
binding to CD1d molecules expressed by cortical thymocytes [9,20-22]. As a result of this alternative 
positive selection, they recognize lipid-derived antigens presented by CD1d molecules [10]. During the 
maturation process, a part of the type I NKT cell population retains expression of the T cell-associated 
marker CD4, resulting in two major populations in mice: CD4+CD8- and CD4-CD8- (double negative, 
DN) type I NKT cells [23,24]. Additionally, Type I NKT cells acquire expression of the NK cell receptor 
(NKR) NK1.1 during maturation [9].  
 
Development of type I NKT cells in humans  
Whereas the thymic development of type I NKT cells is well-defined in mice, it has not as yet been 
studied in details in humans. It has been reported that NKT precursor cells can be identified in thymic 
tissue derived from human embryos and young children [25,26]. Similar to type I NKT cell 
development in mice, human type I NKT cells express cell surface markers that are usually associated 
with both T- and NK cells. For instance, a part of the human type I NKT cell population retains 
expression of the T cell-associated markers CD4 or CD8 during maturation, resulting in three major 
populations in humans: CD4+CD8-, CD4-CD8+ and DN type I NKT cells [27,28]. In addition, a part of the 
human type I NKT cells acquires expression of the NK cell-associated marker CD161 (the human 
counterpart of NK1.1 in mice), the classical NK cell marker in humans CD56 [27-29], and various other 
NK cell-associated receptors [27-31].  
 
Localization of type I NKT cells in humans 
After development and maturation in the thymus, NKT cells migrate to the periphery. In general, 
human type I NKT cells are present in small numbers (<0.1% of total T lymphocytes) in peripheral 
blood (PB), lymph nodes, spleen, thymus, lung, and bone marrow [32-34]. Whereas larger type I NKT 
 The role of Natural Killer T cells in cancer 
21 
 
cell populations reside in the liver, colon, kidney (~1% of total T lymphocytes) [35-37], and omentum 
(~10% of total T lymphocytes) [38]. Importantly, it has to be taken into account that NKT cell numbers 
vary substantially among healthy individuals. For instance, circulating type I NKT cells have been 
reported to comprise more than 5% of the total T lymphocyte population in some individuals [39].  
 
Morphology of NKT cells 
Despite the fact that NKT cells are derived from the T cell lineage, their morphology resembles NK 
cells more closely. NK and NKT cells are both referred to as large granular lymphocytes, whereas T 
cells are described as small and non-granular [40-42]. In addition, NKT cells were reported to have a 
low nuclear-to-cytoplasmic ratio and their nucleus contained dispersed chromatin, similar to NK cells 
[41,43-45].  
 
Characterization and identification of human NKT cell subsets 
In addition to classification of NKT cells in type I and type II NKT cells based on their TCR repertoire, 
human NKT cells can also be classified into functional subsets based on their cytokine secretion 
pattern upon activation, using a similar approach as for TH-cell subsets [7].  
 
Functional type I NKT cell subsets 
At the moment, type I NKT cells can be divided into five different functional subsets (Figure 1). TH1-
like type I NKT cells have been identified in healthy individuals producing TH1-associated cytokines 
such as IFN-γ and TNF-α upon stimulation [7,30,46]. The majority of these type I NKT cells are DN and 
are thought to exert limited cytotoxic function [30,46]. They are able to induce an effective pro-
inflammatory immune cascade through cytokine signaling. Furthermore, a second TH2-like type I NKT 
cell subset with regulatory properties has been described secreting IL-4 and IL-13 upon activation 
[7,30,46]. This type I NKT cell subset mainly consists of CD4+CD8- cells which are able to suppress 
immune responses in various disease models [47-49]. Recently, three additional minor type I NKT cell 
subsets were identified. TH17-like type I NKT cells have been described, secreting the pro-
inflammatory cytokines IL-17, IL-21 and IL-22 when activated [50,51]. Additionally, FOXP3 expressing 
Treg-like type I NKT cells secreting the immunosuppressive cytokine IL-10 have been identified [52], as 
well as TFH-like type I NKT cells secreting IL-21 upon activation [46,53]. Interestingly, murine studies 
showed that functional type I NKT cell subsets (Figure 1) express unique transcription factors and the 





Figure 1. Overview of the different functional human NKT cell subsets. CD1d-restricted human NKT cells can be 
divided into subsets based on their TCR repertoire and cytokine profile. Type I NKT cells express the invariant 
Vα24Jα18 TCR α-chain and can be subdivided into five distinct functional subsets (indicated in green). Additionally, 
type II NKT cells express a diverse TCR repertoire and can be subdivided into two functional subsets (indicated in 
blue). Upon activation, NKT cells secrete a unique pattern of cytokines, indicated for each subtype. Type I and type 
II NKT cells are able to switch between different functional subsets upon interactions within the TME. 
Abbreviations: NKT (natural killer T), TCR (T cell receptor), TH (helper T), Treg (regulatory T), TFH (follicular helper T), 
TME (tumor microenvironment). 
 
 
The fate of type I NKT cells might, however, not be permanently determined at this time since their 
cytokine production upon activation can be influenced by the microenvironment [27,55], similar to 
TH-cell subsets [56]. For instance, the cytokine secretion pattern of type I NKT cells is altered by the 
presence of immunosuppressive cytokines and/or immune cell subsets in the tumor 
microenvironment (TME) [57], as well as co-stimulation via CD28 [58], thereby implying plasticity of 
type I NKT cell subsets. 
 
Identification of type I NKT cell subsets 
NKT cells can be identified from human peripheral blood mononuclear cells (PBMC) with flow 
cytometry using monoclonal antibodies (mAb) and multimers as thoroughly described by Metelitsa et 
al. [59]. For instance, type I NKT cells have often been identified by co-staining with anti-Vα24 (clone 
C15) and anti-Vβ11 (clone C21) mAb [27,29,60,61]. However, this mAb combination leads to 
overestimation of type I NKT cell numbers since conventional T cells can also express Vα24 and Vβ11 
TCR subunits [62,63]. Alternatively, type I NKT cells can be detected with anti-Vα24Jα18 (Clone 6B11) 
mAb [28,31]. Furthermore, α-GalCer-loaded CD1d dimers [64] and tetramers [30,65-67] can be used 
to specifically detect CD1d-restricted type I NKT cells, for instance in combination with anti-CD3, anti-
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Vα24 or anti-Vβ11 mAb. Importantly, Sag et al. reported on detection of cytokines in type I NKT cells 
upon stimulation, which enables accurate identification of different functional NKT cell subsets in 
future studies [68]. Since this approach has not been used in NKT phenotype studies yet, no 
information is available on the phenotype of the different functional NKT cell subsets. 
 
Phenotype of type I NKT cell subsets 
Type I NKT cells constitutively express a variety of T cell markers such as the TCR signaling complex 
CD3, and co-stimulatory receptors CD4, CD8 and CD28 [27-31]. CD4 is expressed by 15-80% of the 
type I NKT cell population [27-29,31], and is sometimes used to subdivide type I NKT cells into CD4- 
and CD4+ populations. Besides, type I NKT cells constitutively express a variety of receptors that are 
usually observed on NK cells, such as the adhesion molecule CD56 and the activating NKR CD161 [27-
30]. Seventeen to 70% of the CD4- type I NKT cells express CD56, in contrast to only a small fraction 
of the CD4+ type I NKT cell population (3-11%) [29]. Interestingly, type I NKT cells acquire a memory-
activated phenotype before birth (unlike NK- and T cells), reflected by high expression of CD45RO and 
low expression of the homing receptor CD62L [28,29,31,69]. This might indicate that these NKT cells 
have been sensitized and activated during fetal life by encountering a natural ligand [69], which 
contributes to the ability of NKT cells to respond fast upon meeting the antigen.  
In addition, type I NKT cells have the ability to induce expression of a number of phenotypic 
markers upon activation and/or interactions within the microenvironment. For instance, type I NKT 
cells can upregulate CD62L expression upon α-GalCer-mediated activation and expansion which can 
serve as a marker for NKT cells with superior survival and proliferative capacity [70]. In addition, CD4+ 
and DN type I NKT cells express CD69, which is involved in lymphocyte proliferation [28,71]. Upon 
cytokine-mediated activation, type I NKT cells upregulate CD69 expression. Furthermore, CD4+, CD8+ 
and DN type I NKT cells express CD27, a co-stimulatory immune-checkpoint molecule involved in the 
control of T cell immunity [28,29,31]. Remarkably, expression of CD27 seems to be downregulated on 
type I NKT cells upon activation with α-GalCer, whereas its expression is upregulated in activated T 
cells [72,73]. This downregulation could be related to the fact that NKT cells already constitute a 
memory phenotype, and therefore do not require CD27 to generate NKT cell immunity and 
maturation upon first antigen encounter. α-GalCer-activated type I NKT cells also express the co-
stimulatory molecule CD40L, and the activation marker CD38 [28,30,31,71]. In addition, type I NKT 
cells express the inhibitory NKR NKG2A, the low affinity Fc receptor CD16, and the activating NKRs 
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proportion of type I NKT cells expressing specific NKRs is highly variable among healthy individuals (1-
85%) and can be altered upon interactions within the TME [31,56,74-78]. In addition to the expression 
of NK- and T cell-associated cell surface markers, type I NKT cells express a wide range of inducible 
cytokine- and chemokine receptors enabling them to respond to various signals [28-31,79-81]. For 
instance, type I NKT cells induce expression of the IL-2 receptor chain CD25 (IL-2RA) upon α-GalCer-
mediated activation [28,29,31], primarily in the CD4+ type I NKT cell population [30]. A different 
pattern is observed regarding the chemokine receptors CCR5, CCR6, CCR7, and CXCR6, which are all 
higher expressed on CD4- type I NKT cells compared to CD4+ type I NKT cells [27,29,30]. Finally, type I 
NKT cells express a variety of markers that are involved in a wide range of functionalities such as 
granzyme B, perforin and CD95L, which play important roles in cytotoxicity [29,31,82].  
 
Functional type II NKT cell subsets 
So far, two distinct functional type II NKT cell subsets have been identified (Figure 1). TH1-like type II 
NKT cells secrete the pro-inflammatory cytokines IFN-γ and TNF-α upon stimulation, whereas TH2-like 
type II NKT cells secrete the regulatory cytokines IL-4 and IL-13 [19,83-85]. Murine studies showed 
that the cytokine profile of type II NKT cells can be influenced in the same way as has been observed 
for type I NKT cells [83], suggesting plasticity of type II NKT cell subsets as well. 
 
Identification of type II NKT cell subsets 
In contrast to type I NKT cells, no specific methods exist to identify the entire type II NKT cell 
population due to the lack of specific markers. Although, several mouse models have been developed 
in order to study the role of type II NKT cells in cancer in vivo. These models include Jα18-/- mice, 
without type I NKT cells, and CD1d-/- mice that lack both type I and type II NKT cells [86-88]. Another 
approach to study type II NKT cells in both mice and humans is by using sulfatide-loaded CD1d 
multimers [19,84,89,90]. However, this approach has not been widely used due to the unstable nature 
of sulfatide-loaded CD1d complexes. Furthermore, since not all type II NKT cells are sulfatide-reactive, 
this method excludes a significant proportion of type II NKT cells [83,89]. As a result, the phenotype 
and function of type II NKT cells remain largely elusive, and new methods are essential in order to 








In many studies, NKT cells are identified with flow cytometry using a combination of anti-CD3 and 
anti-CD56 mAb [31,81,91-95]. Although it is likely that the CD3+CD56+ cell population includes CD1d-
restricted NKT cells, it has to be taken into consideration that conventional T cells have been reported 
to express NK-cell markers as well, including CD56 [17,31,79,80]. Since it is unclear whether 
CD3+CD56+ cells are CD1d-restricted, this population is often referred to as “NKT-like”. An additional 
marker is essential in order to determine which part of the NKT-like cells are true NKT cells and which 
are not. Besides, only a small part of the type I NKT cell population expresses CD56 [29]. Hence, a 
significant proportion of type I NKT cells is excluded from analyses when using the combination of 
anti-CD3 and anti-CD56 mAb. NKT-like cells express co-stimulatory-, cytokine- and chemokine 
receptors, and NKRs that are also expressed by type I NKT cells [27-31,81]. Exceptions are killer-cell 
Ig-like receptors (KIRs) that provide either inhibitory or stimulatory signals upon interaction with 
human leukocyte antigen (HLA) molecules [31,96,97]. KIRs are primarily expressed by NKT-like cells, 
and not by type I NKT cells. 
In conclusion, different functional NKT cell subsets can be identified within the type I and 
type II NKT cell populations. Whereas type I NKT cells are characterized in detail, type II NKT cells are 
not due to lack of specific markers. Studies so far suggest that the expression levels of cell surface 
markers on type I NKT cells are highly variable among healthy individuals. Interestingly, murine studies 
showed that expression patterns of type I NKT cell surface markers are modulated upon cell-cell 
interaction and/or interaction with signaling molecules [74,76]. These phenotypical modulations 
adapt the functional capabilities of the NKT cells, including the production of specific cytokines upon 
activation. These data indicate a high degree of NKT cell plasticity and that type I NKT cells (and 
probably type II NKT cells as well) are able to switch between different phenotypical/functional 
subsets. Studies on human NKT cells are needed to support this hypothesis.  
 
Activation of NKT cells  
Due to expression of both NK- and T cell-associated functional molecules, NKT cells can be activated 
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Activation via T cell-like mechanisms 
First, NKT cells can be activated via their TCR in a T cell-like manner via recognition of glycolipids in 
the context of CD1d molecules [61,98]. CD1d is primarily expressed by antigen-presenting cells (APC) 
but has also been reported to be expressed by some epithelial, parenchymal, and vascular smooth 
muscle cells [99,100]. Importantly, APC are able to present both exogenous and endogenous 
glycolipids in the context of CD1d (Figure 2). Exogenous microbial- and non-microbial-derived 
glycolipids enter APC via different mechanisms as thoroughly reviewed by Bendelac et al. [101] and 
 
 
Figure 2. CD1d-presented glycolipids in APC. APC present exogenous and endogenous glycolipids in the context of 
CD1d. During endosomal trafficking, CD1d molecules relocate from the cell membrane towards a late endosome 
where the bound glycolipid antigens are removed from CD1d and replaced by new glycolipid antigens. Exogenous 
glycolipids (indicated in blue) enter the APC late endosome via endocytosis or phagocytosis (1). Endogenous 
glycolipids (indicated in purple) enter the late endosome as a result of NOD, FPR2 or TLR signaling (2), but the exact 
mechanism is unknown. The exogenous and endogenous glycolipids are loaded into CD1d molecules upon which 
they relocate back to the cell membrane. Abbreviations: APC (antigen presenting cells), NOD (nucleotide-binding 
oligomerization domain), FPR2 (formyl peptide receptor 2), TLR (toll-like receptor). 
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 Barral et al. [102]. For instance, exogenous glycolipids can be captured by the mannose receptor, or 
alternatively, insert themselves directly into the cell membrane of APC, upon which they undergo 
endocytosis. Furthermore, exogenous glycolipids may enter APC with very low-density lipoprotein  
(VLDL) particles via the low-density lipoprotein (LDL) receptor, or via phagocytosis. Finally, scavenger 
receptors can mediate internalization of apoptotic cells and modified LDL, which also leads to entering 
of exogenous glycolipids into APC. During endosomal trafficking, CD1d molecules relocate from the 
cell membrane towards a late endosome where the bound glycolipids are removed from CD1d and 
replaced by new glycolipids (Figure 2) [103,104]. Thereafter, the CD1d molecules relocate back to the  
cell membrane. Additionally, APC also present endogenous glycolipids in the context of CD1d (Figure 
2). For instance, activation of nucleotide-binding oligomerization domain (NOD) -1 and -2 intracellular 
pattern recognition receptors by bacteria, or activation of formyl peptide receptor 2 (FPR2) by serum 
amyloid A-1 (SAA-1), results in loading of endogenous glycolipids into CD1d molecules during 
endosomal CD1d trafficking (Figure 2) [105,106]. Furthermore, Toll-like receptor (TLR) signaling upon 
stimulation with lipopolysaccharide (LPS) was suggested to result in the loading of endogenous 
glycolipids into CD1d molecules [101,107]. The exact mechanism of how these signaling pathways lead 
to the loading of endogenous glycolipids into CD1d is, however, unknown.  
In contrast to TCRs on conventional T cells that recognize specific peptides presented by 
MHC class I or II, the Vα24Jα18 TCR present on type I NKT cells recognizes a diversity of glycolipids 
that are presented by CD1d molecules. For instance, type I NKT cells recognize glycosphingolipids, α-
galactosyldiacylglycerols, diacylglycerols, and phospholipids derived from mycobacteria in addition to 
α-GalCer [108-112]. Furthermore, type I NKT cells can be activated upon encountering the self-
glycolipids isoglobotrihexosylceramide (iGb3) and β-glucosylceramide (β-GluCer) [11,113]. 
Additionally, type II NKT cells have been reported to recognize the self-glycolipids sulfatide and β-
glucopyranosylceramide (β-GlcCer), as well as lysophospholipids and microbial lipids 
[19,83,89,114,115]. As a consequence of their diverse TCR repertoire, different type II NKT cell subsets 
exist, recognizing different lipids [19,85].  
Activated NKT cells are able to kill tumor cells directly in a CD1d-dependent manner [116]. 
This antigen-specific cytotoxicity is CD95/CD95L dependent, unlike NK- and T cells that predominantly 
use perforin/granzyme-mediated mechanisms [116]. Upon activation via their TCR in a CD1d-
dependent manner, NKT cells rapidly expand and secrete a range of cytokines [68,117-121]. Crowe et 
al. reported ~10-fold expansion of type I NKT cell numbers in the murine spleen 2-3 days after injection 
with 2 µg α-GalCer in mice [117]. Besides, ~7-fold and ~3-fold type I NKT cell expansion was reported 
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memory-activated phenotype [69], NKT cells have the ability to respond quickly upon encountering 
an antigen. Within an hour after injection with α-GalCer, a burst of cytokines can be detected in mice. 
For instance, studies reported maximal levels of IFN-γ+ and IL-4+ murine liver- and splenic-derived type 
I NKT cells within 2 hours after α-GalCer activation in vivo [117,118]. Additionally, high IFN-γ (400 
pg/ml) and IL-4 (1500 pg/ml) levels were detected in the serum of these mice 90 minutes after 
injection with 100 ng/ml α-GalCer [118]. Although the percentage of IL-4+ splenic-derived type I NKT 
cells dropped to baseline levels 16 hours after injection of mice with 2 µg α-GalCer, elevated IFN-γ+ 
type I NKT cells could still be detected after 72 hours [117]. In conclusion, NKT cells rapidly secrete a 
range of cytokines following activation with α-GalCer. 
 
Activation via NK cell-like mechanisms 
NKT cells seem to behave similar to NK cells when it comes to their activation. Like in NK cells, 
activation is dependent on the balance between inhibitory and stimulatory signals obtained via NKRs 
and KIRs [122,123]. As discussed above, phenotype studies showed that NKT cells also express a wide 
range of these receptors [27-31]. Activating NKRs are able to recognize a variety of MHC-like 
molecules and cellular targets often referred to as “stress proteins”. For instance, the NKG2D receptor 
recognizes MHC class I-like molecules (MIC) A and B and unique long binding proteins (ULBPs) [124], 
whereas DNAM-1 recognizes the poliovirus receptor (PVR) and Nectin-2 [125]. Besides, NKT cells 
express KIRs, with less-well defined ligands, that provide activating signals [126-129]. Furthermore, 
NKT cells express NKRs and KIRs that provide inhibitory signals upon binding with HLA molecules [130-
135]. When the balance of signals is shifted towards activation, an NKT cell is activated, resulting in 
cytokine production as well as direct killing of tumor cells in a CD1d-independent manner (Figure 3). 
Interestingly, studies showed that inhibitory signals provided by KIRs and/or NKRs were able to 
interrupt TCR signaling in conventional T cells without CD1d restriction [31,131,132,134]. Since NKT 
cells express similar functional receptors, it is likely that similar interruption of TCR signaling also 
occurs in NKT cells (Figure 3). Additionally, a part of the NKT cell population expresses the low affinity 
Fc receptor CD16 which is known to induce antibody-dependent cytotoxicity (ADCC) when present on 
NK cells [136]. This phenomenon has, however, not been studied as yet in relation to NKT cells. In 
conclusion, NKT cells can be activated via different NK- and T cell-associated mechanisms that lead to 
immediate killing of tumor cells and secretion of large amounts of cytokines that have a major 
influence on the immune system. 
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Finally, studies showed that NKT cells - like NK cells - can also be activated by IL-12 in 
combination with IL-18 via cytokine receptors in a CD1d-independent manner (Figure 3) [137-139]. 
These cytokines are secreted by i.e. active macrophages or dendritic cells (DC) [140-142]. Upon 
interaction with IL-12 and IL-18, NKT cells secrete high amounts of IFN-γ, as also observed after CD1d-
dependent and NKR-mediated activation [128,137,138,143]. 
 
 
Figure 3. Activation of NKT cells. Activation of NKT cells is dependent on a balance between activating and 
inhibitory signals. First of all, NKT cells receive activating signals via their TCR that recognize glycolipids in context 
of CD1d. Secondly, NKT cells receive activating signals in a CD1d-independent manner via NKRs upon interaction 
with stress proteins such as MIC-A and MIC-B, ULBPs, Nectin-2, or MLL5 proteins. Additionally, NKT cells receive 
activating signals in a CD1d-independent manner via KIRs with merely unknown ligands. Inhibitory NKRs and KIRs 
that recognize HLA molecules provide inhibitory signals that are able to disrupt both TCR and NKR signaling. When 
the balance is skewed towards activation, NKT cells produce and secrete high amounts of cytokines. In addition, 
NKT cells that are activated via this mechanism are able to kill target cells directly via activation of their TCRs and 
NKRs. Finally, NKT cells - like NK cells - can be activated by a combination of IL-12 and IL-18 which leads to 
production of cytokines. Abbreviations: NKT (natural killer T), TCR (T cell receptor), NKR (natural killer receptor), 
MIC (major histocompatibility complex I-like molecules), ULBP (unique long binding protein), MLL5 (mixed-lineage 
leukemia-5), KIR (killer-cell Ig-like receptor), HLA (human leukocyte antigen), NK (natural killer). 
 
 
NKT cell anergy 
Importantly, murine studies have indicated that overstimulation and chronic activation of type I NKT 




memory-activated phenotype [69], NKT cells have the ability to respond quickly upon encountering 
an antigen. Within an hour after injection with α-GalCer, a burst of cytokines can be detected in mice. 
For instance, studies reported maximal levels of IFN-γ+ and IL-4+ murine liver- and splenic-derived type 
I NKT cells within 2 hours after α-GalCer activation in vivo [117,118]. Additionally, high IFN-γ (400 
pg/ml) and IL-4 (1500 pg/ml) levels were detected in the serum of these mice 90 minutes after 
injection with 100 ng/ml α-GalCer [118]. Although the percentage of IL-4+ splenic-derived type I NKT 
cells dropped to baseline levels 16 hours after injection of mice with 2 µg α-GalCer, elevated IFN-γ+ 
type I NKT cells could still be detected after 72 hours [117]. In conclusion, NKT cells rapidly secrete a 
range of cytokines following activation with α-GalCer. 
 
Activation via NK cell-like mechanisms 
NKT cells seem to behave similar to NK cells when it comes to their activation. Like in NK cells, 
activation is dependent on the balance between inhibitory and stimulatory signals obtained via NKRs 
and KIRs [122,123]. As discussed above, phenotype studies showed that NKT cells also express a wide 
range of these receptors [27-31]. Activating NKRs are able to recognize a variety of MHC-like 
molecules and cellular targets often referred to as “stress proteins”. For instance, the NKG2D receptor 
recognizes MHC class I-like molecules (MIC) A and B and unique long binding proteins (ULBPs) [124], 
whereas DNAM-1 recognizes the poliovirus receptor (PVR) and Nectin-2 [125]. Besides, NKT cells 
express KIRs, with less-well defined ligands, that provide activating signals [126-129]. Furthermore, 
NKT cells express NKRs and KIRs that provide inhibitory signals upon binding with HLA molecules [130-
135]. When the balance of signals is shifted towards activation, an NKT cell is activated, resulting in 
cytokine production as well as direct killing of tumor cells in a CD1d-independent manner (Figure 3). 
Interestingly, studies showed that inhibitory signals provided by KIRs and/or NKRs were able to 
interrupt TCR signaling in conventional T cells without CD1d restriction [31,131,132,134]. Since NKT 
cells express similar functional receptors, it is likely that similar interruption of TCR signaling also 
occurs in NKT cells (Figure 3). Additionally, a part of the NKT cell population expresses the low affinity 
Fc receptor CD16 which is known to induce antibody-dependent cytotoxicity (ADCC) when present on 
NK cells [136]. This phenomenon has, however, not been studied as yet in relation to NKT cells. In 
conclusion, NKT cells can be activated via different NK- and T cell-associated mechanisms that lead to 
immediate killing of tumor cells and secretion of large amounts of cytokines that have a major 
influence on the immune system. 
 The role of Natural Killer T cells in cancer 
29 
 
Finally, studies showed that NKT cells - like NK cells - can also be activated by IL-12 in 
combination with IL-18 via cytokine receptors in a CD1d-independent manner (Figure 3) [137-139]. 
These cytokines are secreted by i.e. active macrophages or dendritic cells (DC) [140-142]. Upon 
interaction with IL-12 and IL-18, NKT cells secrete high amounts of IFN-γ, as also observed after CD1d-
dependent and NKR-mediated activation [128,137,138,143]. 
 
 
Figure 3. Activation of NKT cells. Activation of NKT cells is dependent on a balance between activating and 
inhibitory signals. First of all, NKT cells receive activating signals via their TCR that recognize glycolipids in context 
of CD1d. Secondly, NKT cells receive activating signals in a CD1d-independent manner via NKRs upon interaction 
with stress proteins such as MIC-A and MIC-B, ULBPs, Nectin-2, or MLL5 proteins. Additionally, NKT cells receive 
activating signals in a CD1d-independent manner via KIRs with merely unknown ligands. Inhibitory NKRs and KIRs 
that recognize HLA molecules provide inhibitory signals that are able to disrupt both TCR and NKR signaling. When 
the balance is skewed towards activation, NKT cells produce and secrete high amounts of cytokines. In addition, 
NKT cells that are activated via this mechanism are able to kill target cells directly via activation of their TCRs and 
NKRs. Finally, NKT cells - like NK cells - can be activated by a combination of IL-12 and IL-18 which leads to 
production of cytokines. Abbreviations: NKT (natural killer T), TCR (T cell receptor), NKR (natural killer receptor), 
MIC (major histocompatibility complex I-like molecules), ULBP (unique long binding protein), MLL5 (mixed-lineage 
leukemia-5), KIR (killer-cell Ig-like receptor), HLA (human leukocyte antigen), NK (natural killer). 
 
 
NKT cell anergy 
Importantly, murine studies have indicated that overstimulation and chronic activation of type I NKT 




[117,144-148]. This resembles the response of conventional T cells upon activation in the TME in 
presence of co-inhibitory stimuli or checkpoint molecules like programmed death-ligand 1 (PD-L1) 
[149,150]. Upon binding with α-GalCer in the context of CD1d, type I NKT cells downregulate their TCR 
and NKR expression and upregulate the inhibitory molecules programmed cell death protein 1 (PD-1) 
and B- and T-lymphocyte attenuator (BTLA) [145,147,151], resulting in hyporesponsiveness. 
Furthermore, chronic stimulation of type I NKT cells with α-GalCer in vivo resulted in activation-
induced cell death (AICD) via upregulation of the death receptor CD95, thereby contributing to active 
depletion of type I NKT cells [152,153]. This is most likely a feedback mechanism used by NKT cells in 
order to prevent tissue damage. Anergy induced by α-GalCer also resulted in impaired proliferation 
and production of IFN-γ by type I NKT cells upon α-GalCer restimulation. In contrast, anergic type I 
NKT cells retained their capacity to produce TH2-associated cytokines [145]. Moreover, pretreatment 
with α-GalCer skewed type I NKT cells towards a TH2 or Treg-like profile [154-157]. α-GalCer pretreated 
type I NKT cells acquired characteristics of regulatory cells in vivo, including production and secretion 
of IL-10, which is known to induce and maintain an immunosuppressive TME [154-156]. Chronic 
stimulation of NKT cells in the TME might therefore contribute to immune escape in cancer patients. 
 
The regulatory function of NKT cells 
Depending on which functional NKT cell subsets are involved, both type I and type II NKT cell subsets 
are able to either skew the immune response towards inflammation or towards tolerance. Activated 
NKT cells shape the TME via modulation of cells from both the innate and adaptive immune system 
(Figure 4), thereby implementing an important regulatory function. 
NKT cells are unique in the sense that they can activate and induce full maturation of DC 
[140,141,158]. This maturation requires direct interaction of DC with NKT cells via the TCR-CD1d 
complex in combination with CD40/CD40L co-stimulation. As a result, DC produce IL-12, which further 
drives IFN-γ production by TH1-like NKT cell subsets. In contrast, IL-13 and IL-4, produced by TH2-like 
NKT cell subsets, indirectly suppress T cell function and drive TH2 differentiation, respectively [49,159-
161]. IL-10, produced by Treg-like type I NKT cells drives T cell differentiation towards Tregs, thereby 
contributing to the establishment of an immunosuppressive TME [162]. Finally, the IL-21 producing 
TFH-like type I NKT cell subset interacts directly with B cells that present the same glycolipid in context 
of CD1d as used to activate the NKT cells, resulting in fast immunoglobulin production and affinity 
maturation [53,163-166].  
 




Figure 4. The regulatory function of activated NKT cells. Upon activation, NKT cells have a major influence on other 
immune cells. NKT cells can induce full maturation of DC upon which they activate T cells and induce TH1 
differentiation. Activated T cells interact with B cells resulting in their activation, as well as production of 
immunoglobulins and affinity maturation. The TFH type I NKT cell subset provides cognate help for B cells which 
promotes the production of immunoglobulins and affinity maturation. Additionally, NKT cells can reverse the 
phenotype of immune suppressive neutrophils. Upon activation, NKT cells are also able to activate NK cells and 
macrophages, and induce a functional shift of monocytes towards a DC-like phenotype. Finally, NKT cells can drive 
T cell differentiation to either a TH1-, TH2- or Treg-profile, dependent on the NKT subsets involved. Abbreviations: 
NKT (natural killer T), DC (dendritic cells), TH (helper T), TFH (follicular helper T), NK (natural killer), Treg (regulatory 
T), N (neutrophil), MФ (macrophage). 
 
 
In addition to production of large amounts of cytokines as discussed above, NKT cells secrete 
a range of chemokines upon activation, including RANTES, Eotaxin, MIP-1α and MIP-1β, that lead to 
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[167]. IFN-γ secreted by TH1-like NKT cell subsets then leads to the local activation of NK cells, 
neutrophils and macrophages [168-170]. Furthermore, granulocyte macrophage colony-stimulating 
factor (GM-CSF), IFN-γ and IL-4 secreted by NKT cells may shift the functional capacity of monocytes 
towards a more dendritic cell-like phenotype which contributes to the activation of T cells and, 
indirectly, B cells [171,172]. NKT cells are also able to reverse the phenotype of immune suppressive 
neutrophils by reducing secretion of IL-10 and enhancing IL-12 production in a CD1d-dependent 
manner [106]. 
In conclusion, NKT cells are able to rapidly respond to a wide variety of glycolipids and stress 
proteins using T- and NK cell-like mechanisms, respectively. Although NKT cells comprise a minor 
immune cell subset in most organs, they have a major effect on immune regulation since they can 
skew an immune response towards inflammation or tolerance in a very short time by secreting pro- 
or anti-inflammatory cytokines. Besides, NKT cells have the ability to kill tumor cells directly upon 
activation but, probably reflected by their relative low numbers, NKT cells primarily have a regulatory 
function. Based on this information, it is clear that NKT cells are not just cells with NK- and T cell 
properties: by combining characteristics of both cell types, NKT cells are able to add unique functions 
to the immune response. NKT cells may play a uniquely central role during the very first steps in the 
initiation of an anti-tumor immune response. The main reasons are the ability of NKT cells to respond 
fast by influencing other immune cells, resulting in amplification or dampening of the immune 
response. 
 
The in vitro and in vivo anti-tumor activity of NKT cells  
Type I NKT cells in tumor immunity 
Twenty years ago, it was first reported that the glycolipid α-GalCer, discovered in marine sponges, had 
potent anti-tumor activity in vivo [173-175]. Mice that were intravenously inoculated with B-16 
(melanoma) or intraperitoneally inoculated with EL-4 (lymphoma) cells showed a significantly 
prolonged lifespan after injection with α-GalCer, with a stronger potency than the typical 
chemotherapeutic agent mitomycin C [173]. A role for NKT cells in this anti-tumor activity was 
suggested a few years later when it was discovered that α-GalCer is recognized by type I NKT cells via 
their TCR in the context of CD1d, leading to their activation [176]. Thereafter, studies showed that 
type I NKT cells were the key effectors of anti-tumor responses in a murine B-16 melanoma metastasis 
model [177-179]. For instance, Toura et al. reported that activation of type I NKT cells via injection 
with α-GalCer-pulsed-DC resulted in complete eradication of established B-16 melanoma liver 
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metastases [179]. Administration of α-GalCer to activate type I NKT cells even prevented primary 
tumor formation in different in vivo models [180]. In contrast, mice lacking type I NKT cells were more 
prone to chemical or p53 loss-induced tumor development [181-183]. Recently, it was reported that 
type I NKT cells also play a role in preventing metastatic disease in a 4T1 mammary carcinoma model 
[184]. Upon resection of the primary breast tumors, treatment with α-GalCer-pulsed-DC limited 
formation of tumor metastases, prolonged survival, and provided curative outcomes in ~45% of the 
mice. Thereafter, it was shown that α-GalCer-pulsed-DC could also be combined with the 
chemotherapeutics cyclophosphamide or gemcitabine in order to enhance survival of mice with 
metastatic disease [185]. Importantly, studies showed that the anti-metastatic effect of α-GalCer was 
impaired in NK cell-depleted or IFN-γ-deficient mice [186,187]. Smyth et al. showed that IFN-γ 
production by type I NKT cells and subsequent IFN-γ production by NK cells was crucial for α-GalCer-
mediated tumor protection [178]. In line with these results, it was observed that the TH2-skewing 
synthetic α-GalCer-analogue OCH provided less tumor protection in the CT26 mouse model compared 
to α-GalCer [188]. In contrast, studies reported that analogues of α-GalCer, which skewed the cytokine 
profile of type I NKT cells towards TH1, provided superior protection against metastases formation 
compared to α-GalCer [189-191]. This implicates a crucial role for type I NKT cells with a TH1 cytokine 
profile in anti-tumor activity.  
After the discovery of the important role of activated type I NKT cells in anti-tumor 
responses in vivo, studies focused on the mechanisms used by these NKT cells in order to eradicate 
tumor cells. As mentioned above, CD1d is primarily expressed by APC, although malignant 
haematopoietic cells have also been reported to express CD1d on their cell membrane [4,192-194]. 
Additionally, there is evidence that solid tumors also express CD1d, including renal cell and colorectal 
carcinomas [195,196]. Upon activation with α-GalCer, type I NKT cells were able to kill CD1d+ tumor 
cells in a CD1d-dependent manner [4,192-194,196]. In order to kill tumor cells directly via CD1d 
interaction, they need to present glycolipids that can be recognized by NKT cells. There is evidence 
from murine studies that type I NKT cells can be activated by tumor-derived glycolipids that are cross-
presented by APC in the context of CD1d [197-200]. However, until now, the nature of tumor-
glycolipids that are recognized by NKT cells remains poorly elucidated. Since the cytolysis and 
eradication of tumor cells via type I NKT cells was shown to be dependent on CD1d expression on their 
cell surface, it was suggested that CD1d expression might be a predictor of whether α-GalCer-
activated type I NKT cells are able to eradicate tumor cells or not [3,4]. However, other studies showed 
that CD1d- haematopoietic cells could also be killed directly by type I NKT cells, for instance via NKG2D 
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NKR activation, even in the absence of CD1d. Moreover, although type I NKT cells are capable of killing 
tumor cells directly, they primarily mediate anti-tumor activity via the activation of downstream 
immune effector cells as demonstrated by human and mouse studies [4,178,203,204]. Especially TH1-
like type I NKT cells play an important role in this anti-tumor activity via secretion of large amounts of 
IFN-γ, which leads to generation of tumor-specific CD8+ cytotoxic T cells, and rapid activation of NK 
cells [4,178,189,203-205].  
 
Type II NKT cells in tumor immunity 
In contrast to type I NKT cells, only limited information is available regarding the role of type II NKT 
cells in cancer. Although, some in vivo models provided important information. In general, type II NKT 
cells are associated with immunosuppression and tumor progression. For instance, murine carcinoma 
and lymphoma models showed that the tumor burden of CD1d−/− mice, without type I and type II NKT 
cells, was lower compared to Jα18−/− mice that lack type I NKT cells only [86-88]. Injections with 
sulfatide increased the number of tumor nodules in a CT26 colon carcinoma lung metastasis mouse 
model, via activation of type II NKT cells [206]. Besides, administration of sulfatide abrogated the 
protective effect of α-GalCer-activated type I NKT cells against tumor development. Type II NKT cells 
were reported to produce IL-13 through the IL-4R-STAT6 pathway, which was necessary for 
downregulation of tumor immunosurveillance in a 15-12RM fibrosarcoma mouse model [49]. 
Thereafter, it was shown that IL-13 induced TGF-β-secreting myeloid derived suppressor cells (MDSC) 
in vivo that inhibited tumor-specific T cells [159,207]. A role for MDSC in inhibition of anti-tumor 
immunosurveillance was supported by the study of Renukaradhya et al. that showed large numbers 
of these cells at the tumor site of B cell lymphoma-bearing Jα18−/− mice without type I NKT cells [87]. 
This implicates an important role for type II NKT cells in suppression of immunosurveillance in cancer. 
Although, Zhao et al. showed in an in vivo murine model that activation of type II NKT cells with CpG 
oligodeoxynucleotides resulted in anti-tumor activity of these cells via the production of IFN-γ 
[83,208]. The involvement of IFN-γ implies that type II NKT cells are able to contribute to anti-tumor 
responses, but only when the TH1-like subset is involved. 
In conclusion, a crucial role is implicated for type I NKT cells with a TH1 cytokine profile in 
anti-tumor activity. In addition, although it is generally accepted that the type II NKT cell population 
promotes tumor growth, there is evidence that TH1-like type II NKT cells can be involved in anti-tumor 
responses. Hence, the role of NKT cells in malignancies is highly dependent on which functional type 
I or type II NKT cell subsets are involved.  
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The function and phenotype of NKT cells in patients diagnosed with cancer 
Several human studies have addressed the presence, function and/or phenotype of NKT cells in cancer 
patients. Here, we will focus on both tumor-infiltrating and circulating NKT cells.  
 
Tumor-infiltrating NKT cells 
Studies showed a difference in the presence of NKT cells between tumor tissue and non-tumor tissue. 
The frequency of type I NKT cells was reported to be higher in intrahepatic malignant tumors and 
colorectal carcinomas compared to normal liver tissue and normal mucosa, respectively [209,210]. 
The opposite pattern was reported by Kenna et al. who showed a significantly lower presence of liver-
infiltrating type I NKT cells in colorectal liver metastases compared to healthy liver tissue [35]. In 
addition, several studies showed a correlation between infiltrating NKT cell numbers and clinical 
outcome. High numbers of tumor-infiltrating type I NKT cells correlated with a relatively good clinical 
outcome in patients diagnosed with colorectal cancer and neuroblastoma [210,211]. High density of 
NK/NKT cells was also associated with prolonged overall survival in periampullary adenocarcinoma 
(including pancreatic cancer) patients [212]. Accordingly, absence of infiltrating type I NKT cells and 
low numbers of infiltrating NKT-like cells correlated with poor patient survival and disease progression 
in neuroblastoma and gastric cancer, respectively [91,213].  
The function and phenotype of infiltrating type I NKT cells was addressed in studies on 
hepatocellular carcinoma, colorectal cancer and neuroblastoma [35,210,213]. Lower expression of 
CD56 and CD161 was reported on infiltrating type I NKT cells in tumor-bearing livers compared to 
normal livers [35]. Additionally, in a study on colorectal cancer, expression of the activation markers 
CD69L and FasL was reported on a larger fraction of infiltrating type I NKT cells in tumor tissue 
compared to normal mucosa [210]. Tumor-infiltrating type I NKT cells expressed IFN-γ and granzyme 
B, but the authors did not compare the expression of these markers to that of type I NKT cells in 
normal mucosa [210]. Additionally, it was observed that type I NKT cell infiltration in neuroblastomas 
was associated with CCL2 expression on tumor cells, indicating that expression of homing receptors 
on tumors was essential for infiltration of type I NKT cells in neuroblastoma [213]. Furthermore, in 
two studies [91,92] the function and phenotype of infiltrating NKT-like cells in tumors were described. 
Peng et al. reported impaired effector function of infiltrating NKT-like cells in gastric cancer-derived 
tumor tissue compared to non-tumor tissue, characterized by decreased expression of IFN-γ, TNF-α, 
granzyme B and Ki-67 [91]. Furthermore, this study also showed decreased expression of the 
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and DNAM-1 on NKT-like cells in tumor tissue compared to non-tumor tissue. In addition, a study on 
patients with hepatocellular carcinoma showed that NKT-like cells in tumor tissue expressed FOXP3 
and lost expression of IFN-γ and perforin compared to NKT-like cells in non-tumor tissue [92].  
In conclusion, tumor-infiltrating type I NKT cells and NKT-like cells may express less 
activating receptors, homing receptors and proliferation markers, and produce lower amounts of TH1-
associated cytokines compared to type I NKT cells and NKT-like cells in healthy tissue, indicating 
tolerance and not anti-tumor activity. 
 
Circulating NKT cells 
In addition, studies also showed altered function of circulating type I NKT cells in cancer patients. For 
instance, the number of circulating type I NKT cells was significantly decreased in patients with 
different cancers compared to healthy controls [214-222]. In line with the results on infiltrating type I 
NKT cells, low circulating type I NKT cell numbers correlated with poor clinical outcome in patients 
with head and neck squamous cell carcinoma [215,216]. Interestingly, late-stage cancer patients 
presented with lower type I NKT cell numbers than early-stage cancer patients with oral squamous 
cell carcinoma or laryngeal cancer [219,222], suggesting cancer-mediated depletion of NKT cells. After 
resection of the primary tumor, type I NKT cell numbers did not increase in patients with different 
cancer types [214,221]. In contrast, circulating NKT-like cell numbers were not decreased in patients 
diagnosed with laryngeal cancer, gastric cancer or hepatocellular carcinoma [91,92,221].  
Besides being reduced in numbers, circulating type I NKT cells are often functionally 
impaired in patients [217,219,220,223-225]. For instance, circulating type I NKT cells derived from 
patients with prostate cancer or oral squamous cell carcinoma had a TH2-biased cytokine profile 
[219,220]. Furthermore, type I NKT cells obtained from patients with advanced cancer stages showed 
impaired cytokine production and proliferative capacity upon ex vivo activation with α-GalCer 
[217,220,223]. In accordance with this observation, lower numbers of IFN-γ-producing type I NKT cells 
were observed in patients with colon carcinoma, head and neck cancer, breast cancer, or renal cell 
carcinoma compared to healthy controls [214]. These changes in cytokine profile imply that type I NKT 
cells switched from a TH1- towards a TH2-like NKT cell subset.  
In conclusion, reduced frequency of circulating NKT cells and altered phenotype, resulting 
in altered function, of both infiltrating and circulating NKT cells are often observed in cancer patients, 
especially in patients with late-stage disease. Since altered function was not observed in infiltrating 
NKT cells in healthy tissue, it can be argued that this altered function of NKT cells is cancer/TME-
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mediated: tumors may suppress the immune system, and skew the cytokine profile of NKT cells from 
TH1 towards TH2 in order to escape from recognition and elimination. Although the mechanisms 
behind the cancer/TME-mediated altered function of NKT cells are not fully understood, studies 
suggested a role for metabolic derivative lactic acid [226], the production of soluble factors by tumors 
such as sMIC [227], and the expression of CD1d by tumors [195,228]. 
 
Shaping the TME by NKT cells 
Shaping the TME by TH1-like NKT subsets 
As discussed above, TH1-like NKT cells are promising candidates to initiate effective anti-tumor 
immune responses. TH1-like NKT cells might play an important role in anti-tumor responses by shaping 
the TME (Figure 5). For instance, they have been reported to co-localize with tumor-associated 
macrophages (TAM) with an M2-polarized phenotype that promote tumor growth and progression 
[156,229]. This co-localization resulted in CD1d-dependent killing of TAM that cross-presented tumor-
derived glycolipids in vivo [198,230]. Furthermore, TH1-like NKT cells and secondary activated NK cells 
contributed to the inhibition of tumor angiogenesis by IFN-γ via suppression of M2-polarized TAM 
[231,232]. Finally, Courtney et al. showed that type I NKT cells were able to kill CD1d+ M2 TAM or 
polarize M2 TAM towards an M1-polarized phenotype via GM-CSF production [233]. Hence, the 
presence of TH1-like type I NKT cells might minimize the presence of tumor growth-promoting M2-
polarized TAM in the TME. On the other side, an immature tolerogenic DC subset has been described 
that produces reduced amounts of IL-12 and high amounts of IL-10, resulting in an 
immunosuppressive TME [234]. As a result, tolerogenic DC skew differentiation of naïve T cells into 
Tregs, which might lead to immune escape of tumor cells [235-237]. Since TH1-like NKT cells are able to 
fully mature DC, the presence of immature tolerogenic DC might be minimized in tumors where 
sufficient numbers of these NKT cells are present. Importantly, TH1-like NKT cells are able to stimulate 
both tumor antigen-restricted T cells that recognize tumor cells with HLA expression and effector NK 
cells that eliminate tumor cells with low or absent HLA expression [235]. In this way, immune escape 
of tumor cells might be prevented. Additionally, as discussed above, tumors have been reported to 
express CD1d on their cell membrane [195,196], and might therefore be killed in a CD1d-dependent 
manner. Besides, tumors are reported to express high cell surface densities of stress-related proteins 
that activate the NKRs NKG2D and DNAM-1 [238,239], suggesting that these cells can also be killed in 
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Figure 5. The dual role of NKT cells in cancer. During early tumor development, TH1-like NKT cells may induce an 
effective anti-tumor response via direct killing of tumor cells upon interaction with stress proteins and CD1d 
molecules, respectively. Additionally, activated TH1-like NKT cells secrete high amounts of IFN-γ, which may lead 
to generation of tumor-specific CD8+ cytotoxic T cells and rapid activation of NK cells that kill tumor cells. Besides, 
activated NKT cells can induce maturation of DC in a CD1d-dependent manner, resulting in TH1 differentiation and 
activation of tumor-specific CD8+ T cells. Finally, activated TH1-like NKT cells can kill M2-polarized TAM in a CD1d-
dependent manner, thereby preventing their tumor growth-promoting effects. During tumor progression, TH1-like 
NKT cells can become anergic and may switch to TH2-/Treg-like NKT cell subsets that facilitate tumor progression 
and immune escape. For instance, Treg-like NKT cells can promote differentiation of M2-polarized TAM and Tregs. 
Tregs inhibit tumor-specific T cells via cell-cell interactions, and secretion of IL-10 and TGF-β. Additionally, TH2-like 
NKT cells can inhibit tumor-specific T cells via production of large amounts of IL-13. TH2- and Treg-like NKT cell 
subsets might be able to kill tumor cells, either via CD1d-dependent or CD1d-independent mechanisms. However, 
overstimulated NKT cells produce large amounts of immunosuppressive cytokines, resulting in a net effect of 
immunosuppression. Receptors that are known to be involved in NKT cell-mediated anti-tumor responses are 
indicated in the figure. The functional NKT cell subsets indicated in the figure can be both type I and type II NKT 
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cells as illustrated in figure 1. Abbreviations: NKT (natural killer T), TH (helper T), NK (natural killer), DC (dendritic 
cells), TAM (tumor-associated macrophages), Treg (regulatory T), TME (tumor microenvironment), NKR (natural 
killer receptor), TCR (T cell receptor), HLA (human leukocyte antigen). 
 
 
including carcinomas, sarcomas, neuroblastomas and melanomas [240-243]. Since inhibitory NKRs 
and KIRs prevent NKT cell activation upon interaction with HLA molecules (Figure 3), NKT cells might 
be able to directly kill tumor cells with low HLA expression, similar to NK cells. NKT cells may have, 
however, primarily a regulatory function, suggesting that the anti-tumor activity mediated by direct 
killing of tumor cells is of lesser importance. 
 
Shaping the TME by TH2-/Treg-like NKT subsets 
As discussed in the previous chapter, the phenotype and function of TH1-like subsets is frequently 
altered in patients. The NKT cell population in patients is skewed towards a TH2 profile, proliferative 
impaired and, additionally, reduced in size. These data indicate many similarities with 
overstimulated/anergic NKT cells. During cancer progression, NKT cells may be exposed to chronic 
stimulation, which is known to induce anergy and skew NKT cells towards immunosuppressive 
subsets. Moreover, chronic stimulation of NKT cells activates AICD, which might explain the reduced 
NKT cell population observed in cancer patients. Based on this hypothesis, we propose that TH1-like 
NKT cells induce an effective anti-tumor response during early tumor development and perhaps 
prevent further tumor development in many cases. However, in some cases, at some point during 
tumor progression, NKT cells become overstimulated. As a result, a part of the NKT cell population is 
deleted in cancer patients via AICD. Additionally, the remaining NKT cells become hyporesponsive, or 
switch to TH2-/Treg-like NKT cell subsets, thereby facilitating tumor progression and immune escape 
(Figure 5). TH2- and Treg-like NKT cell subsets do not produce IFN-γ which is responsible for most of the 
anti-tumor effects of TH1-like NKT cells as discussed above. In contrast, TH2-/Treg-like NKT cells produce 
large amounts of IL-13 and IL-10, respectively, that suppress the TME (i.e. via fibroblasts and MDSC), 
thereby indirectly stimulating tumor progression. Additionally, Treg-like NKT cells promote 
differentiation of M2-polarized TAM and Tregs that are also able to suppress the TME via production 
of IL-10 [155,156]. In contrast to TH1-like NKT cells, TH2-like NKT cells are not capable of inducing DC 
maturation and do therefore not induce activation of tumor-specific T cells [158]. TH2-like NKT cell 
subsets further inhibit the activation of tumor-specific T cells via secretion of IL-13 [49,159,160], while 
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TH2- and Treg-like NKT cell subsets might still be able to kill tumor cells, either via CD1d-dependent or 
CD1d-independent mechanisms. However, overstimulated NKT cells produce large amounts of 
immunosuppressive cytokines, resulting in a net effect of immunosuppression. TH2- and Treg-like NKT 
cell subsets, therefore, counteract the anti-tumor effects of TH1-like NKT cells and, additionally, 
actively promote tumor progression.  
In conclusion, we discussed evidence supporting our hypothetical model (Figure 5) that TH1-
like NKT cells are responsible for initiating effective anti-tumor immune responses during early tumor 
development. When NKT cells become overstimulated and anergic due to tumor progression, a part 
of the NKT cell population is deleted in cancer patients. Additionally, the remaining NKT cells lose their 
anti-tumor function and start facilitating immune escape and tumor progression. In summary, we 
illustrated three problems regarding NKT cells in cancer patients. First, the numbers are lower 
compared to healthy individuals. Second, NKT cells are often anergic in cancer patients. Third, NKT 
cells are often skewed towards immunosuppressive TH2-like subsets. 
 
Current NKT cell-based immunotherapy for the treatment of cancer 
Because of their potential to induce effective anti-tumor responses in vivo, several NKT cell-based 
immunotherapies in humans have been developed over the past years as thoroughly reviewed by Nair 
et al. [246]. These immunotherapies primarily focused on activation and expansion of the type I NKT 
cell population.  
For instance, a phase I clinical trial was executed in which intravenous (i.v.) injections of 50–
4800 µg/m2 α-GalCer were administered to 24 patients with different solid tumors [218]. The majority 
of patients presented with reduced numbers of type I NKT cells at baseline (median 333 cells/ml PB) 
compared to healthy donors (median 1013 cells/ml PB). Following α-GalCer administration, NKT cells 
disappeared from the circulation within 24 hours. Although not investigated in details in this study, 
recovery of NKT cell numbers was not observed within a week. Furthermore, increased serum levels 
of TNF-α and GM-CSF were detected in 5 patients and increased serum IFN-γ levels were detected in 
1 patient after α-GalCer administration. A phase II trial using administration of α-GalCer was not 
executed. Additionally, clinical trials were conducted in which patients were injected with α-GalCer-
pulsed autologous DC [247-253]. These injections resulted in expansion of the type I NKT cell 
population in some patients [247-253]. For instance, Chang et al. reported >100-fold expansion of 
type I NKT cells in 5 patients upon i.v. injections with 5 x 106 α-GalCer-pulsed DC [248]. Besides NKT 
cell expansion, treatment with α-GalCer-pulsed DC also increased the systemic levels of IFN-γ in 
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patients [247-253]. Treatment did, however, not result in a clinical tumor response in the majority of 
patients [247-253]. In addition, a phase II study reported stable disease in 5/17 patients with non-
small cell lung cancer (NSCL) upon i.v. administration of α-GalCer-pulsed IL-2/GM-CSF-cultured PBMC 
(1 x 109 cells/m2) [252]. Patients with increased IFN-γ producing TH1-like type I NKT cells after 
treatment showed a prolonged median survival time compared to non-responsive patients. These 
data indeed indicate a crucial role for TH1-like type I NKT cells in anti-tumor immune responses and 
emphasize the essential need for expansion of this NKT cell population in cancer patients. Hence, 
immunotherapeutic approaches focused on skewing NKT cells towards an TH1 profile should be 
developed. 
In later clinical trials, ex vivo-activated type I NKT cells were adoptively transferred to 
patients diagnosed with NSCL, advanced melanoma or head and neck squamous cell carcinoma, in 
some cases in combination with α-GalCer-pulsed APC [254-257]. In this therapy, PBMC obtained from 
the patient, i.e. by leukapheresis, were cultured in the presence of IL-2 and α-GalCer to facilitate 
proliferation and activation of the type I NKT cell population. Thereafter, the ex vivo-activated type I 
NKT cells were administered to the patients. Phase I and II clinical trials were conducted in which 
patients with head and neck carcinomas received nasal submucosal injections of 1 x 108 α-GalCer-
pulsed APC, in combination with intra-arterial infusion of 5 x 107 ex vivo-activated autologous type I 
NKT cells via tumor-feeding arteries [256,257]. Tumor regression and stable disease were reported in 
10/10 of these patients [256]. These clinical responses did, however, not correlate with the induction 
of immunological responses in blood (i.e. increase in type I NKT cell numbers and/or IFN-γ-producing 
type I NKT cells and NK cells). Additionally, ex-vivo-activated type I NKT cells were adoptively 
transferred to patients diagnosed with advanced or recurrent NSCL (1 x 107/m2 or 5 x 107/m2 NKT cells 
per infusion) or advanced melanoma (~4 x 106 – ~2 x 108 NKT cells per infusion) in phase I clinical trials 
[254,255]. Treatment was well-tolerated and resulted in stable disease in 2/9 NSCL patients and 3/9 
patients with advanced melanoma, respectively. However, the majority of patients developed 
progressive disease. This might be due to the fact that the numbers of administered ex vivo-activated 
autologous type I NKT cells were too low in comparison to the tumor load. Obtaining sufficient 
numbers of type I NKT cells might be a major challenge since type I NKT cell numbers are low in 
general, and especially in patients with cancer.  
Recently, studies focused on increasing the specificity of NKT cells by transducing them with 
chimeric antigen receptors (CARs) that are not HLA- or CD1d-restricted [58,70,258]. Additionally, α-
GalCer/CD1d-antitumor fusion proteins were suggested as a treatment for cancer patients. For 
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antigens induced potent anti-tumor activity in vitro and in vivo [259,260]. Recently, Horn et al. showed 
that CD3xPD-L1 Bi-specific T cell engagers (BiTEs) activated both T cells and NKT cells to kill PD-L1+ 
tumor cells in vitro [261]. Another strategy that was suggested for treatment of patients with solid 
tumors is vaccination with NKT-activating agents in combination with tumor antigens. For instance, a 
phase I study showed detectable NKT cell activity in patients with high-risk melanoma upon treatment 
with cancer/testis (CA) antigen-loaded DC in combination with α-GalCer [262]. However, in our 
opinion, increasing the specificity of NKT cells is not the most promising method of increasing the 
effectiveness of NKT-based immunotherapies. The strength of NKT cells does not rest in their cytotoxic 
capacities, but in their regulatory function. When the appropriate subsets are activated (i.e. TH1-like 
NKT cells), NKT cells might shift the tolerogenic and immunosuppressive state of both innate and 
adaptive cells towards anti-tumor activity. Therefore, instead of increasing the specificity of NKT cells, 
immunotherapies should focus on the most important function of NKT cells, their regulatory function. 
In conclusion, several NKT cell-based immunotherapies have been tested in clinical trials. To 
date, a beneficial effect in a minority of cancer patients has been reported. These clinical trials were 
mainly based on the activation and expansion of type I NKT cells with α-GalCer. As addressed in our 
hypothetical model (Figure 5), NKT cells may switch to immunosuppressive functional subsets or 
become anergic due to chronic stimulation during cancer progression which might explain the 
absence of beneficial clinical responses in patients upon treatment with α-GalCer. We propose that it 
is essential to prevent and break NKT cell anergy in cancer patients, and skew NKT cells in cancer 
patients towards TH1-like subsets with anti-tumor activity in addition to expansion of the NKT cell 
population. 
 
Focus of future NKT cell-based immunotherapies 
In this review, we discussed the role of NKT cells in cancer and conclude that NKT cells play a central 
role in anti-cancer treatment due to their important regulatory function. In order to improve NKT cell-
based immunotherapies for treatment of cancer patients, several aspects of the current treatment 
strategies need further attention. 
 
Expansion of the NKT cell population 
TH1-like NKT cells (either type I or type II) have the potential to induce effective anti-tumor responses. 
Combined with the fact that their numbers are decreased in cancer patients, it is essential to expand 
this cell population in patients. For instance, induced pluripotent stem cells (iPSCs) might be used to 
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expand the numbers of autologous NKT cells in patients ex vivo [263-265]. Furthermore, culturing 
methods aiming at obtaining high numbers of NKT cells must be optimized. At the moment, according 
to the Clinical Trials registry, multiple clinical trials (Available at: 
https://clinicaltrials.gov/ct2/show/NCT02562963, https://clinicaltrials.gov/ct2/show/NCT03198923, 
https://clinicaltrials.gov/ct2/show/NCT01801852) are ongoing that study the safety and clinical 
efficacy of adoptive type I NKT cell transfer in patients with solid tumors. As discussed in this review, 
this infusion should be accompanied by a protocol that prevents induction of NKT cell anergy and 
generation of immunosuppressive NKT cell subsets.  
 
Prevention and breaking of NKT cell anergy 
Until now, only a limited number of studies focused on prevention or breaking of NKT cell anergy. 
Parekh et al. showed that blockade of the interaction between PD-1 and its ligands prevented the 
induction of type I NKT cell anergy in vivo [266]. Blockade of the PD-1/PD-L1 axis was, however, unable 
to reverse established NKT cell anergy [266,267]. Additionally, in vitro and in vivo studies showed that 
stimulation of type I NKT cells with IL-2 overcomes anergy and restores their capacity to proliferate 
[145,147]. The proliferative capacity of patient-derived type I NKT cells was also reported to increase 
upon COX-2 inhibition or culture with G-CSF [223,268]. It might, therefore, be an option to treat 
patients with a combination of anti-PD-1 antibody, such as nivolumab, combined with IL-2/G-CSF or 
COX-2 inhibition in order to prevent and reverse NKT cell anergy. 
 
Skewing of NKT cells towards TH1-like subsets 
NKT cells in which anergy was reversed retained their TH2-biased cytokine profile upon IL-2 stimulation 
and did not change back towards a TH1-like subset with anti-tumor activity [147]. It is therefore also 
necessary to use agents that are able to skew the cytokine profile of activated NKT cells towards a TH1 
profile, which means a change in functional subset. For instance, culturing of patient-derived TH2-
biased type I NKT cells with IL-12 resulted in IFN-γ production of these cells in response to α-GalCer in 
vitro [220]. Additionally, Laurent et al. showed that chemical modification of the α-GalCer compound 
was able to increase TH1-associated cytokine production by activated type I NKT cells, whereas 
stimulation of type I NKT cells with conventional α-GalCer resulted in production of both TH1- and TH2-
associated cytokines [269]. Other synthetic agonists have also been described that induce a TH1-
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cell activating agents in cancer patients might skew the cytokine profile of NKT cells towards a TH1 
profile while simultaneously preventing the induction of anergy. 
 
Concluding remarks 
Due to their important regulatory function, NKT cells are promising candidates for immunotherapies 
in patients diagnosed with cancer. However, NKT cell-based immunotherapies that focus on activating 
NKT cells have resulted in beneficial clinical responses in a minority of patients so far. In this review, 
we illustrated a hypothetical model regarding the role of NKT cells in solid tumors based on their 
function and phenotype. During early tumor development, TH1-like NKT cell subsets have the potential 
to initiate effective anti-tumor immune responses against tumors. However, when NKT cells become 
overstimulated and anergic during tumor progression, they lose their anti-tumor function and start 
facilitating immune escape. The role of NKT cells in cancer might therefore be more dynamic than 
initially thought. So far, studies have primarily focused on methods to activate and expand the type I 
NKT cell population in patients, but the contribution of functionally altered NKT cells to the failure of 
NKT cell-based immunotherapies has been largely ignored. In this review, we conclude that there 
should be three important focuses of future research in cancer patients: (1) expansion of the NKT cell 
population, (2) prevention and breaking of NKT cell anergy, and (3) skewing of NKT cells towards TH1-
like subsets with anti-tumor activity.  
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Objective: As the development and progression of colorectal cancer (CRC) are known to be affected 
by the immune system, cell subsets such as T cells, natural killer (NK) cells, and natural killer T (NKT) 
cells are considered interesting targets for immunotherapy- and clinical biomarker research. Until 
now, the role of systemic immune profiles in tumor progression remains unclear. In this study, we 
aimed to characterize the immunophenotype of circulating T cells, NK cells, and NKT-like cells in 
patients with CRC, and to subsequently correlate these immunophenotypes to clinical follow-up data.  
 
Methods: Using multiparameter flow cytometry, the subset distribution and immunophenotype of T 
cells (CD3+CD56-), CD56dim NK cells (CD3-CD56dim), CD56bright NK cells (CD3-CD56bright), and NKT-like 
(CD3+CD56+) cells were investigated in peripheral blood mononuclear cell (PBMC) samples from 71 
CRC patients and 19 healthy donors.  
 
Results: CRC patients showed profound differences in immune cell subset distribution and their 
immunophenotype compared to healthy donors, as characterized by increased percentage of 
regulatory T cells, and reduced expression level of the natural cytotoxicity receptors NKp44 and NKp46 
on both CD56dim NK cells and NKT-like cells. Finally, we showed in a multivariate analysis that above 
median percentage of CD16+ NKT-like cells was independently associated with shorter disease-free 
survival in CRC patients.  
 
Conclusion: The altered phenotype of circulating immune cell subsets in CRC and its association with 
clinical outcome highlight the potential use of PBMC subsets as prognostic biomarkers in CRC, thereby 








Colorectal cancer (CRC) is a major contributor to cancer-related morbidity and mortality [1]. 
Approximately one million new cases of CRC arise per year throughout the world, with more than half 
a million deaths annually [1]. For colorectal tumors that have not spread to distant sites, surgery is 
the primary treatment [2]. However, around 25% of the patients present with unresectable metastatic 
disease at the time of diagnosis, and up to 50% percent of early stage patients develop recurrence or 
dissemination of the disease following surgery [3]. In order to reduce the risk of relapse and to prolong 
the survival of patients with metastatic disease, treatment strategies need to be optimized. Therefore, 
biomarker application is important since it provides information for therapeutic decision making. As 
the development and progression of CRC are known to be affected by the immune system, cell subsets 
such as T cells, natural killer (NK) cells, and natural killer T (NKT) cells are considered interesting targets 
for immunotherapy- and clinical biomarker research. Importantly, the phenotype of circulating 
lymphocyte subsets may reflect the local immune response in the tumor microenvironment (TME), 
thereby providing potentially important information regarding disease progression in CRC [4-6].  
Different T cell subsets have been described over the years, each with distinct functions that 
promote, or inhibit, anti-tumor immune responses. For instance, cytotoxic (CD8+) T cells recognize 
tumor-associated antigens presented by classical HLA class I molecules. Additionally, CD4+ T cells play 
an important regulatory role via secretion of cytokines and activation of cytotoxic T cells and B cells 
[7]. Regulatory T cells (Treg), a subpopulation of CD4+ T cells, have an immunosuppressive function [8]. 
In order to escape immune recognition by cytotoxic T cells, tumor cells may down-regulate classical 
HLA class I expression [9]. Studies showed that aberrant HLA class I expression commonly occurs in 
colorectal tumors [10-14]. These tumors represent potential targets for NK cells [15], which are known 
to be able to recognize and kill tumor cells with down-regulated HLA class I molecules [16,17].  
NK cells can be subdivided based on their CD56 expression: CD56bright NK cells are generally 
associated with immunoregulatory properties and production of pro-inflammatory cytokines, while 
CD56dim NK cells primarily exert cytotoxic functions [18,19]. The NK cell activity is dependent on a 
delicate balance between activating and inhibitory signals from cell surface receptors [20]. The 
activating signals are mediated by a wide array of receptors including natural killer group 2-C (NKG2C), 
natural killer group 2-D (NKG2D), DNAX accessory molecule-1 (DNAM-1), CD161, and natural 
cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46. Additionally, CD16 (FcγRIII) on NK cells 
mediates antibody-dependent cell-mediated cytotoxicity (ADCC) [21]. Furthermore, CD8 is considered 
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express a range of receptors that provide inhibitory signals upon stimulation. NK cell inhibitory 
receptors include natural killer group 2-A (NKG2A), and killer cell immunoglobulin (Ig)-like receptors 
CD158a and CD158b.  
Apart from NK- and T cells, peripheral blood comprises other leucocyte subsets with the 
ability to induce anti-tumor effects. For instance, NKT cells constitute a unique subset of T cells that 
lie at the interface between innate and adaptive immunity. Unlike conventional T cells, NKT cells 
express a T cell receptor that recognizes glycolipids presented by the HLA-like molecule CD1d [23]. 
Besides, NKT cells express various markers typically associated with NK cells (activating- and inhibitory 
cell surface receptors) [24]. NKT cells possess cytotoxic capabilities, but are primarily considered to 
have an important regulatory function via the secretion of large amounts of pro- or anti-inflammatory 
cytokines upon activation, thereby resulting in amplification or dampening of the immune response 
[25]. Due to a lack of specific markers, it is not possible as yet to identify the entire NKT cell population 
using flow cytometry or immunohistochemistry [25]. In many studies, co-expression of CD3 and CD56 
is used to identify NKT cells [26-31]. Although it is likely that the CD3+CD56+ cell population includes 
“true” CD1d-restricted NKT cells, it has to be taken into account that conventional T cells have also 
been reported to express CD56 [32,33]. Thus, since it is unclear whether all CD3+CD56+ cells are CD1d 
restricted, this population is often referred to as “NKT-like”.  
In this study, we aimed to characterize the immunophenotype of circulating T cells, NK cells, 
and NKT-like cells in CRC patients using multiparameter flow cytometry, and to subsequently correlate 
these immunophenotypes to clinical follow-up data.  
 
Materials and methods 
Study population 
The study population comprised patients diagnosed with CRC who underwent surgical resection of 
their colorectal tumor at the Leiden University Medical Center (LUMC, the Netherlands) between 2001 
and 2007. From these patients, peripheral blood samples were collected within a month prior to 
surgery. In the present study, patients with histologically proven primary colorectal tumors, Tumor-
Node-Metastasis (TNM) stage 0-IV, surgical R0 resection, and a minimal amount of 5 million 
cryopreserved peripheral blood mononuclear cells (PBMCs) were included (N=87). Patients with 
multiple colorectal tumors at the time of diagnosis or resection were excluded. Patient follow-up was 
performed until August 2017, with a median follow-up time of 12 years (range 0.1-15.8 years). 
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Peripheral blood samples obtained from 19 healthy donors (Dept. of Hematology, LUMC) served as 
controls.  
 
Isolation of peripheral blood mononuclear cells 
PBMCs were isolated by Ficoll-Paque (density 1.077g/ml, provided by the apothecary LUMC) density-
gradient centrifugation. All PBMC samples were cryopreserved in liquid nitrogen until time of analysis 
in freezing medium containing 20% heat-inactivated FCS (Thermo Fisher Scientific, Waltham, MA, 
USA) and 10% DMSO (Avantor, Center Valley, PA, USA). Additionally, PBMCs were isolated from the 
buffy coat of a healthy donor obtained from the Blood Bank at Aarhus University Hospital (Dept. 
Clinical Immunology, Aarhus University Hospital, Skejby, Denmark) which was used as an internal 
control in the flow cytometry experiments. After isolation using Histopaque (Sigma-Aldrich, St. Louis, 
MO, USA) density-gradient centrifugation, these PBMCs were cryopreserved at -150°C until time of 
use in RPMI-1640 medium (Lonza, Basel, Switzerland) containing 20% heat-inactivated FCS (GE 
Healthcare, Little Chalfont, United Kingdom), and 10% DMSO (Sigma-Aldrich). 
 
Flow cytometry antibody staining 
Extensive immunophenotyping of circulating T cells, NK cells, and NKT-like cells was performed using 
multiparameter flow cytometry with directly fluorochrome-conjugated mouse mAb (Supplementary 
Table 1). Briefly, PBMCs were thawed at 37°C, washed in PBS (Lonza)/10% FCS (GE Healthcare), and 
cell count was determined using a NucleoCounter®NC-250™ (ChemoMetec, Allerod, Denmark) 
according to the manufacturer’s instructions. PBMCs were adjusted to a concentration of 10x106 
cells/ml and blocked for non-specific Ab binding in PBS/0.5% BSA (Merck Millipore, Billerica, MA, 
USA)/0.09% sodium azide buffer (Ampliqon, Odense, Denmark) with 5% human AB serum (from a 
batch of healthy donors obtained from the Blood Bank at Aarhus University Hospital) or 50 μg/ml 
human Ig (Human Ig, CSL Behring, Bern, Switzerland) for 15 minutes. Three multicolor flow cytometry 
panels were designed for the identification of circulating T cells, NK cells, and NKT-like cells 
(Supplementary Table 1). For each flow panel, a cocktail of Ab was prepared in BD brilliant stain buffer 
(BD Biosciences) in order to prevent aggregation of brilliant violet fluorochromes. PBMCs (0.5x106 
cells) were incubated with the antibody cocktails in the dark for 30 min at room temperature (flow 
panel 1 and 2) or at 4°C (flow panel 3), as these conditions provided optimal binding for the included 
Ab in each panel. To exclude dead cells from the analysis, a live/dead fixable near-infrared dead cell 
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the Ab cocktails, the cells were washed twice in PBS/0.5% BSA/0.09% sodium azide buffer. Next, 
PBMCs were fixed in PBS/0.9% formaldehyde (Sigma-Aldrich) before analysis.  
 
Flow cytometry data analysis 
Samples were analyzed immediately after staining on the LSR Fortessa (BD Biosciences) flow 
cytometer running FACSDivaTM software version 8.0 (BD Biosciences). The data set was analyzed using 
FlowJo software version 10.1 (Tree Star Inc., Ashland, OR, USA). In each experiment, PBMCs derived 
from the same buffy coat (described above) were included as an internal control. Instrument 
performance was verified daily using the Cytometer Setup & Tracking (CS&T) system (BD Biosciences), 
applying CS&T application settings to ensure comparable flow cytometry results over time. 
Compensation was carried out with CompBeads (BD Biosciences), OneComp eBeads (eBioscience, Inc., 
San Diego, CA), CompBeads Plus (BD Biosciences), and ArC reactive beads (Life Technologies) 
according to the manufacturer’s protocol. The threshold for positive staining was determined using 
unstained- or fluorescence minus one (FMO) controls when necessary [34,35]. FMO controls were 
used for CD56, CD158a, and NKG2A in flow panel 1. Since there was no spectral overlap between the 
fluorochromes brilliant violet 711 (CD158a) and allophycocyanin (NKG2A), FMO controls for CD158a 
and NKG2A were combined in a fluorescence minus two (FM2) control following proper verification. 
Furthermore, an FMO control for CD56 in flow panel 2 was included. To identify circulating T cells, NK 
cells, and NKT-like cells, a sequential gating strategy for each flow panel was created based on the 
buffy coat internal control sample (Supplementary Figure 1, 2, and 3). The expression of phenotypic 
markers on circulating T cells, NK cells and NKT-like cells was then evaluated by the median 
fluorescence intensity (MFI) and/or the percentage of positive cells. The markers CD3, CD14 and CD56 
were strictly used for gating and not studied in further detail. 
 
Corrections and statistical analyses 
The NKG2A antibody was changed regarding isotype and clone during the flow cytometry experiments 
due to low quality of a newly ordered Ab batch. The internal control buffy coat was used to correct 
for differences in the MFI and percentage of positive lymphocytes regarding NKG2A between the two 
used Ab clones. Statistical analyses were conducted using SPSS statistical software (IBM SPSS Statistics 
23, Chicago, USA). The Mann-Whitney U test was used to compare the age of the CRC patients with 
the healthy donors. The sex of CRC patients was compared with healthy donors using a Pearson Chi-
square test. Additionally, independent samples T tests and Mann-Whitney U tests, where appropriate, 
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were used in order to compare patients with healthy donors and to evaluate differences in patient 
and tumor characteristics. Furthermore, the Spearman correlation test was used to study the relation 
of phenotypic markers on different immune cell subsets. Throughout the text, the median 
percentages or MFI are reported including standard deviations (SD). Kaplan-Meier analyses and Log-
rank tests were used to investigate and compare survival within patient subgroups. Our primary 
clinical endpoint was disease-free survival (DFS), which was defined as the time from surgery until 
recurrence of disease or death, whichever came first, or end of follow-up (censored). Cox regression 
analysis was used for univariate and multivariate analyses for DFS. We corrected for multiple testing 
using the Benjamini-Hochberg method, by which adjusted P-values were calculated (indicated by P*) 




In total, flow cytometry data of 71/87 (81.6%) CRC patients could be included in the analysis. Eight 
samples were excluded due to low viability of the PBMCs (<50% viable cells). Additionally, samples 
from two patients were obtained prior to resection of liver metastases instead of the primary 
colorectal tumor and, therefore, also excluded from further analysis. Furthermore, four patients were 
excluded from this study due to a confirmed diagnosis of Lynch syndrome. Finally, two patients were 
excluded due to pre-surgical chemotherapy before sample collection. Eleven patients included in the 
study had undergone local radiotherapy prior to the collection of the blood sample. Since local 
radiotherapy is unlikely to affect the immune system systemically, these patients were not excluded 
from this study. Table 1 summarizes the clinico-pathological characteristics of the 71 CRC patients 
included in the analyses, together with 19 healthy donors. When comparing the CRC patients with the 
healthy donors, no significant difference was observed in relation to sex (Table 1). A trend was 
observed towards a higher age in the CRC patients compared to the healthy donors, which was not 
statistically significant (Table 1). Flow cytometry panels 1 and 2 (NK cells and NKT-like cells) were 
investigated in all included 71 CRC patients and 19 healthy donors. Flow cytometry panel 3 (T cells) 
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the healthy donors. The sex of CRC patients was compared with healthy donors using a Pearson Chi-
square test. Additionally, independent samples T tests and Mann-Whitney U tests, where appropriate, 
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were used in order to compare patients with healthy donors and to evaluate differences in patient 
and tumor characteristics. Furthermore, the Spearman correlation test was used to study the relation 
of phenotypic markers on different immune cell subsets. Throughout the text, the median 
percentages or MFI are reported including standard deviations (SD). Kaplan-Meier analyses and Log-
rank tests were used to investigate and compare survival within patient subgroups. Our primary 
clinical endpoint was disease-free survival (DFS), which was defined as the time from surgery until 
recurrence of disease or death, whichever came first, or end of follow-up (censored). Cox regression 
analysis was used for univariate and multivariate analyses for DFS. We corrected for multiple testing 
using the Benjamini-Hochberg method, by which adjusted P-values were calculated (indicated by P*) 
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samples were excluded due to low viability of the PBMCs (<50% viable cells). Additionally, samples 
from two patients were obtained prior to resection of liver metastases instead of the primary 
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statistically significant (Table 1). Flow cytometry panels 1 and 2 (NK cells and NKT-like cells) were 
investigated in all included 71 CRC patients and 19 healthy donors. Flow cytometry panel 3 (T cells) 






Table 1. Patient demographics and tumor characteristics. In this study, the immunophenotype of peripheral blood 
immune cell profiles was investigated in 71 CRC patients and 19 healthy donors.  
  CRC patients Healthy donors  
  (N=71) (N=19) P-value 
Age*     0.059 
Mean (years) 65.6 55.6  
Range (years) 25-85 22-83   
Sex     0.557 
Female  32 (45.1%) 10 (52.6%)  
Male 39 (54.9%) 9   (47.4%)   
Tumor location       
Colon 59 (83.1%)   
Rectum 12 (16.9%)     
TNM classification       
Stage 0 4   (5.6%)   
Stage I 10 (14.1%)   
Stage II 22 (35.2%)   
Stage III 22 (33.8%)   
Stage IV 8   (11.3%)     
Tumor differentiation       
Well/moderate 55 (77.5%)   
Poor 13 (18.3%)   
Unknown 3   (4.2%)     
Tumor-positive lymph nodes       
Yes 30 (56.3%)   
No 40 (42.3%)   
Unknown 1   (1.4%)     
Neoadjuvant radiotherapy       
Yes 10 (14.1%)   
No 61 (85.9%)     
Adjuvant chemotherapy       
Yes 27 (38.0%)   
No 44 (62.0%)     
*Age at time of surgery 
 
 
Increased percentage of circulating regulatory T cells in colorectal cancer patients compared 
to healthy donors 
In this study, we compared the immunophenotype of circulating T cells (CD3+CD56-), NK cells (CD3-
CD56+), and NKT-like cells (CD3+CD56+) between CRC patients and healthy donors. First of all, the 
distribution of the different immune cell subsets was studied (Table 2). We hypothesized that CRC 
patients would present with a general immunocompromised state of circulating immune cells, 
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reflected by a shift in the balance between cytotoxic and regulatory cell subsets. Similar proportions 
of circulating T cells (P*=0.883), NK cells (P*=0.768), and NKT-like cells (P*=0.904) (% of total 
lymphocytes) were observed in CRC patients and healthy donors (Figure 1A;1E;1H respectively). 
Furthermore, no differences were observed in the distribution of circulating CD8+ (P*=0.670) and CD4+ 
(P*=0.689) T cells (% of T cells) or distribution of circulating CD56dim (P*=0.197) and CD56bright 
(P*=0.196) NK cell populations (% of NK cells) (Figure 1B;1C;1F;1G respectively). In contrast, CRC 
patients presented with an increased percentage of circulating CD127lowCD25+ Treg (P*<0.001) (% of 
CD3+CD4+ T cells) (Figure 1D) compared to healthy donors. 
 
 
Table 2. Comparison between peripheral blood immune cell profiles in CRC patients and healthy donors. The 
distribution of circulating immune cell subsets and their immunophenotype was compared between CRC patients 
(N=71) and healthy donors (N=19). P-values were corrected for multiple testing using the Benjamini-Hochberg 
method, by which adjusted P-values were calculated (indicated by P*). P*-values ≤0.05 were considered 
statistically significant and are indicated in bold. 
  Healthy controls (N=19) CRC patients (N=71)   
  Mean SD Mean SD P-value Corrected P*-value 
Subset distribution            
T cells (%)* 59.4 8.2 57.5 13.2 0.669T 0.883 
  CD8+ T cells (%)* 20.7 8.3 18.7 10.4 0.378U 0.670 
  CD4+ T cells (%)* 42.1 6.1 44.3 12.2 0.400T 0.689 
    CD127lowCD25+ Treg (%)* 5.5 0.5 7.7 2.4 0.000U 0.000 
NK cells (%) 12.8 5.4 15.4 8.5 0.508U 0.768 
  CD56dim NK cells (%) 93.4 4.2 95.0 4.2 0.054U 0.197 
  CD56bright NK cells (%) 6.6 4.2 5.1 4.2 0.057U 0.196 
NKT-like cells (%) 4.3 2.8 6.1 6.4 0.656U 0.904 
CD56dim NK cells           
CD16+ (%) 85.3 6.1 83.7 10.2 0.909U 0.989 
CD158a+ (%) 35.2 17.1 31.9 16.9 0.477U 0.739 
CD158b+ (%) 37.0 11.4 37.5 14.7 0.786U 0.937 
NKG2A+ (%) 45.6 19.3 43.4 19.0 0.656T 0.884 
NKG2A+ (MFI) 6398 2138 7368 2459 0.275U 0.533 
NKG2C+ (%) 13.7 13.0 16.2 17.9 0.909U 0.972 
NKG2C+ (MFI) 2506 2797 2965 3094 0.213U 0.440 
CD161 (MFI) 3111 804 3057 1130 0.816T 0.903 
CD8+ (%) 34.3 14.3 31.5 14.4 0.467U 0.742 
CD8+ (MFI) 3481 774 3067 1159 0.067U 0.208 
DNAM-1 (MFI) 560 106 548 146 0.741T 0.919 
NKG2D+ (%) 89.9 4.4 91.4 4.9 0.134U 0.346 
NKG2D+ (MFI) 3600 1108 3429 1113 0.554T 0.818 
NKp30 (MFI) 1960 752 1630 900 0.052U 0.202 
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Table 1. continued 
  Healthy controls (N=19) CRC patients (N=71)   
  Mean SD Mean SD P-value Corrected P*-value 
NKp44 (MFI) 131 13 115 26 0.002U 0.041 
NKp46+ (%) 48.7 18.0 34.7 16.9 0.002T 0.031 
NKp46 (MFI) 732 345 478 271 0.003U 0.031 
CD56bright NK cells            
CD16+ (%) 3.0 2.8 2.5 1.8 0.415U 0.695 
CD158a+ (%) 6.6 4.2 7.0 4.8 0.793U 0.928 
CD158b+ (%) 6.4 3.0 8.6 5.5 0.097U 0.273 
NKG2A+ (%) 6.6 4.6 4.5 3.3 0.044U 0.210 
NKG2A+ (MFI) 17020 7986 19052 5829 0.165 U 0.365 
NKG2C+ (%) 1.9 2.2 1.2 1.1 0.145U 0.333 
NKG2C+ (MFI) 1760 967 3038 3831 0.017U 0.105 
CD161 (MFI) 2128 568 1767 578 0.012U 0.093 
CD8+ (%) 2.4 1.6 1.8 1.7 0.044U 0.195 
CD8+ (MFI) 2951 886 3098 1318 0.945U 0.977 
DNAM-1 (MFI) 765 130 782 161 0.675T 0.872 
NKG2D+ (%) 6.2 4.1 4.7 3.7 0.062U 0.202 
NKG2D+ (MFI) 5321 1354 6210 1837 0.037U 0.191 
NKp30 (MFI) 2145 418 2413 769 0.048T 0.198 
NKp44+ (%) 2.0 1.5 1.3 1.2 0.024U 0.135 
NKp44 (MFI) 252 49 236 78 0.099U 0.267 
NKp46+ (%) 86.1 8.1 80.7 14.3 0.135U 0.322 
NKp46 (MFI) 2343 613 2090 812 0.211T 0.451 
NKT-like cells            
CD16+ (%) 35.6 17.6 24.6 13.7 0.013U 0.090 
CD158a+ (%) 12.0 12.9 9.4 9.8 0.957U 0.973 
CD158b+ (%) 18.8 19.2 19.2 19.2 0.793U 0.910 
NKG2A+ (%) 31.9 25.4 28.3 21.0 0.692U 0.876 
NKG2A+ (MFI) 4529 4416 3444 3757 0.604U 0.851 
NKG2C+ (%) 15.0 15.6 14.2 13.3 0.909U 0.955 
NKG2C+ (MFI) 2308 2256 3205 3300 0.283U 0.532 
CD161 (MFI) 4509 4407 4445 5434 0.452U 0.737 
CD8+ (%) 64.1 16.9 70.4 17.9 0.134U 0.332 
CD8+ (MFI) 11870 6011 11673 5556 0.968U 0.968 
DNAM-1 (MFI) 847 211 766 279 0.238T 0.476 
NKG2D+ (%) 85.4 14.5 88.6 10.7 0.345U 0.629 
NKG2D+ (MFI) 4730 1589 4995 2041 0.602T 0.868 
NKp30 (MFI) 217 70.1 250 136 0.797U 0.898 
NKp44+ (%) 1.4 1.0 1.4 1.2 0.774U 0.941 
NKp44 (MFI) 134 17 120 33 0.002U 0.025 
NKp46+ (%) 5.4 1.9 4.6 2.8 0.011U 0.097 
NKp46 (MFI) 112 53 61 47 0.000U 0.000 
* T cells were investigated in 10 healthy donors and 47 CRC patients 
T Independent samples T test 
U Mann-Whitney U test 




Figure 1. The peripheral blood immune cell subset distribution in CRC patients compared to healthy donors. The 
distribution of circulating immune cell subsets was compared between CRC patients (grey dots) and healthy donors 
(black dots). A. The total percentage of T cells (% CD3+CD56- cells of total lymphocytes). B. Percentage of CD8+ T 
cells (% of total T cells). C. Percentage of CD4+ T cells (% of total T cells). D. Percentage of Treg (% of CD3+CD4+ T 
cells). E. The total percentage of NK cells (% CD3-CD56+ cells of total lymphocytes). F. Percentage of CD56dim NK 
cells (% of total NK cells). G. Percentage of CD56bright NK cells (% of total NK cells). H. The total percentage of NKT-
like cells (% CD3+CD56+ cells of total lymphocytes). The bars show median percentage of the respective immune 
cell subset including 95% CI. 
 
 
Reduced expression of natural cytotoxicity receptors on circulating CD56dim NK cells and NKT-
like cells from colorectal cancer patients compared to healthy donors 
We subsequently evaluated the immunophenotype of circulating NK cells and NKT-like cells in CRC 
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Figure 1. The peripheral blood immune cell subset distribution in CRC patients compared to healthy donors. The 
distribution of circulating immune cell subsets was compared between CRC patients (grey dots) and healthy donors 
(black dots). A. The total percentage of T cells (% CD3+CD56- cells of total lymphocytes). B. Percentage of CD8+ T 
cells (% of total T cells). C. Percentage of CD4+ T cells (% of total T cells). D. Percentage of Treg (% of CD3+CD4+ T 
cells). E. The total percentage of NK cells (% CD3-CD56+ cells of total lymphocytes). F. Percentage of CD56dim NK 
cells (% of total NK cells). G. Percentage of CD56bright NK cells (% of total NK cells). H. The total percentage of NKT-
like cells (% CD3+CD56+ cells of total lymphocytes). The bars show median percentage of the respective immune 
cell subset including 95% CI. 
 
 
Reduced expression of natural cytotoxicity receptors on circulating CD56dim NK cells and NKT-
like cells from colorectal cancer patients compared to healthy donors 
We subsequently evaluated the immunophenotype of circulating NK cells and NKT-like cells in CRC 




cell subset and NKT-like subset were comparable between CRC patients and healthy donors (P*=0.239 
and P*=0.941, respectively) (Figure 2A;2B). In contrast, the expression level (MFI) of NKp44 was 
decreased in CRC patients on both CD56dim NK cells (P*=0.041) and NKT-like cells (P*=0.025) compared 
to healthy donors (Figure 2D;2E). Interestingly, the presence (P=0.013) and expression (P<0.001) of 
NKp44 on CD56dim NK cells and NKT-like cells strongly correlated (Figure 2C;2F). Hence, patients with 
a low percentage positive cells or expression level of NKp44 for CD56dim NK cells also had a low 
percentage positive cells or expression level of NKp44 for NKT-like cells and the other way around. 
Additionally, we observed a decreased percentage of NKp46+ cells within the CD56dim NK cell subset  
compared to healthy donors (P*=0.031) (Figure 2G), whereas in the NKT-like cell population, no 
statistically significant difference was found, only a trend (P*=0.097) (Figure 2H). In contrast to NKp44, 
the percentage NKp46+ cells did not correlate (only a trend) between CD56dim NK cells and NKT-like 
cells (P=0.098) (Fig. 2i). Furthermore, the expression level of NKp46 was decreased on both CD56dim 
NK cells (P*=0.031) and NKT-like cells (P*<0.001) in CRC patients compared to healthy donors (Figure 
2J;2K). Expression level of NKp46 strongly correlated on CD56dim NK cells and NKT-like cells (P=0.004) 
(Figure 2L). In contrast to the CD56dim NK cell and NKT-like cell populations, the percentage positive 
cells and expression level of NKp44 and NKp46 were not decreased in the CD56bright NK cell population 
(Table 2). No differences in other phenotypic markers were observed related to NK cells or NKT-like 
cells between CRC patients and healthy donors (Table 2).  
 
No correlation between distribution of immune cell subsets and immunophenotype of 
circulating lymphocytes and tumor characteristics 
After discovering different peripheral blood immune cell profiles in CRC patients compared to healthy 
donors, the relationship with disease stage was investigated. The course of tumor progression entails 
a series of stages that ultimately leads to the formation of metastases in distant organs. It is 
hypothesized that the systemic immune system is activated during tumor progression in CRC upon 
disruption of the basal membrane located underneath the intestinal epithelium which allows tumor 
cells to grow into surrounding tissue and to enter blood vessels. As such, CRC patients were subdivided 
according to their TNM at the time of diagnosis into patients without disruption of the basal 
membrane (stage 0/I, N=13), and patients with disruption of the basal membrane (stage II/III/IV, 
N=58). No differences were observed in the distribution of immune cell subsets or their 
immunophenotype between CRC patients with or without disruption of the basal membrane. 
Furthermore, we did not observe any correlation between the immune cell subset distribution or  




Figure 2. The peripheral blood immunophenotype of CD56dim NK cells and NKT-like cells in CRC patients compared 
to healthy donors. The peripheral blood immune cell profile was compared between CRC patients (grey dots) and 
healthy donors (black dots). A. The percentage of NKp44+ CD56dim NK cells. B. Percentage of NKp44+ NKT-like cells. 
C. Correlation between the percentage of NKp44+ CD56dim NK cells and NKT-like cells. D. Expression level of NKp44 
on CD56dim NK cells. E. Expression level of NKp44 on NKT-like cells. F. Correlation between expression level of 
NKp44 on CD56dim NK cells and NKT-like cells. G. Percentage of NKp46+ CD56dim NK cells. H. Percentage of NKp46+ 
NKT-like cells. I. Correlation between the percentage of NKp46+ CD56dim NK cells and NKT-like cells. J. Expression 
level of NKp46 on CD56dim NK cells K. Expression level of NKp46 on NKT-like cells. L. Correlation between expression 
level of NKp46 on CD56dim NK cells and NKT-like cells. The bars show median percentage or expression level of the 






cell subset and NKT-like subset were comparable between CRC patients and healthy donors (P*=0.239 
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Figure 2. The peripheral blood immunophenotype of CD56dim NK cells and NKT-like cells in CRC patients compared 
to healthy donors. The peripheral blood immune cell profile was compared between CRC patients (grey dots) and 
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immunophenotype of circulating lymphocytes and tumor location, lymph node invasion or tumor 
differentiation grade (data not shown). 
 
Association between the peripheral blood immune cell profile and disease-free survival of 
colorectal cancer patients 
We subsequently wondered whether peripheral blood immune cell profiles were associated with 
clinical outcome in CRC patients. Therefore, survival plots as well as univariate and multivariate 
analyses were generated for stage II and III CRC patients at risk of developing metastases. The median 
percentage of positive cells or expression level of the immunophenotypic marker was used as cutoff. 
Kaplan-Meier plots and Log-rank tests revealed that CRC patients with above-median (>6.9%, N=12)  
 
 
Figure 3. Relationship between the immune subset distribution and immunophenotype of circulating lymphocyte 
subsets with DFS of CRC patients. DFS curves are shown for stage II and III CRC patients (N=49) at risk for 
development of metastases. Stratifications were based on the median percentage of positive cells or expression 
level of the respective immunophenotypic marker. A. The percentage of Treg (% CD3+CD4+ T cells). B. NKp30 
expression level on CD56bright NK cells. C. Percentage of CD16+ circulating NKT-like cells and, D. Percentage of 
CD158a+ NKT-like cells. * This marker was only studied in 25 CRC patients at risk for development of metastasis 
(stage II and III). 
 Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer 
77 
 
percentage of circulating Treg showed a trend towards shorter DFS compared to CRC patients with 
below-median (N=13) percentage (P=0.062) (Figure 3A), with a hazard ratio (HR) of 2.551 (95% 
confidence interval (CI) 0.921-7.069, P=0.072). Furthermore, survival analyses revealed that above-
median (MFI >2327, N=24) expression of NKp30 on CD56bright NK cells (P=0.042) and above-median 
percentage (>20.3%, N=24) of CD16+ NKT-like cells (P<0.001) were associated with short DFS in CRC 
patients, with a HR of 2.143 (95% CI 1.009-4.551, P=0.047) and 4.697 (95% CI 2.046-10.783, P<0.001), 
respectively (Figure 3B;3C). In contrast, CRC patients with above-median (>5.1%, N=24) percentage of 
inhibitory receptor CD158a+ NKT-like cells showed a trend towards shorter DFS compared to patients 
with below-median (N=25) percentage (P=0.068) (Figure 3D) with a HR of 1.969 (95% CI 0.937-4.136, 
P=0.074). A multivariate analysis was performed for DFS in CRC patients which revealed that above-
median percentage of activating receptor CD16+ NKT-like cells (HR 4.192, 95% CI 1.578-11.137, 
P=0.004) remained significantly associated with shorter DFS in CRC patients when corrected for age, 
sex, tumor stage and lymph node invasion (Table 3). Thus, the presence of CD16 on circulating NKT-
like cells may be a novel prognostic biomarker candidate for clinical outcome of CRC patients. No other 
correlations between immunophenotype and DFS were observed (Supplementary table 2).  
 
Discussion 
Recently, a new scoring system based on the immune profile in the tumor area, the ‘immunoscore’, 
has shown to be a strong prognostic biomarker in CRC [37-41]. High density of CD3+ and CD8+ tumor-
infiltrating lymphocytes was reported to correlate with good clinical outcome in CRC [37,39-41]. We 
hypothesized that the distribution and phenotype of circulating immune cell subsets may reflect the 
local immune response in the TME, thereby providing potentially important information regarding 
disease progression and therapeutic decision making in CRC. In order to elucidate the role of the 
peripheral blood immune system in tumor progression and metastasis in CRC, this study aimed to 
characterize the distribution and immunophenotype of circulating T cells, NK cells, and NKT-like cells 
in CRC patients. These peripheral blood immune cell profiles were subsequently correlated to clinical 
follow-up data.  
We first demonstrated that CRC patients present with alterations in peripheral blood 
immune subset distribution. We observed a significant increase in the percentage of circulating Treg in 
CRC patients compared to healthy donors. This observation is in line with other studies [6,42,43], and 
suggests tumor escape in CRC by increasing Treg which are known to suppress the immune system and, 
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Table 3. Univariate and multivariate analyses for DFS of CRC patients. Univariate and multivariate analyses for DFS 
were generated for stage II and III CRC patients (N=49) at risk for development of metastases. The median 
percentage of positive cells or median expression level was used as a cutoff (≤ median (N=25) and > median 
(N=24)). P-values, HRs, and their CIs were estimated from a Cox proportional hazard regression model, in which 
the first category was used as reference group. Statistically significant P-values are indicated in bold. Abbreviations: 
Ref. (reference group). 
  Univariate analysis Multivariate analysis** 
Parameters HR 95% CI P-value HR 95% CI P-value 
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* Age at time of surgery 
** Corrected for age, sex, tumor stage and lymph node invasion 
*** This marker was only studied in 25 CRC patients at risk for development of metastasis (stage II and III) 
 
 
Additionally, we demonstrated that CRC patients present with an altered 
immunophenotype of circulating CD56dim NK cells compared to healthy donors, characterized by 
reduced expression of the NCRs NKp44 and NKp46. These findings are consistent with previous studies 
that showed a reduced number of activating receptor (e.g. NKG2D, NKp30, NKp46, and DNAM-1)-
positive NK cells in peripheral blood of patients with CRC [4,5]. Additionally, NK cells with 
downregulated activating receptors showed impaired IFN-γ secretion and degranulation upon 
 Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer 
79 
 
activation, thereby implying impaired function [4]. These studies did, however, not discriminate 
between the two major subpopulations of NK cells, namely CD56dim and CD56bright NK cells, which are 
known to differ in phenotype as well as function [18,19]. Whereas CD56dim NK cells have the potential 
to kill tumor cells, CD56bright NK cells primarily produce large amounts of cytokines [18,19]. We showed 
that circulating CD56dim NK cells were phenotypically altered in CRC patients, whereas CD56bright NK 
cells were not, suggesting that this NK cell subset, involved in cytokine production, is phenotypically, 
and thereby probably also functionally, not altered in CRC patients. This implicates different roles of 
CD56dim and CD56bright NK cells in cancer progression, thereby emphasizing the need to discriminate 
between these NK cell subsets in future studies. Furthermore, we also showed downregulation of the 
NCRs NKp44 and NKp46 on circulating NKT-like cells in CRC patients compared to healthy donors. In 
contrast to NK cells, the immunophenotype of circulating NKT cells (in both healthy donors and cancer 
patients) is not well defined due to the lack of specific markers to identify this immune cell subset. To 
our knowledge, only one study reported on the immunophenotype of circulating NKT-like cells in CRC. 
This study showed significantly lower numbers of circulating NKG2D+ NKT-like cells in CRC patients 
with metastatic disease compared to healthy donors [46]. Our results suggest that presence of a 
tumor affects expression levels of NKp44 and NKp46 receptors on both CD56dim NK cells and NKT-like 
cells. Over the years, many studies have focused on the effects of a tumor on NK cell function. For 
instance, NK cells in the TME adapt to survive hypoxic stress by upregulating hypoxia-inducible factor 
(HIF)-1α which is associated with impaired upregulation of NKp44 and NKp46 in response to activating 
cytokines such as IL-2, IL-12, IL-15 and IL-21 [47]. Furthermore, immune cells and fibroblasts in the 
TME may produce immunosuppressive cytokines and signal molecules that downregulate [48-50] or 
prevent IL-2-induced upregulation [51,52] of NCRs on NK cells. Furthermore, tumor cells may induce 
downregulation of NCRs on NK cells as a response to hypoxic stress via prostaglandin E2 production 
or lactate release [53,54]. Finally, tumor cells may alter the function of NK cells via overexpression of 
NK cell ligands. For instance, overexpression of proliferating cell nuclear antigen (PCNA) by tumor cells 
impaired NKp44-mediated NK cell attack in an in vitro model [55,56]. Whether PCNA also actively 
downregulates the NKp44 receptor on NK cells is not clear and requires additional research. In 
conclusion, we observed reduced expression of the NCRs NKp44 and NKp46 on circulating CD56dim NK 
cells and NKT-like cells in CRC patients, which may be caused by the presence of the tumor via various 
mechanisms, resulting in functional impairment in these subsets, thereby promoting tumor escape.  
Furthermore, we addressed the question whether the peripheral blood immune cell profile 
in CRC patients was related to tumor stage. Although the peripheral blood immune cell profile was 




Table 3. Univariate and multivariate analyses for DFS of CRC patients. Univariate and multivariate analyses for DFS 
were generated for stage II and III CRC patients (N=49) at risk for development of metastases. The median 
percentage of positive cells or median expression level was used as a cutoff (≤ median (N=25) and > median 
(N=24)). P-values, HRs, and their CIs were estimated from a Cox proportional hazard regression model, in which 
the first category was used as reference group. Statistically significant P-values are indicated in bold. Abbreviations: 
Ref. (reference group). 
  Univariate analysis Multivariate analysis** 
Parameters HR 95% CI P-value HR 95% CI P-value 







































      












      


































NKp30 CD56bright NK cells (MFI) 
≤ MFI 2327 





























































* Age at time of surgery 
** Corrected for age, sex, tumor stage and lymph node invasion 
*** This marker was only studied in 25 CRC patients at risk for development of metastasis (stage II and III) 
 
 
Additionally, we demonstrated that CRC patients present with an altered 
immunophenotype of circulating CD56dim NK cells compared to healthy donors, characterized by 
reduced expression of the NCRs NKp44 and NKp46. These findings are consistent with previous studies 
that showed a reduced number of activating receptor (e.g. NKG2D, NKp30, NKp46, and DNAM-1)-
positive NK cells in peripheral blood of patients with CRC [4,5]. Additionally, NK cells with 
downregulated activating receptors showed impaired IFN-γ secretion and degranulation upon 
 Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer 
79 
 
activation, thereby implying impaired function [4]. These studies did, however, not discriminate 
between the two major subpopulations of NK cells, namely CD56dim and CD56bright NK cells, which are 
known to differ in phenotype as well as function [18,19]. Whereas CD56dim NK cells have the potential 
to kill tumor cells, CD56bright NK cells primarily produce large amounts of cytokines [18,19]. We showed 
that circulating CD56dim NK cells were phenotypically altered in CRC patients, whereas CD56bright NK 
cells were not, suggesting that this NK cell subset, involved in cytokine production, is phenotypically, 
and thereby probably also functionally, not altered in CRC patients. This implicates different roles of 
CD56dim and CD56bright NK cells in cancer progression, thereby emphasizing the need to discriminate 
between these NK cell subsets in future studies. Furthermore, we also showed downregulation of the 
NCRs NKp44 and NKp46 on circulating NKT-like cells in CRC patients compared to healthy donors. In 
contrast to NK cells, the immunophenotype of circulating NKT cells (in both healthy donors and cancer 
patients) is not well defined due to the lack of specific markers to identify this immune cell subset. To 
our knowledge, only one study reported on the immunophenotype of circulating NKT-like cells in CRC. 
This study showed significantly lower numbers of circulating NKG2D+ NKT-like cells in CRC patients 
with metastatic disease compared to healthy donors [46]. Our results suggest that presence of a 
tumor affects expression levels of NKp44 and NKp46 receptors on both CD56dim NK cells and NKT-like 
cells. Over the years, many studies have focused on the effects of a tumor on NK cell function. For 
instance, NK cells in the TME adapt to survive hypoxic stress by upregulating hypoxia-inducible factor 
(HIF)-1α which is associated with impaired upregulation of NKp44 and NKp46 in response to activating 
cytokines such as IL-2, IL-12, IL-15 and IL-21 [47]. Furthermore, immune cells and fibroblasts in the 
TME may produce immunosuppressive cytokines and signal molecules that downregulate [48-50] or 
prevent IL-2-induced upregulation [51,52] of NCRs on NK cells. Furthermore, tumor cells may induce 
downregulation of NCRs on NK cells as a response to hypoxic stress via prostaglandin E2 production 
or lactate release [53,54]. Finally, tumor cells may alter the function of NK cells via overexpression of 
NK cell ligands. For instance, overexpression of proliferating cell nuclear antigen (PCNA) by tumor cells 
impaired NKp44-mediated NK cell attack in an in vitro model [55,56]. Whether PCNA also actively 
downregulates the NKp44 receptor on NK cells is not clear and requires additional research. In 
conclusion, we observed reduced expression of the NCRs NKp44 and NKp46 on circulating CD56dim NK 
cells and NKT-like cells in CRC patients, which may be caused by the presence of the tumor via various 
mechanisms, resulting in functional impairment in these subsets, thereby promoting tumor escape.  
Furthermore, we addressed the question whether the peripheral blood immune cell profile 
in CRC patients was related to tumor stage. Although the peripheral blood immune cell profile was 




PBMC subsets was observed in relation with tumor stage of CRC patients. Hence, differences in the 
peripheral blood immune cell profile were mainly related to the fact that these patients had a 
colorectal tumor rather than to tumor stage. We did, however, observe a relationship between the 
immune subset distribution and phenotype of circulating PBMCs and clinical outcome. This suggests 
that circulating immune cell profiles have prognostic value (i.e. biomarker candidates) for the 
identification of patients with low tumor grades with a high risk of developing metastatic disease. In 
general, it is hypothesized that decreased percentages of cytotoxic immune cell subsets or expression 
levels of activating receptors and increased percentages of regulatory immune cell subsets or 
expression levels of inhibitory receptors represent an immunocompromised state of the immune 
system and would therefore be correlated with shorter DFS in CRC patients [4,57,58]. In line with this 
hypothesis, our results revealed that CRC patients with high numbers of circulating Treg showed a trend 
towards shorter DFS compared to patients with low numbers of circulating Treg, an association also 
observed by others. For instance, an association was reported between Treg-mediated suppression of 
tumor-specific CD4+ T cells prior to surgery and tumor recurrence in CRC patients at 12 months [59], 
whereas FOLFIRI (levo-leucovorin, 5-fluorouracil, irinotexan)- bevacizumab therapy of metastatic CRC 
patients was associated with better clinical outcome, but also with reduced numbers of circulating 
Treg [60,61]. Additionally, in line with our hypothesis, patients with a high percentage of inhibitory 
receptor CD158a+ circulating NKT-like cells showed a trend towards shorter DFS. Since the CD158a 
receptor recognizes HLA class I molecules, it would be interesting to study HLA class I tumor cell 
expression in primary colorectal tumors to investigate whether there is an association with the 
presence of circulating CD158a+ NKT-like immune cells. In contrast with the hypothesis, we observed 
a statistically significant association between a high expression level of activating receptor NKp30 on 
circulating CD56bright NK cells and a high percentage of CD16+ circulating NKT-like cells and short DFS 
in CRC patients. A multivariate analysis revealed that the latter, high percentage of CD16+ NKT-like 
cells, was even independently associated with shorter DFS in CRC patients. From these observations, 
it might be deduced that the NKp30 and CD16 receptors are activated during the course of tumor cell 
dissemination. The exact role of the NKp30 and CD16 receptors in the process of dissemination in CRC 
patients has yet to be elucidated. Possibly, the status of these receptors in patients with poor clinical 
outcome might affect the tumor immune response, thus acting as an active selection mechanism by 
which tumor cells escape immune-mediated destruction. In that case, it would for instance be likely 
that ligands for these receptors on tumor cells are downregulated. 
In conclusion, we demonstrated profound differences in subset distribution and 
immunophenotype of PBMCs in CRC patients compared to healthy donors, characterized by an 
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increased percentage of Treg, and reduced expression of NCRs NKp44 and NKp46 on both CD56dim NK 
cells and NKT-like cells. Additionally, a multivariate analysis revealed that above median percentage 
of CD16+ NKT-like cells was independently associated with shorter DFS in CRC patients. These findings 
highlight the potential use of circulating lymphocyte subsets as prognostic biomarkers in CRC and 
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Objective: The subset distribution and immunophenotype of circulating immune cells (“peripheral 
blood immune cell profile”) may reflect tumor development and response to cancer treatment. In 
order to use the peripheral blood immune cell profile as biomarker to monitor patients over time, it 
is crucial to know how immune cell subsets respond to therapeutic interventions. In this study, we 
investigated the effects of tumor resection and adjuvant therapy on the peripheral blood immune cell 
profile in patients with colon carcinoma (CC).  
 
Methods: The subset distribution and immunophenotype of T cells (CD3+CD56-), CD56dim NK cells (CD3-
CD56dim), CD56bright NK cells (CD3-CD56bright), and NKT-like cells (CD3+CD56+) were studied in 
preoperative and postoperative peripheral blood mononuclear cell (PBMC) samples of 24 patients 
with CC by multiparameter flow cytometry. Changes in immunophenotype of circulating immune cells 
after tumor resection were studied in patients treated with and without (capecitabine-based) 
adjuvant therapy.  
 
Results: The NKT-like cell (% of total PBMCs) and CD8+ T cell (% of total T cells) populations expanded 
in the peripheral blood of non-adjuvant treated CC patients after surgery. NK- and NKT-like cells 
showed upregulation of activating receptors and downregulation of inhibitory receptors in non-
adjuvant treated CC patients after surgery. These changes were not observed in the peripheral blood 
of adjuvant treated CC patients.  
 
Conclusions: Our results suggest tumor-induced suppression of NK- and NKT-like cells in CC patients, 
an effect that could not be detected after tumor resection. In contrast, adjuvant therapy maintained 








Colon carcinoma (CC) is a tumor type with a high incidence and, combined with rectal cancer, globally 
accounting for more than 1 million new cases and around 600.000 deaths annually [1-3]. Despite 
improved surgical procedures and adjuvant treatment strategies, around 30% of the patients, without 
metastatic disease at time of diagnosis, develop recurrence or dissemination of the disease following 
successful resection of the primary tumor [4]. Currently, different biomarkers are evaluated for their 
prognostic value that may be used to identify cancer patients at risk of disease progression. Hence, 
biomarker application in cancer patients is crucial since it may provide information for therapeutic 
decision making, including decisions on the frequency of clinical follow-up, thereby possibly 
prolonging survival and reducing the risk of recurrence in cancer patients. Over the past decades, it 
has become clear that immunosurveillance plays a pivotal role in colon cancer by protecting the host 
against tumor development and progression. For instance, the immunoscore, representing CD3+/CD8+ 
T lymphocyte density in tumor tissue, is a strong prognostic factor in colorectal cancer (CRC) [5-9]. 
Low density of cytotoxic (CD8+) tumor-infiltrating T cells was reported to correlate with poor clinical 
outcome in CRC [5,6,10,11]. However, it must be realized that the immunoscore can only be 
determined once at time of surgery because it is performed on resection material. Therefore, it does 
not provide information regarding treatment response of patients over time. In general, immune cells 
are present in relatively low numbers in the tissue of primary tumors, whereas they are abundantly 
present in peripheral blood. Interestingly, the subset distribution and immunophenotype of 
circulating immune cells (“peripheral blood immune cell profile”) are associated with clinical outcome 
of CRC patients [12]. In contrast to the immunoscore, the peripheral blood immune cell profile can be 
monitored in patients over time since it only requires blood sampling.  
The peripheral blood comprises different immune cell subsets, among which are natural 
killer (NK) cells that can be subdivided based on their CD56 expression. CD56dim NK cells have an 
important cytotoxic function while CD56bright NK cells are generally associated with production of pro-
inflammatory cytokines and immunoregulatory properties [13,14]. Furthermore, peripheral blood 
contains a unique natural killer T (NKT) cell population with characteristics of both NK cells and NKT 
cells. Co-expression of CD3 and CD56 can be used to identify this immune subset in the circulation 
using flow cytometry, which is often referred to as “NKT-like” [15]. Like other immune cell subsets, 
NK and NKT-like cell activity is dependent on a delicate balance between activating and inhibitory 
signals from cell surface receptors [16]. The activating signals are mediated by a wide array of 
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molecule-1 (DNAM-1), CD161, and natural cytotoxicity receptors NKp30, NKp44, and NKp46, that 
recognize a variety of stress-induced molecules that may be present on tumor cells. Additionally, the 
CD16 (FcγRIII) receptor mediates antibody-dependent cell-mediated cytotoxicity and CD8 enhances 
the cytolytic activity of NK cells [17,18]. NK cell inhibitory receptors include natural killer group 2-A 
(NKG2A), and killer cell immunoglobulin (Ig)-like receptors CD158a and CD158b that recognize human 
leukocyte antigen (HLA) class I molecules. Recently, we [12] and others [19-21] showed that the 
peripheral blood immune cell profile is altered in CRC patients compared to healthy donors, 
characterized by downregulation of activating receptors on circulating CD56dim NK cells and NKT-like 
cells.  
Several studies reported a critical role for the tumor microenvironment (TME) in shaping 
NK- and NKT-like receptor-mediated anti-tumor immunity [15,22,23]. For instance, immune-
modulating effects of NK cells have been attributed to hypoxic conditions [24], and 
immunosuppressive cytokines and signaling molecules [23,25,26] present in the TME. As a result of 
these immune modulations, NK- and NKT-like cells may downregulate activating receptors and, as a 
result, may become functionally impaired, thereby promoting tumor escape. Up till now, it is unclear 
whether TME-induced immune-modulations of circulating NK- and NKT-like cells are reversible. 
Furthermore, chemotherapy, often used for adjuvant treatment of CRC patients, has been reported 
to have an immunosuppressive effect on the immune system, including overall impairment of NK cell 
responses [27]. In order to use the peripheral blood immune cell profile as biomarker to monitor 
cancer patients over time, it is crucial to know how immune cell subsets respond to therapeutic 
interventions. In a recent paper [12], we studied the preoperative peripheral blood immune cell 
profile in patients with CRC. In this study, we investigated the peripheral blood immune cell profile in 
patients with available postoperative blood samples in order to study the effects of tumor resection 
and adjuvant therapy. It was not possible to study the effects of tumor resection and adjuvant therapy 
in patients with rectum tumors due to limited sample availability. Therefore, we focused on patients 
with colon tumors. Additionally, we selected patients with Tumor-Node-Metastasis (TNM) stage II and 
III who are at risk for development of metastases after surgery and are, therefore, the patients that 
would qualify for biomarker monitoring over time. In summary, our collection of peripheral blood 
mononuclear cells (PBMCs) before and after tumor resection enabled, for the first time, to study the 
effects of tumor resection as well as adjuvant therapy on the subset distribution and 
immunophenotype of circulating T-, NK- and NKT-like cells in CC patients. 
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Materials & Methods 
Study population 
The study population comprised patients diagnosed with CC who underwent surgical resection of their 
primary tumor at the Leiden University Medical Center (LUMC, the Netherlands) between 2001 and 
2007. Patients were included in this study based on availability of PBMC samples. PBMC samples were 
collected within a month prior to surgery and ≥2 months after surgery (mean 8.2 months after surgery, 
range 2.2-17.7). When the patient started adjuvant therapy directly after surgery, postoperative 
PBMC samples were obtained after therapy completion. These samples were obtained ≥5 months 
after the final therapy date (mean 8.4 months after surgery, range 6.7-13.7). Most adjuvant therapy 
cycles consisted of 3 weeks of therapy, therefore, the included postoperative PBMC samples were 
obtained ≥4 months after therapy completion. In the present study, patients with histologically 
proven primary CC, TNM stage II and III, surgical R0 resection, and a minimal amount of 5 million 
cryopreserved preoperative as well as postoperative PBMCs were included (N=26). Clinicopathological 
data of all patients were available. All blood samples were obtained after approval by the Medical 
Ethical Committee of the LUMC (protocol number P000.193). All procedures performed in this study 
were in accordance with the ethical standards of the Dutch law (“WMO”, medical research involving 
human subjects act), and with the 1964 Helsinki declaration and its later amendments or comparable 
ethical standards. All CC patients included in this study agreed to our use of their PBMCs and data for 
research purposes prior to blood sampling via written informed consent and they moreover agreed 
to anonymous publication of the resulting data. 
 
Isolation of peripheral blood mononuclear cells 
PBMCs from CC patients were isolated and cryopreserved as previously described [12]. PBMCs were 
also isolated from the buffy coat of a random blood donor obtained from the Blood Bank at Aarhus 
University Hospital (Dept. Clinical Immunology, Aarhus University Hospital, Skejby, Denmark), which 
was used as an internal control in the flow cytometry experiments [12].  
 
Flow cytometry antibody staining and data analysis 
All preoperative PBMC samples from CC patients were previously immunophenotyped and reported 
on as part of a CRC study [12]. All postoperative PBMC samples selected for the current study were 
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standard protocol and the cell concentration was adjusted to 10x106 cells/ml. PBMCs were then 
blocked for 15-30 minutes at room temperature with 50 μg/ml human IgG (CSL Behring, Bern, 
Switzerland) and subsequently stained with two distinct antibody panels containing selected NK- and 
NKT cell markers as previously described [12]. After the staining procedure, samples were fixed in PBS 
supplemented with 0.9% formaldehyde (Sigma-Aldrich, St. Louis, MO) and analyzed the same day by 
flow cytometry on a 4-laser equipped LSRFortessa (BD Biosciences, San Diego, CA) using Diva 7.0 
software (BD Biosciences). Results were analyzed with FlowJo software v10.1 (Tree Star Inc., Ashland, 
OR). The buffy coat was used as an internal control in order to check for any inter-experimental 
variation. Expression of phenotypic markers on peripheral blood T-, NK- and NKT-like cells was 
evaluated by the median fluorescence intensity (MFI) and/or the percentage of positive cells. A 
compensation matrix was calculated to compensate for spillover of signal into other channels in the 
multicolor flow cytometry experiments. This matrix was set up using single stains on CompBeads (BD 
Biosciences,) OneComp eBeads (eBioscience, San Diego, CA), CompBeads Plus (BD Biosciences), and 
ArC reactive beads (Life Technologies). A standardized gating strategy based on a healthy donor buffy 
coat was used in order to study the distribution of markers on specific lymphocyte subsets as 
described previously [12].  
 
Statistical analyses 
Statistical analyses were conducted using SPSS statistical software (IBM SPSS Statistics 23, Chicago, 
USA). The age of patients treated with adjuvant therapy was compared with the age of patients 
treated without adjuvant therapy using the Mann Whitney-U test. Preoperative and postoperative 
PBMC samples from patients were compared using the paired samples T test and Wilcoxon signed-
rank test, for normally distributed and not normally distributed variables respectively. We corrected 
for multiple testing using the Benjamini-Hochberg method, by which adjusted P-values were 




The subset distribution and immunophenotype of circulating T-, NK-, and NKT-like cells was studied 
pre- and postoperatively in patients diagnosed with CC TNM stage II and III (N=26). One postoperative 
sample was excluded due to low viability of the PBMCs (<50% viable cells). Additionally, one patient 
was diagnosed with Lynch syndrome. Since tumors from patients with Lynch syndrome are 
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immunologically different compared to tumors from patients with sporadic cancer [29], this patient 
was excluded from analyses, resulting in a total study population of 24 patients. One patient had 
undergone local radiotherapy prior to the collection of the preoperative PBMC sample. In total, 15 
patients underwent surgical resection of their tumor only (non-adjuvant treated group) and 9 patients 
received additional therapy after surgery (adjuvant treated group). Two of these 9 patients were 
treated with capecitabine monotherapy, six patients were treated with a combination of capecitabine 
and oxaliplatin, and one patient was treated with a combination of capecitabine, oxaliplatin and 
bevacizumab. Table 1 summarizes the clinicopathological characteristics of the 24 patients included 
in the analyses. Patients undergoing adjuvant therapy were younger (median 56 years) compared to 
patients that did not receive adjuvant therapy (median 73 years, P=0.002). The low number of patients 
did not allow for analyzing the peripheral blood immune cell profile according to age. 
 
 
Table 1. Patient demographics and tumor characteristics. Clinicopathological data of the 24 CC patients in this 
study. Abbreviations: CC (colon carcinoma), TNM (Tumor-Node-Metastasis). 
  CC patients CC patients CC patients 
  Total population No adjuvant therapy Adjuvant therapy* 
  (N=24) (N=15) (N=9) 
Age at time of surgery       
Median (years) 65 73 56 
Range (years) 25-85 56-85 25-71 
Sex       
Female  11 (45.8%) 7 (46.7%) 4 (44.4%) 
Male 13 (54.2%) 8 (53.3%) 5 (55.6%) 
TNM classification       
Stage II 12 (50.0%) 10 (66.7%) 2 (22.2%) 
Stage III 12 (50.0%) 5 (33.3%) 7 (77.8%) 
Tumor differentiation       
Well/moderate 21 (87.5%) 12 (80.0%) 9 (100%) 
Poor 3 (12.5%) 3 (20.0%) 0 (0%) 
Neoadjuvant radiotherapy       
Yes 1 (4.2%) 1 (6.7%) 0 (0%) 
No 23 (95.8%) 14 (93.3%) 9 (100%) 







standard protocol and the cell concentration was adjusted to 10x106 cells/ml. PBMCs were then 
blocked for 15-30 minutes at room temperature with 50 μg/ml human IgG (CSL Behring, Bern, 
Switzerland) and subsequently stained with two distinct antibody panels containing selected NK- and 
NKT cell markers as previously described [12]. After the staining procedure, samples were fixed in PBS 
supplemented with 0.9% formaldehyde (Sigma-Aldrich, St. Louis, MO) and analyzed the same day by 
flow cytometry on a 4-laser equipped LSRFortessa (BD Biosciences, San Diego, CA) using Diva 7.0 
software (BD Biosciences). Results were analyzed with FlowJo software v10.1 (Tree Star Inc., Ashland, 
OR). The buffy coat was used as an internal control in order to check for any inter-experimental 
variation. Expression of phenotypic markers on peripheral blood T-, NK- and NKT-like cells was 
evaluated by the median fluorescence intensity (MFI) and/or the percentage of positive cells. A 
compensation matrix was calculated to compensate for spillover of signal into other channels in the 
multicolor flow cytometry experiments. This matrix was set up using single stains on CompBeads (BD 
Biosciences,) OneComp eBeads (eBioscience, San Diego, CA), CompBeads Plus (BD Biosciences), and 
ArC reactive beads (Life Technologies). A standardized gating strategy based on a healthy donor buffy 
coat was used in order to study the distribution of markers on specific lymphocyte subsets as 
described previously [12].  
 
Statistical analyses 
Statistical analyses were conducted using SPSS statistical software (IBM SPSS Statistics 23, Chicago, 
USA). The age of patients treated with adjuvant therapy was compared with the age of patients 
treated without adjuvant therapy using the Mann Whitney-U test. Preoperative and postoperative 
PBMC samples from patients were compared using the paired samples T test and Wilcoxon signed-
rank test, for normally distributed and not normally distributed variables respectively. We corrected 
for multiple testing using the Benjamini-Hochberg method, by which adjusted P-values were 




The subset distribution and immunophenotype of circulating T-, NK-, and NKT-like cells was studied 
pre- and postoperatively in patients diagnosed with CC TNM stage II and III (N=26). One postoperative 
sample was excluded due to low viability of the PBMCs (<50% viable cells). Additionally, one patient 
was diagnosed with Lynch syndrome. Since tumors from patients with Lynch syndrome are 
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immunologically different compared to tumors from patients with sporadic cancer [29], this patient 
was excluded from analyses, resulting in a total study population of 24 patients. One patient had 
undergone local radiotherapy prior to the collection of the preoperative PBMC sample. In total, 15 
patients underwent surgical resection of their tumor only (non-adjuvant treated group) and 9 patients 
received additional therapy after surgery (adjuvant treated group). Two of these 9 patients were 
treated with capecitabine monotherapy, six patients were treated with a combination of capecitabine 
and oxaliplatin, and one patient was treated with a combination of capecitabine, oxaliplatin and 
bevacizumab. Table 1 summarizes the clinicopathological characteristics of the 24 patients included 
in the analyses. Patients undergoing adjuvant therapy were younger (median 56 years) compared to 
patients that did not receive adjuvant therapy (median 73 years, P=0.002). The low number of patients 
did not allow for analyzing the peripheral blood immune cell profile according to age. 
 
 
Table 1. Patient demographics and tumor characteristics. Clinicopathological data of the 24 CC patients in this 
study. Abbreviations: CC (colon carcinoma), TNM (Tumor-Node-Metastasis). 
  CC patients CC patients CC patients 
  Total population No adjuvant therapy Adjuvant therapy* 
  (N=24) (N=15) (N=9) 
Age at time of surgery       
Median (years) 65 73 56 
Range (years) 25-85 56-85 25-71 
Sex       
Female  11 (45.8%) 7 (46.7%) 4 (44.4%) 
Male 13 (54.2%) 8 (53.3%) 5 (55.6%) 
TNM classification       
Stage II 12 (50.0%) 10 (66.7%) 2 (22.2%) 
Stage III 12 (50.0%) 5 (33.3%) 7 (77.8%) 
Tumor differentiation       
Well/moderate 21 (87.5%) 12 (80.0%) 9 (100%) 
Poor 3 (12.5%) 3 (20.0%) 0 (0%) 
Neoadjuvant radiotherapy       
Yes 1 (4.2%) 1 (6.7%) 0 (0%) 
No 23 (95.8%) 14 (93.3%) 9 (100%) 
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Expansion of NKT-like and CD8+ T cell populations in peripheral blood after surgery in non-
adjuvant treated CC patients 
First, the effects of tumor resection and adjuvant therapy on the distribution of peripheral blood 
immune subsets were studied in non-adjuvant treated (N=15) and adjuvant treated (N=9) CC patients 
(Table 2). The percentages of total NK cells (% CD3-CD56+ cells of total PBMCs), CD56dim NK cells (% of 
total NK cells), and CD56bright NK cells (% of total NK cells) did neither change in non-adjuvant treated 
 
 
Figure 1. Effects of tumor resection and adjuvant therapy on the peripheral blood immune cell subset distribution 
in CC patients. Multiparameter flow cytometry was used to study the peripheral blood immune profile in PBMC 
samples from CC patients. The distribution of circulating immune cell subsets was compared before and after 
surgery in CC patients that did (N=9) or did not (N=15) receive adjuvant therapy. A. Total percentage of NK cells (% 
CD3-CD56+ cells of total PBMCs). B. Percentage of CD56dim NK cells (% of total NK cells). C. Percentage of CD56bright 
NK cells (% of total NK cells). D. Total percentage of NKT-like cells (% CD3+CD56+ cells of total PBMCs). E. Total 
percentage of T cells (% CD3+CD56- cells of total PBMCs). F. Percentage of CD8+ T cells (% of total T cells). Pre- and 
postoperative samples from each patient are connected with a line. P*-values ≤0.05 were considered statistically 
significant. Abbreviations: CC (colon carcinoma), PBMCs (peripheral blood mononuclear cells), NK (natural killer), 
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 patients nor in adjuvant treated patients after resection of the primary tumor (Figure 1A;1B;1C,  
respectively). The percentage of NKT-like cells (% CD3+CD56+ cells of total PBMCs) increased 
(P*=0.049) in non-adjuvant treated patients after surgery (Figure 1D). Furthermore, although the 
percentage of total T cells (% CD3+CD56- cells of total PBMCs) was not altered in non-adjuvant treated 
patients after resection of the primary tumor (Figure 1E), the percentage of CD8+ T cells (% of total T 
cells) was significantly increased (P*=0.034, Figure 1F). No change was observed in the percentage of 
NKT-like cells or CD8+ T cells in adjuvant treated patients after surgery.  
 
Increased expression of activating receptors and downregulation of inhibitory receptors on 
NK cells in peripheral blood after surgery in non-adjuvant treated CC patients 
After analyzing the distribution of immune cell subsets, we compared the immunophenotype of NK- 
and NKT-like cells before and after tumor resection in non-adjuvant treated and adjuvant treated CC 
patients (Table 2). Within the CD56dim NK cell population, the expression levels of activating receptors 
NKp44 (P*=0.036) and NKG2D (P*=0.045) increased after surgery in non-adjuvant treated patients 
(Figure 2A;2B, respectively). Additionally, a trend was observed towards a higher expression level of 
the co-stimulatory molecule CD8 in non-adjuvant treated patients after surgery (P*=0.060) (Figure 
2C). 
 
Figure 2. Effects of tumor resection and adjuvant therapy on the immunophenotype of CD56dim NK cells in CC 
patients. Multiparameter flow cytometry was used to study the peripheral blood immune profile in PBMC samples 
from CC patients. The immunophenotype of CD56dim NK cells was compared before and after surgery in CC patients 
that did (N=9) or did not (N=15) receive adjuvant therapy. A. Expression level of NKp44 on CD56dim NK cells. B. 
Expression level of NKG2D on NKG2D+CD56dim NK cells. C. Expression level of CD8 on CD8+CD56dim NK cells. Pre- 
and postoperative samples from each patient are connected with a line. Statistically significant P*-values are 
indicated in bold. Abbreviations: CC (colon carcinoma), MFI (median fluorescence intensity), NK (natural killer), ns 
(not significant). 
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The expression levels of NKp44, NKG2D and CD8 did not change on CD56dim NK cells after tumor 
resection in adjuvant treated patients (Figure 2A;2B;2C, respectively). In line with these results, a 
trend towards increased expression levels of NKG2D (P*=0.051) and CD8 (P*=0.051) was observed on 
CD56bright NK cells in non-adjuvant treated patients (Figure 3A;3B, respectively). No change in 
expression levels of NKG2D and CD8 was observed on CD56bright NK cells after tumor resection in 
adjuvant treated patients. The expression level of the inhibitory receptor NKG2A (P*=0.045) on 
CD56bright cells decreased in non-adjuvant treated patients after surgery (Figure 3C). In contrast, the 
percentage of stimulatory receptor CD16+ CD56bright NK cells was also decreased (P*=0.040) in non- 
adjuvant treated patients after tumor resection (Figure 3D). The expression level of NKG2A and the 
 
 
Figure 3. Effects of tumor resection and adjuvant therapy on the immunophenotype of CD56bright NK cells in CC 
patients. Multiparameter flow cytometry was used to study the peripheral blood immune profile in PBMC samples 
from CC patients. The immunophenotype of CD56bright NK cells was compared before and after surgery in CC 
patients that did (N=9) or did not (N=15) receive adjuvant therapy. A. Expression level of NKG2D on 
NKG2D+CD56bright NK cells. B. Expression level of CD8 on CD8+CD56bright cells. C. Expression level of NKG2A on 
NKG2A+CD56bright NK cells. D. Percentage of CD16+CD56bright NK cells. Pre- and postoperative samples from each 
patient are connected with a line. Statistically significant P*-values are indicated in bold. Abbreviations: CC (colon 
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percentage of CD16+ cells did not change after surgery in adjuvant treated patients. In summary, 
circulating NK cells acquired expression of cell surface markers associated with functional activity after 
surgery in non-adjuvant treated CC patients as compared to before surgery. 
 
Increased expression of activating receptors and downregulation of inhibitory receptors on 
NKT-like cells in peripheral blood after surgery in non-adjuvant treated CC patients 
Within the NKT-like cell subset, the percentages of NKT-like cells expressing the inhibitory receptors 
CD158a or NKG2A decreased in non-adjuvant treated patients after surgery (P*=0.048 and P*=0.030, 
respectively), whereas no change was observed in adjuvant treated patients (Figure 4A;4B). In 
contrast, the expression levels of activating receptors NKG2D (P*=0.048) and co-stimulatory receptor 
CD8 (P*=0.030) on NKT-like cells increased in non-adjuvant treated patients after surgery (Figure 
4C;4D). No change in NKT-like cell expression levels of NKG2D and CD8 were observed after surgery 
in adjuvant treated patients (Figure 4C;4D). Additionally, an increased percentage of NKp44+ NKT-like 
cells was observed in non-adjuvant treated patients after surgery (P*=0.040, Figure 4E). The 
expression level of NKp44 on NKT-like cells showed a similar pattern as the percentage of NKp44+ NKT-
like cells and was increased in non-adjuvant treated patients after surgery (P*=0.038, Figure 4F). The 
percentage of NKp44+ NKT-like cells, as well as the expression level of NKp44 on NKT-like cells, did not 
change in adjuvant treated patients after surgery (Figure 4E;4F). In summary, as also observed for the 
immunophenotype of NK cells, NKT-like cells acquired expression of cell surface markers associated 
with functional activity after surgery in non-adjuvant treated CC patients.  
 
Discussion 
As shown in our recent study [12], the peripheral blood immune cell profile comprises a potential pool 
of biomarkers in CRC. We hypothesized that this profile might change upon therapeutic interventions. 
Therefore, we studied the peripheral blood immune profile in available postoperative PBMC samples 
(N=24) from TNM stage II and III CC patients included in our previous study [12]. Our collection of 
PBMCs before and after tumor resection enabled, for the first time, to study the effects of tumor 
resection as well as adjuvant therapy on the subset distribution and immunophenotype of circulating 
immune cells in CC. Here, we focused on NK- and NKT-like cell subsets as several studies have reported 
an altered phenotype of these cells in peripheral blood of CRC patients compared to healthy donors, 
characterized by downregulation of activating receptors, which suggests impaired function of these 
immune cell subsets in cancer patients [12,19,20]. A critical role of the TME was implied in shaping  
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Figure 4. Effects of tumor resection and adjuvant therapy on the immunophenotype of NKT-like cells in CC patients. 
Multiparameter flow cytometry was used to study the peripheral blood immune profile in PBMC samples from CC 
patients. The immunophenotype of NKT-like cells was compared before and after surgery in CC patients that did 
(N=9) or did not (N=15) receive adjuvant therapy. A. Percentage of CD158a+NKT-like cells. B. Percentage of 
NKG2A+NKT-like cells. C. Expression level of NKG2D on NKG2D+NKT-like cells. D. Expression level of CD8 on 
CD8+NKT-like cells. E. Percentage of NKp44+NKT-like cells. F. Expression level of NKp44 on NKT-like cells. Pre- and 
postoperative samples from each patient are connected with a line. Statistically significant P*-values are indicated 
in bold. Abbreviations: CC (colon carcinoma), CI (confidence interval), MFI (median fluorescence intensity), NKT 
(natural killer T), ns (not significant). 
 
 
NK- and NKT-like receptor-mediated anti-tumor immunity [15,22,23], which could be a result of 
hypoxic conditions, immunosuppressive cytokines, or fibroblasts present in the TME [23-26].  
We observed changes in peripheral blood immune cell profile after resection of the primary 
tumor in non-adjuvant treated patients, including expansion of NKT-like (% of total PBMCs) and CD8+ 
T (% of total T cells) cell populations. An increase in percentage of these cell types was also observed 
after surgery in non-adjuvant treated patients with laryngeal cancer [30]. Importantly, the reported 
expansion of the NKT-like and CD8+ T cell populations in the present study and by Klatka et al. [30] is 
relative, and does not provide information about a change in absolute numbers of these immune 
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frozen PBMCs, not whole blood. Thus, trying to make measurements of cells/ml would be highly 
affected by the Ficoll procedure and sample preparation. This is a limitation of our study and should 
be considered when drawing conclusions. Grimm et al. reported no absolute increase of CD8+ T cells 
in patients with oral squamous cell carcinoma (OSCC) after surgery [31], suggesting no effect on 
absolute immune cell numbers after surgery. However, it must be realized that this study was focused 
on OSCC patients that might have a different preoperative peripheral blood immune profile compared 
to CC patients which might also respond different to tumor resection. Furthermore, OSCC patients are 
often treated with neoadjuvant radiotherapy which might influence the immune system over a long 
period of time. The study by Grimm et al. did not specify neoadjuvant and/or adjuvant treatment of 
the included OSCC patients in their study. Up till now, studies reported on the numbers of circulating 
immune cells and subset distribution in cancer patients after surgery [30-32], but not on the 
immunophenotype of specific immune cell subsets. It is important that this is considered since the 
immunophenotype of immune cells is closely related to their function. Hence, expansion of the NKT-
like cell population in CC patients after surgery does not necessarily mean that more effector cells are 
present. In this study, we showed that expression of activating receptors including NKG2D, NKp44, 
and CD8, was upregulated on NKT-like cells after surgery in non-adjuvant treated patients. 
Additionally, we observed a decrease in the percentage of inhibitory receptor CD158a+ and NKG2A+ 
NKT-like cells, suggesting that the NKT-like cell population expands and acquires expression of cell 
surface markers associated with functional activity in CC patients after tumor resection. In contrast to 
studies on laryngeal cancer [30] and oral squamous cell carcinoma [31], we did not observe expansion 
of the NK cell population after tumor resection. We did, however, observe a change in 
immunophenotype of NK cells resembling the pattern observed in NKT-like cells. Hence, we observed 
upregulation of activating receptors NKG2D, NKp44 and CD8 on CD56dim NK cells in non-adjuvant 
treated CC patients after tumor resection. In line with this, upregulation of activating receptors NKG2D 
and CD8 was observed on CD56bright NK cells as well as downregulation of the inhibitory receptor 
NKG2A after tumor resection in non-adjuvant treated CC patients, suggesting that both CD56dim NK 
and CD56bright NK cells acquired a more active phenotype after tumor resection and, therefore, 
possibly recovered from TME-induced immunosuppression. The only activating marker that was 
downregulated in CC patients after tumor resection was the percentage of CD16+ cells within the 
CD56bright NK cell population, suggesting differences in TME-induced recovery of CD56dim and CD56bright 
NK cells. This is in line with a previous study in which we also reported differences in 
immunophenotype of CD56dim in comparison with CD56bright NK cells in preoperative CRC patients [12], 
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implicating different roles for NK cell subsets in patients, thereby emphasizing the need to analyze 
these subsets separately.  
Several studies investigated short-term effects of surgical resection on the immune system 
in cancer patients (1-14 days after surgery) [32-36], whereas only a few studies focused on the long-
term effects (≥6 weeks after surgery). Although these studies did not investigate the expression of 
different activating and inhibitory cell surface receptors, they all report expansion of cytotoxic 
immune cell subsets after surgery, including NK cells, NKT cells, and CD8+ T cells [30-32], suggesting a 
more active immune system in patients after tumor resection, which is in line with our results. 
Importantly, the changes in immunophenotype of NK- and NKT-like cells observed in our study after 
surgery were restricted to patients that did not receive any adjuvant therapy, suggesting that adjuvant 
therapy delays or even prevents the recovery of TME-induced suppression of NK- and NKT-like cells. 
As the postoperative samples from adjuvant treated patients were obtained ≥5 months after the final 
therapy date, this implies long lasting immunosuppressive effects of adjuvant therapy. This is in line 
with a study in breast cancer patients that reported decreased numbers of CD4+ T cells and B cells 
even 9 months after completion of chemotherapy [37]. 
The fact that therapeutic interventions influenced the peripheral blood immune cell profile 
in CC patients, has consequences regarding its biomarker potential. In an ideal situation, biomarkers 
such as circulating immune cells could be used to monitor treatment response and risk of recurrence 
in patients over time. Our data suggest that TME-induced immunosuppression is de-activated after 
resection of the primary tumor. In theory, patients without complete resection of the tumor or 
patients with micrometastases after tumor resection still have a TME present which could mean that 
TME-induced immunosuppression of NK- and NKT-like cells is not removed. Despite the small sample 
size of our cohort and statistical correction for multiple testing, we still found significant results in our 
study. Further research is required to investigate whether the peripheral blood immune cell profile 
can be used as biomarker to determine the presence of residual tumor cells in cancer patients.  
In conclusion, we observed expansion of NKT-like cells and CD8+ T cells, and activation of 
both NK- and NKT-like cells after tumor resection in CC patients. This suggests TME-induced 
suppression of NK cells and NKT-like cells, an effect that could not be detected after surgical resection 
of the primary tumor. The changes in peripheral blood immune cell profile after tumor resection were 
restricted to patients that did not receive any adjuvant therapy, suggesting that adjuvant therapy 
delays or even prevents the recovery of TME-induced suppressed NK- and NKT-like cells in CC patients 




frozen PBMCs, not whole blood. Thus, trying to make measurements of cells/ml would be highly 
affected by the Ficoll procedure and sample preparation. This is a limitation of our study and should 
be considered when drawing conclusions. Grimm et al. reported no absolute increase of CD8+ T cells 
in patients with oral squamous cell carcinoma (OSCC) after surgery [31], suggesting no effect on 
absolute immune cell numbers after surgery. However, it must be realized that this study was focused 
on OSCC patients that might have a different preoperative peripheral blood immune profile compared 
to CC patients which might also respond different to tumor resection. Furthermore, OSCC patients are 
often treated with neoadjuvant radiotherapy which might influence the immune system over a long 
period of time. The study by Grimm et al. did not specify neoadjuvant and/or adjuvant treatment of 
the included OSCC patients in their study. Up till now, studies reported on the numbers of circulating 
immune cells and subset distribution in cancer patients after surgery [30-32], but not on the 
immunophenotype of specific immune cell subsets. It is important that this is considered since the 
immunophenotype of immune cells is closely related to their function. Hence, expansion of the NKT-
like cell population in CC patients after surgery does not necessarily mean that more effector cells are 
present. In this study, we showed that expression of activating receptors including NKG2D, NKp44, 
and CD8, was upregulated on NKT-like cells after surgery in non-adjuvant treated patients. 
Additionally, we observed a decrease in the percentage of inhibitory receptor CD158a+ and NKG2A+ 
NKT-like cells, suggesting that the NKT-like cell population expands and acquires expression of cell 
surface markers associated with functional activity in CC patients after tumor resection. In contrast to 
studies on laryngeal cancer [30] and oral squamous cell carcinoma [31], we did not observe expansion 
of the NK cell population after tumor resection. We did, however, observe a change in 
immunophenotype of NK cells resembling the pattern observed in NKT-like cells. Hence, we observed 
upregulation of activating receptors NKG2D, NKp44 and CD8 on CD56dim NK cells in non-adjuvant 
treated CC patients after tumor resection. In line with this, upregulation of activating receptors NKG2D 
and CD8 was observed on CD56bright NK cells as well as downregulation of the inhibitory receptor 
NKG2A after tumor resection in non-adjuvant treated CC patients, suggesting that both CD56dim NK 
and CD56bright NK cells acquired a more active phenotype after tumor resection and, therefore, 
possibly recovered from TME-induced immunosuppression. The only activating marker that was 
downregulated in CC patients after tumor resection was the percentage of CD16+ cells within the 
CD56bright NK cell population, suggesting differences in TME-induced recovery of CD56dim and CD56bright 
NK cells. This is in line with a previous study in which we also reported differences in 
immunophenotype of CD56dim in comparison with CD56bright NK cells in preoperative CRC patients [12], 
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implicating different roles for NK cell subsets in patients, thereby emphasizing the need to analyze 
these subsets separately.  
Several studies investigated short-term effects of surgical resection on the immune system 
in cancer patients (1-14 days after surgery) [32-36], whereas only a few studies focused on the long-
term effects (≥6 weeks after surgery). Although these studies did not investigate the expression of 
different activating and inhibitory cell surface receptors, they all report expansion of cytotoxic 
immune cell subsets after surgery, including NK cells, NKT cells, and CD8+ T cells [30-32], suggesting a 
more active immune system in patients after tumor resection, which is in line with our results. 
Importantly, the changes in immunophenotype of NK- and NKT-like cells observed in our study after 
surgery were restricted to patients that did not receive any adjuvant therapy, suggesting that adjuvant 
therapy delays or even prevents the recovery of TME-induced suppression of NK- and NKT-like cells. 
As the postoperative samples from adjuvant treated patients were obtained ≥5 months after the final 
therapy date, this implies long lasting immunosuppressive effects of adjuvant therapy. This is in line 
with a study in breast cancer patients that reported decreased numbers of CD4+ T cells and B cells 
even 9 months after completion of chemotherapy [37]. 
The fact that therapeutic interventions influenced the peripheral blood immune cell profile 
in CC patients, has consequences regarding its biomarker potential. In an ideal situation, biomarkers 
such as circulating immune cells could be used to monitor treatment response and risk of recurrence 
in patients over time. Our data suggest that TME-induced immunosuppression is de-activated after 
resection of the primary tumor. In theory, patients without complete resection of the tumor or 
patients with micrometastases after tumor resection still have a TME present which could mean that 
TME-induced immunosuppression of NK- and NKT-like cells is not removed. Despite the small sample 
size of our cohort and statistical correction for multiple testing, we still found significant results in our 
study. Further research is required to investigate whether the peripheral blood immune cell profile 
can be used as biomarker to determine the presence of residual tumor cells in cancer patients.  
In conclusion, we observed expansion of NKT-like cells and CD8+ T cells, and activation of 
both NK- and NKT-like cells after tumor resection in CC patients. This suggests TME-induced 
suppression of NK cells and NKT-like cells, an effect that could not be detected after surgical resection 
of the primary tumor. The changes in peripheral blood immune cell profile after tumor resection were 
restricted to patients that did not receive any adjuvant therapy, suggesting that adjuvant therapy 
delays or even prevents the recovery of TME-induced suppressed NK- and NKT-like cells in CC patients 




as a biomarker in CC, but should also be considered when developing cancer immunotherapy for CC 
patients. 




1. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 
2008. Eur J Cancer 2010, 46, 765-781, doi:10.1016/j.ejca.2009.12.014. 
2. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; 
Bray, F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J 
Cancer 2013, 49, 1374-1403, doi:10.1016/j.ejca.2012.12.027. 
3. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; 
Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 
2012. Int J Cancer 2015, 136, E359-386, doi:10.1002/ijc.29210. 
4. Van Cutsem, E., Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic 
colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 
2014, Suppl 3, iii1-9. 
5. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, 
M.; Berger, A.; Wind, P., et al. Type, density, and location of immune cells within human colorectal 
tumors predict clinical outcome. Science 2006, 313, 1960-1964, doi:10.1126/science.1129139. 
6. Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Berger, A.; Bindea, G.; Meatchi, T.; Bruneval, P.; Trajanoski, Z.; 
Fridman, W.H.; Pages, F., et al. Histopathologic-based prognostic factors of colorectal cancers are 
associated with the state of the local immune reaction. J Clin Oncol 2011, 29, 610-618, 
doi:10.1200/JCO.2010.30.5425. 
7. Finn, O.J. Host response in tumor diagnosis and prognosis: importance of immunologists and 
pathologists alliance. Exp Mol Pathol 2012, 93, 315-318, doi:10.1016/j.yexmp.2012.10.013. 
8. Galon, J.; Mlecnik, B.; Bindea, G.; Angell, H.K.; Berger, A.; Lagorce, C.; Lugli, A.; Zlobec, I.; Hartmann, A.; 
Bifulco, C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant 
tumours. J Pathol 2014, 232, 199-209, doi:10.1002/path.4287. 
9. Mlecnik, B.; Bindea, G.; Angell, H.K.; Maby, P.; Angelova, M.; Tougeron, D.; Church, S.E.; Lafontaine, L.; 
Fischer, M.; Fredriksen, T., et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a 
Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity 2016, 44, 698-711, 
doi:10.1016/j.immuni.2016.02.025. 
10. Galon, J.; Mlecnik, B.; Bindea, G.; Angell, H.K.; Berger, A.; Lagorce, C.; Lugli, A.; Zlobec, I.; Hartmann, A.; 
Bifulco, C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant 
tumours. J. Pathol. 2014, 232, 199-209. 
11. Pages, F.; Mlecnik, B.; Marliot, F.; Bindea, G.; Ou, F.S.; Bifulco, C.; Lugli, A.; Zlobec, I.; Rau, T.T.; Berger, 
M.D., et al. International validation of the consensus Immunoscore for the classification of colon cancer: 
a prognostic and accuracy study. Lancet 2018, 391, 2128-2139, doi:10.1016/S0140-6736(18)30789-X. 
12. Krijgsman, D.; de Vries, N.L.; Skovbo, A.; Andersen, M.N.; Swets, M.; Bastiaannet, E.; Vahrmeijer, A.L.; 
van de Velde, C.J.H.; Heemskerk, M.H.M.; Hokland, M., et al. Characterization of circulating T-, NK-, and 
NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer 
Immunol Immunother 2019, 10.1007/s00262-019-02343-7, doi:10.1007/s00262-019-02343-7. 
13. Cooper, M.A.; Fehniger, T.A.; Caligiuri, M.A. The biology of human natural killer-cell subsets. Trends 
Immunol 2001, 22, 633-640. 
14. Jonges, L.E.; Albertsson, P.; van Vlierberghe, R.L.; Ensink, N.G.; Johansson, B.R.; van de Velde, C.J.; 
Fleuren, G.J.; Nannmark, U.; Kuppen, P.J. The phenotypic heterogeneity of human natural killer cells: 
presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 2001, 53, 103-110. 
15. Krijgsman, D.; Hokland, M.; Kuppen, P.J.K. The Role of Natural Killer T Cells in Cancer-A Phenotypical 




as a biomarker in CC, but should also be considered when developing cancer immunotherapy for CC 
patients. 




1. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher, E. Estimates of cancer incidence and mortality in Europe in 
2008. Eur J Cancer 2010, 46, 765-781, doi:10.1016/j.ejca.2009.12.014. 
2. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; 
Bray, F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J 
Cancer 2013, 49, 1374-1403, doi:10.1016/j.ejca.2012.12.027. 
3. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; 
Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 
2012. Int J Cancer 2015, 136, E359-386, doi:10.1002/ijc.29210. 
4. Van Cutsem, E., Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic 
colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 
2014, Suppl 3, iii1-9. 
5. Galon, J.; Costes, A.; Sanchez-Cabo, F.; Kirilovsky, A.; Mlecnik, B.; Lagorce-Pages, C.; Tosolini, M.; Camus, 
M.; Berger, A.; Wind, P., et al. Type, density, and location of immune cells within human colorectal 
tumors predict clinical outcome. Science 2006, 313, 1960-1964, doi:10.1126/science.1129139. 
6. Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Berger, A.; Bindea, G.; Meatchi, T.; Bruneval, P.; Trajanoski, Z.; 
Fridman, W.H.; Pages, F., et al. Histopathologic-based prognostic factors of colorectal cancers are 
associated with the state of the local immune reaction. J Clin Oncol 2011, 29, 610-618, 
doi:10.1200/JCO.2010.30.5425. 
7. Finn, O.J. Host response in tumor diagnosis and prognosis: importance of immunologists and 
pathologists alliance. Exp Mol Pathol 2012, 93, 315-318, doi:10.1016/j.yexmp.2012.10.013. 
8. Galon, J.; Mlecnik, B.; Bindea, G.; Angell, H.K.; Berger, A.; Lagorce, C.; Lugli, A.; Zlobec, I.; Hartmann, A.; 
Bifulco, C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant 
tumours. J Pathol 2014, 232, 199-209, doi:10.1002/path.4287. 
9. Mlecnik, B.; Bindea, G.; Angell, H.K.; Maby, P.; Angelova, M.; Tougeron, D.; Church, S.E.; Lafontaine, L.; 
Fischer, M.; Fredriksen, T., et al. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a 
Stronger Predictor of Patient Survival Than Microsatellite Instability. Immunity 2016, 44, 698-711, 
doi:10.1016/j.immuni.2016.02.025. 
10. Galon, J.; Mlecnik, B.; Bindea, G.; Angell, H.K.; Berger, A.; Lagorce, C.; Lugli, A.; Zlobec, I.; Hartmann, A.; 
Bifulco, C., et al. Towards the introduction of the 'Immunoscore' in the classification of malignant 
tumours. J. Pathol. 2014, 232, 199-209. 
11. Pages, F.; Mlecnik, B.; Marliot, F.; Bindea, G.; Ou, F.S.; Bifulco, C.; Lugli, A.; Zlobec, I.; Rau, T.T.; Berger, 
M.D., et al. International validation of the consensus Immunoscore for the classification of colon cancer: 
a prognostic and accuracy study. Lancet 2018, 391, 2128-2139, doi:10.1016/S0140-6736(18)30789-X. 
12. Krijgsman, D.; de Vries, N.L.; Skovbo, A.; Andersen, M.N.; Swets, M.; Bastiaannet, E.; Vahrmeijer, A.L.; 
van de Velde, C.J.H.; Heemskerk, M.H.M.; Hokland, M., et al. Characterization of circulating T-, NK-, and 
NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer 
Immunol Immunother 2019, 10.1007/s00262-019-02343-7, doi:10.1007/s00262-019-02343-7. 
13. Cooper, M.A.; Fehniger, T.A.; Caligiuri, M.A. The biology of human natural killer-cell subsets. Trends 
Immunol 2001, 22, 633-640. 
14. Jonges, L.E.; Albertsson, P.; van Vlierberghe, R.L.; Ensink, N.G.; Johansson, B.R.; van de Velde, C.J.; 
Fleuren, G.J.; Nannmark, U.; Kuppen, P.J. The phenotypic heterogeneity of human natural killer cells: 
presence of at least 48 different subsets in the peripheral blood. Scand J Immunol 2001, 53, 103-110. 
15. Krijgsman, D.; Hokland, M.; Kuppen, P.J.K. The Role of Natural Killer T Cells in Cancer-A Phenotypical 




16. Biassoni, R., Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors 
and co-receptors. Immunol Rev 2001, 181, 203-214. 
17. Dutertre, C.A.; Bonnin-Gelize, E.; Pulford, K.; Bourel, D.; Fridman, W.H.; Teillaud, J.L. A novel subset of 
NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function. J 
Leukoc Biol 2008, 84, 1511-1520, doi:10.1189/jlb.0608343. 
18. Addison, E.G.; North, J.; Bakhsh, I.; Marden, C.; Haq, S.; Al-Sarraj, S.; Malayeri, R.; Wickremasinghe, R.G.; 
Davies, J.K.; Lowdell, M.W. Ligation of CD8alpha on human natural killer cells prevents activation-
induced apoptosis and enhances cytolytic activity. Immunology 2005, 116, 354-361, 
doi:10.1111/j.1365-2567.2005.02235.x. 
19. Peng, Y.P., Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive analysis of the percentage of 
surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, 
gastric cancer, and colorectal cancer. J Transl Med 2013, 11, 262, doi:1479-5876-11-262 
[pii];10.1186/1479-5876-11-262 [doi]. 
20. Rocca, Y.S., Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, et al. Altered phenotype in 
peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 2013, 
19, 76-85, doi:1753425912453187 [pii];10.1177/1753425912453187 [doi]. 
21. Gharagozloo, M.; Rezaei, A.; Kalantari, H.; Bahador, A.; Hassannejad, N.; Maracy, M.; Nouri, N.; Sedghi, 
M.; Ghazanfari, H.; Bayat, B. Decline in peripheral blood NKG2D+CD3+CD56+ NKT cells in metastatic 
colorectal cancer patients. Bratisl Lek Listy 2018, 119, 6-11, doi:10.4149/BLL_2018_002. 
22. Baginska, J.; Viry, E.; Paggetti, J.; Medves, S.; Berchem, G.; Moussay, E.; Janji, B. The critical role of the 
tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 
2013, 4, 490, doi:10.3389/fimmu.2013.00490. 
23. Vitale, M.; Cantoni, C.; Pietra, G.; Mingari, M.C.; Moretta, L. Effect of tumor cells and tumor 
microenvironment on NK-cell function. Eur J Immunol 2014, 44, 1582-1592, doi:10.1002/eji.201344272. 
24. Balsamo, M.; Manzini, C.; Pietra, G.; Raggi, F.; Blengio, F.; Mingari, M.C.; Varesio, L.; Moretta, L.; Bosco, 
M.C.; Vitale, M. Hypoxia downregulates the expression of activating receptors involved in NK-cell-
mediated target cell killing without affecting ADCC. Eur J Immunol 2013, 43, 2756-2764, 
doi:10.1002/eji.201343448. 
25. Han, B.; Mao, F.Y.; Zhao, Y.L.; Lv, Y.P.; Teng, Y.S.; Duan, M.; Chen, W.; Cheng, P.; Wang, T.T.; Liang, Z.Y., 
et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with 
Tumor Progression in Human Gastric Cancer. J Immunol Res 2018, 2018, 6248590, 
doi:10.1155/2018/6248590. 
26. Valayer, A.; Brea, D.; Lajoie, L.; Avezard, L.; Combes-Soia, L.; Labas, V.; Korkmaz, B.; Thibault, G.; 
Baranek, T.; Si-Tahar, M. Neutrophils can disarm NK cell response through cleavage of NKp46. J Leukoc 
Biol 2017, 101, 253-259, doi:10.1189/jlb.3AB0316-140RR. 
27. Bracci, L.; Schiavoni, G.; Sistigu, A.; Belardelli, F. Immune-based mechanisms of cytotoxic 
chemotherapy: implications for the design of novel and rationale-based combined treatments against 
cancer. Cell Death Differ 2014, 21, 15-25, doi:10.1038/cdd.2013.67. 
28. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to 
multiple testing. Journal of the Royal Statistical Society. Series B. 1995, 57, 289-300. 
29. Lynch, H.T.; Drescher, K.M.; de la Chapelle, A. Immunology and the Lynch syndrome. Gastroenterology 
2008, 134, 1246-1249, doi:10.1053/j.gastro.2008.02.008. 
30. Klatka, J.; Grywalska, E.; Hymos, A.; Krasowska, E.; Mielnik, M.; Siwicka-Gieroba, D.; Markowicz, J.; 
Trojanowski, P.; Olszanski, W.; Rolinski, J. Subpopulations of natural killer-T-like cells before and after 
surgical treatment of laryngeal cancer. Cent Eur J Immunol 2017, 42, 252-258, 
doi:10.5114/ceji.2017.70967. 
 Effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile 
107 
 
31. Grimm, M.; Feyen, O.; Hofmann, H.; Teriete, P.; Biegner, T.; Munz, A.; Reinert, S. Immunophenotyping 
of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour 
Biol 2016, 37, 3807-3816, doi:10.1007/s13277-015-4224-2. 
32. Angka, L.; Martel, A.B.; Kilgour, M.; Jeong, A.; Sadiq, M.; de Souza, C.T.; Baker, L.; Kennedy, M.A.; Kekre, 
N.; Auer, R.C. Natural Killer Cell IFNgamma Secretion is Profoundly Suppressed Following Colorectal 
Cancer Surgery. Ann Surg Oncol 2018, 25, 3747-3754, doi:10.1245/s10434-018-6691-3. 
33. Molling, J.W.; Kolgen, W.; van der Vliet, H.J.; Boomsma, M.F.; Kruizenga, H.; Smorenburg, C.H.; 
Molenkamp, B.G.; Langendijk, J.A.; Leemans, C.R.; von Blomberg, B.M., et al. Peripheral blood IFN-
gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent 
of tumor type or tumor load. Int J Cancer 2005, 116, 87-93, doi:10.1002/ijc.20998. 
34. Dovsak, T.; Ihan, A.; Didanovic, V.; Kansky, A.; Verdenik, M.; Hren, N.I. Effect of surgery and radiotherapy 
on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced 
oral cancer. BMC Cancer 2018, 18, 235, doi:10.1186/s12885-018-4136-9. 
35. Wang, W.H.; Xu, H.Y.; Zhao, Z.M.; Zhang, G.M.; Lin, F.W. Dynamic and significant changes of T-cell 
subgroups in breast cancer patients during surgery and chemotherapy. Int Immunopharmacol 2018, 65, 
279-283, doi:10.1016/j.intimp.2018.09.039. 
36. Lachmann, G.; von Haefen, C.; Kurth, J.; Yuerek, F.; Spies, C. Innate immunity recovers earlier than 
acquired immunity during severe postoperative immunosuppression. Int J Med Sci 2018, 15, 1-9, 
doi:10.7150/ijms.21433. 
37. Verma, R.; Foster, R.E.; Horgan, K.; Mounsey, K.; Nixon, H.; Smalle, N.; Hughes, T.A.; Carter, C.R. 
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer 






16. Biassoni, R., Cantoni C, Pende D, Sivori S, Parolini S, Vitale M, et al. Human natural killer cell receptors 
and co-receptors. Immunol Rev 2001, 181, 203-214. 
17. Dutertre, C.A.; Bonnin-Gelize, E.; Pulford, K.; Bourel, D.; Fridman, W.H.; Teillaud, J.L. A novel subset of 
NK cells expressing high levels of inhibitory FcgammaRIIB modulating antibody-dependent function. J 
Leukoc Biol 2008, 84, 1511-1520, doi:10.1189/jlb.0608343. 
18. Addison, E.G.; North, J.; Bakhsh, I.; Marden, C.; Haq, S.; Al-Sarraj, S.; Malayeri, R.; Wickremasinghe, R.G.; 
Davies, J.K.; Lowdell, M.W. Ligation of CD8alpha on human natural killer cells prevents activation-
induced apoptosis and enhances cytolytic activity. Immunology 2005, 116, 354-361, 
doi:10.1111/j.1365-2567.2005.02235.x. 
19. Peng, Y.P., Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive analysis of the percentage of 
surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, 
gastric cancer, and colorectal cancer. J Transl Med 2013, 11, 262, doi:1479-5876-11-262 
[pii];10.1186/1479-5876-11-262 [doi]. 
20. Rocca, Y.S., Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, et al. Altered phenotype in 
peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun 2013, 
19, 76-85, doi:1753425912453187 [pii];10.1177/1753425912453187 [doi]. 
21. Gharagozloo, M.; Rezaei, A.; Kalantari, H.; Bahador, A.; Hassannejad, N.; Maracy, M.; Nouri, N.; Sedghi, 
M.; Ghazanfari, H.; Bayat, B. Decline in peripheral blood NKG2D+CD3+CD56+ NKT cells in metastatic 
colorectal cancer patients. Bratisl Lek Listy 2018, 119, 6-11, doi:10.4149/BLL_2018_002. 
22. Baginska, J.; Viry, E.; Paggetti, J.; Medves, S.; Berchem, G.; Moussay, E.; Janji, B. The critical role of the 
tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front Immunol 
2013, 4, 490, doi:10.3389/fimmu.2013.00490. 
23. Vitale, M.; Cantoni, C.; Pietra, G.; Mingari, M.C.; Moretta, L. Effect of tumor cells and tumor 
microenvironment on NK-cell function. Eur J Immunol 2014, 44, 1582-1592, doi:10.1002/eji.201344272. 
24. Balsamo, M.; Manzini, C.; Pietra, G.; Raggi, F.; Blengio, F.; Mingari, M.C.; Varesio, L.; Moretta, L.; Bosco, 
M.C.; Vitale, M. Hypoxia downregulates the expression of activating receptors involved in NK-cell-
mediated target cell killing without affecting ADCC. Eur J Immunol 2013, 43, 2756-2764, 
doi:10.1002/eji.201343448. 
25. Han, B.; Mao, F.Y.; Zhao, Y.L.; Lv, Y.P.; Teng, Y.S.; Duan, M.; Chen, W.; Cheng, P.; Wang, T.T.; Liang, Z.Y., 
et al. Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with 
Tumor Progression in Human Gastric Cancer. J Immunol Res 2018, 2018, 6248590, 
doi:10.1155/2018/6248590. 
26. Valayer, A.; Brea, D.; Lajoie, L.; Avezard, L.; Combes-Soia, L.; Labas, V.; Korkmaz, B.; Thibault, G.; 
Baranek, T.; Si-Tahar, M. Neutrophils can disarm NK cell response through cleavage of NKp46. J Leukoc 
Biol 2017, 101, 253-259, doi:10.1189/jlb.3AB0316-140RR. 
27. Bracci, L.; Schiavoni, G.; Sistigu, A.; Belardelli, F. Immune-based mechanisms of cytotoxic 
chemotherapy: implications for the design of novel and rationale-based combined treatments against 
cancer. Cell Death Differ 2014, 21, 15-25, doi:10.1038/cdd.2013.67. 
28. Benjamini, Y.; Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to 
multiple testing. Journal of the Royal Statistical Society. Series B. 1995, 57, 289-300. 
29. Lynch, H.T.; Drescher, K.M.; de la Chapelle, A. Immunology and the Lynch syndrome. Gastroenterology 
2008, 134, 1246-1249, doi:10.1053/j.gastro.2008.02.008. 
30. Klatka, J.; Grywalska, E.; Hymos, A.; Krasowska, E.; Mielnik, M.; Siwicka-Gieroba, D.; Markowicz, J.; 
Trojanowski, P.; Olszanski, W.; Rolinski, J. Subpopulations of natural killer-T-like cells before and after 
surgical treatment of laryngeal cancer. Cent Eur J Immunol 2017, 42, 252-258, 
doi:10.5114/ceji.2017.70967. 
 Effects of tumor resection and adjuvant therapy on the peripheral blood immune cell profile 
107 
 
31. Grimm, M.; Feyen, O.; Hofmann, H.; Teriete, P.; Biegner, T.; Munz, A.; Reinert, S. Immunophenotyping 
of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue. Tumour 
Biol 2016, 37, 3807-3816, doi:10.1007/s13277-015-4224-2. 
32. Angka, L.; Martel, A.B.; Kilgour, M.; Jeong, A.; Sadiq, M.; de Souza, C.T.; Baker, L.; Kennedy, M.A.; Kekre, 
N.; Auer, R.C. Natural Killer Cell IFNgamma Secretion is Profoundly Suppressed Following Colorectal 
Cancer Surgery. Ann Surg Oncol 2018, 25, 3747-3754, doi:10.1245/s10434-018-6691-3. 
33. Molling, J.W.; Kolgen, W.; van der Vliet, H.J.; Boomsma, M.F.; Kruizenga, H.; Smorenburg, C.H.; 
Molenkamp, B.G.; Langendijk, J.A.; Leemans, C.R.; von Blomberg, B.M., et al. Peripheral blood IFN-
gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent 
of tumor type or tumor load. Int J Cancer 2005, 116, 87-93, doi:10.1002/ijc.20998. 
34. Dovsak, T.; Ihan, A.; Didanovic, V.; Kansky, A.; Verdenik, M.; Hren, N.I. Effect of surgery and radiotherapy 
on complete blood count, lymphocyte subsets and inflammatory response in patients with advanced 
oral cancer. BMC Cancer 2018, 18, 235, doi:10.1186/s12885-018-4136-9. 
35. Wang, W.H.; Xu, H.Y.; Zhao, Z.M.; Zhang, G.M.; Lin, F.W. Dynamic and significant changes of T-cell 
subgroups in breast cancer patients during surgery and chemotherapy. Int Immunopharmacol 2018, 65, 
279-283, doi:10.1016/j.intimp.2018.09.039. 
36. Lachmann, G.; von Haefen, C.; Kurth, J.; Yuerek, F.; Spies, C. Innate immunity recovers earlier than 
acquired immunity during severe postoperative immunosuppression. Int J Med Sci 2018, 15, 1-9, 
doi:10.7150/ijms.21433. 
37. Verma, R.; Foster, R.E.; Horgan, K.; Mounsey, K.; Nixon, H.; Smalle, N.; Hughes, T.A.; Carter, C.R. 
Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer 




A method for semi-automated image analysis
of HLA class I tumor epithelium expression
in rectal cancer
Daniëlle Krijgsman, Ronald L.P. van Vlierberghe, Vaios Evangelou, 
Alexander L. Vahrmeijer, Cornelis J.H. van de Velde, 
Cornelis F.M. Sier, Peter J.K. Kuppen
Eur J Histochem. 2019 May 20;63(2):3028
CHAPTER 5
A method for semi-automated image analysis
of HLA class I tumor epithelium expression
in rectal cancer
Daniëlle Krijgsman, Ronald L.P. van Vlierberghe, Vaios Evangelou, 
Alexander L. Vahrmeijer, Cornelis J.H. van de Velde, 
Cornelis F.M. Sier, Peter J.K. Kuppen





Biomarkers may hold the key towards development and improvement of personalized cancer 
treatment. For instance, tumor expression of immune system-related proteins may reveal the tumor 
immune status and, accordingly, determine choice for type of immunotherapy. Therefore, objective 
evaluation of tumor biomarker expression is needed but often challenging. For instance, human 
leukocyte antigen (HLA) class I tumor epithelium expression is cumbersome to quantify by eye due to 
its presence on both tumor epithelial cells and tumor stromal cells, as well as tumor-infiltrating 
immune cells. In this study, we solved this problem by setting up an immunohistochemical (IHC) 
double staining using a tissue microarray (TMA) of rectal tumors wherein HLA class I expression was 
colored with a blue chromogen, whereas non-epithelial tissue was visualized with a brown 
chromogen. We subsequently developed a semi-automated image analysis method that identified 
tumor epithelium as well as the percentage of HLA class I-positive tumor epithelium. Using this 
technique, we compared HCA2/HC10 and EMR8-5 antibodies for the assessment of HLA class I tumor 
expression and concluded that EMR8-5 is the superior antibody for this purpose. This IHC double 








Tissue biomarkers have a variety of applications and their use in the field of oncology is widespread. 
Immunohistochemistry (IHC) is used worldwide regarding morphological and pathological evaluation 
of tumor biomarkers, but several limitations and difficulties have been reported [1,2]. The evaluation 
of IHC staining’s of tumor tissue sections usually relies on visual microscopic inspection, manual 
annotation procedures, and inter-observer agreement. This method is prone to subjective criteria and 
will always be qualitative rather than quantitative. In our opinion, computer-assisted image analysis 
is crucial for determination of oncological biomarkers to acquire quantitative, objective and 
reproducible data, especially for large cohorts as used in tissue microarrays (TMAs).  
In this study, human leukocyte antigen (HLA) class I was chosen as tissue biomarker of interest 
for semi-automated analysis on a TMA of rectal cancer. Via presentation of tumor-associated antigens 
by HLA class I molecules, tumor cells can be recognized and killed by cytotoxic T cells. HLA molecules, 
therefore, play an important role in anti-tumor immune responses. Several cancer types, including 
rectal cancer, have been reported to downregulate HLA class I expression [3-5], which might lead to 
tumor escape from T cells. Studies showed that the degree of HLA class I expression on tumor cells 
contains important information regarding clinical outcome of patients for various cancer types [3-11]. 
Therefore, tumor HLA class I expression evaluation may be important for clinical cancer prognosis, but 
may also be included in the choice of immunotherapy for specific cancer patients. Unfortunately, HLA 
class I expression is cumbersome to quantify by eye on tumor epithelium, specifically due to its high 
heterogeneity in expression pattern and its presence on both tumor epithelial cells and tumor stromal 
cells, as well as tumor-infiltrating immune cells. Additionally, the evaluation of HLA class I expression 
is complicated due to the widespread use of antibodies that only recognize a selection of HLA class I 
A, B, and C alleles, such as HCA2 and HC10 [12-14]. These two antibodies are often combined to study 
HLA class I expression in order to cover the detection of as many different HLA class I alleles as possible 
[4-6,15]. Unfortunately, HCA2 cross-reacts with non-classical HLA class I molecules HLA-E, HLA-F, and 
HLA-G [12,13], thereby possibly leading to overestimation of the total HLA class I tumor expression. 
The introduction of a novel monoclonal antibody, EMR8-5, recognizing, and only recognizing, HLA 
class I A, B, and C alleles [16], may circumvent undetected reactivity and unwanted cross reactivity. In 
conclusion, HLA class I is a difficult and therefore particularly suited tissue biomarker for setting up 
semi-automated analysis. 
In order to solve the problem of discriminating between tumor epithelium and non-epithelial 
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whereas all non-epithelial tissue, i.e. stromal cells, blood vessels, and immune cells, was colored with 
a brown chromogen. Using a negative selection method, tumor epithelium could automatically be 
selected by excluding all brown-stained non-epithelial tissue. With this method we scored HLA class I 
expression in tumor epithelium in a TMA of primary tumors from rectal cancer patients. Next, we 
investigated whether EMR8-5 better detects HLA class I expression in tumor epithelium in rectal 
cancer than the combined HCA2/HC10 antibodies.  
 
Materials and Methods 
Study population 
The study population consisted of 495 patients diagnosed with rectal cancer included in the Dutch 
total mesorectal excision (TME) trial (January 12th, 1996, DUT-KWF-CKVO-9504, EORTC-40971, EU-
96020) who underwent TME surgery without pre-operative radiotherapy [7]. All patients included in 
the TME trial gave written informed consent for participation and retrospective use of samples 
gathered during the trial. A TMA was produced as described in the study by Reimers et al. [5], and 
used in this study. Tissue sections (4 µm) of the TMA blocks were cut following a standard procedure 
and transferred onto glass slides using tape. 
 
Antibodies 
The mouse monoclonal antibodies HCA2 and HC10 were used, which were kindly provided by Prof. 
Dr. J. Neefjes (LUMC, Leiden, The Netherlands). HCA2 recognizes the heavy chains of all HLA-A 
molecules except HLA-A24, as well as some HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G heavy chains 
[12,13]. HC10 is known to react with HLA-B and HLA-C heavy chains and with some alleles of HLA-A 
heavy chains (HLA-A*10, A*28, A*29, A*30, A*31, A*32, and A*33) [14]. Furthermore, the mouse 
monoclonal antibody EMR8-5 (ab70328, AbCam, Cambridge, UK) was used, which is reported to be 
an anti-pan classical HLA class I antibody, recognizing HLA-A, -B, and -C alleles [16]. It has been shown 
to strongly react with the extracellular domains that were tested (i.e. HLA- A*2402, A*0101, A*1101, 
A*0201, A*0207, B*0702, B*0801, B*1501, B*3501, B*4001, B*4002, B*4006, B*4403, Cw*0102, 
Cw*0801, Cw*1202, and Cw*1502) [16]. Additionally, a mix of rabbit polyclonal antibodies targeting 
collagen I, collagen VI, and elastin (ab34710, ab6588, and ab23747 respectively, all from AbCam) was 
used in order to stain extracellular matrix (ECM), to stain stromal tissue and blood vessels in tumor 
tissue. A rabbit monoclonal anti-CD45 antibody (ab40763, AbCam) was included to target tumor-
infiltrating immune cells. For each antibody, the dilution to obtain optimal staining was determined.  




An IHC double staining was set up wherein HLA expression was visualized with blue chromogen, 
whereas tumor stromal tissue, blood vessels, and tumor-infiltrating immune cells were colored with 
brown chromogen. Briefly, 4 µm thick TMA sections were deparaffinized and rehydrated followed by 
heat-mediated antigen retrieval in EnvisionTM FLEX target retrieval solution low pH (DAKO, Glostrup, 
Denmark) using a PT Link module (DAKO, Glostrup, Denmark). Endogenous peroxidase and 
phosphatase activity were blocked for 10 minutes with BloxAll solution (Vector Laboratories, 
Burlingame, USA). Two distinct antibody mixes were prepared in PBS/BSA 1% containing mouse 
(either HCA2/HC10 or EMR8-5) and rabbit antibodies (against collagen I, collagen VI, elastin and CD45) 
in the predetermined optimal dilutions. Tissue sections were then incubated overnight with either the 
HCA2/HC10-ECM-CD45 antibody mix or the EMR8-5-ECM-CD45 antibody mix. The following day, 
sections were incubated with AP-labelled secondary anti-mouse antibodies (MACH-2 Mouse AP-
polymer, Biocare Medical, CA, USA) and developed with a Vector Blue Substrate kit (Vector 
Laboratories, Burlingame, USA). Sections were subsequently incubated with anti-rabbit HRP-labelled 
secondary antibodies (Rabbit Envision, DAKO, Glostrup, Denmark) and developed with a DAB 
substrate kit (DAKO, Glostrup, Denmark). Note that the TMA tissue sections were not counterstained 
with haematoxylin, like in a standard IHC staining procedure. Finally, the sections were dehydrated 
and mounted with Ecomount (Biocare Medical, CA, USA).  
 
Semi-automated image analyses 
Stained sections were scanned using an IntelliSite Digital pathology slide scanner (Philips, Eindhoven, 
The Netherlands). Images of the scanned sections were opened with Philips Digital Pathology Solution 
software (release 2.3.1.1, Philips Electronics). Single tumor TMA cores were then identified within the 
scanned sections and exported as JPEG images (20x magnification). Next, the JPEG images were 
imported into AxioVision digital image processing software (release 4.9.1, Zeiss) and HLA class I 
expression in the TMA tumor cores was assessed as percentage HLA class I-positive tumor epithelium 
from the tumor epithelium area using the following method (For detailed description, see 
supplementary data). In short, the tissue area of interest in the TMA core was annotated manually in 
AxioVision software, thereby excluding necrotic areas and artefacts as a result of the staining 
procedure to prevent interference with the analysis. The first step of the computer-assisted analysis 
was tissue selection based on a threshold in the RGB channels (determined for each staining) for 
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containing <350,000 pixel2 in the tissue area (equivalent to <10% tissue area of the total core area) 
were excluded from analysis. In the second step, tumor epithelium was identified using hue luminance 
saturation (HLS) settings to discriminate between brown-stained stromal tissue, blood vessels, 
immune cells and HLA class I-positive or negative tumor epithelium. To correct for deposition of blue 
chromogen outside the tissue area, the settings for this step in the analysis were manually adapted 
for each TMA core. TMA cores with <5% tumor epithelium area (of the total tissue area) were excluded 
from analysis. Finally, HLA class I-positive tumor epithelium was identified within the total defined 
tumor epithelium area. This was accomplished by generation of a black and white image which was 
sorted into 256 levels of greyscale from black (0) to white (255). The two independent observers then 
determined the threshold for positive staining based on blinded assessment of five randomly selected 
TMA cores using the following method. The threshold for positive staining was decreased by 1 level 
at a time by the person responsible for the automated analysis until the independent observers 
indicated that the threshold resulted in optimal separation of HLA class I-positive and negative tumor 
epithelium. The mean of the 5 determined thresholds was used as cut-off value. Finally, to include the 
whole cell area of an HLA class I-positively stained tumor cell, the non-stained area within the cell (i.e. 
cytoplasm and nucleus) was included into the total tumor area considered as HLA class I-positive. The 
percentage of HLA class I-positive tumor epithelium among the total tumor epithelium area was semi-
automatically scored in steps of 0.1%. In addition, HLA class I scores were categorized as follows: 
<60%, 60-80%, 80-95%, or 95-100% HLA class I-positive tumor epithelium.  
 
Statistical analyses 
The percentage of HLA class I-positive tumor epithelium expression was compared between 
assessment by HCA2/HC10 and EMR8-5 antibodies using the Spearman correlation test. Furthermore, 
a Chi square test was used to correlate HLA class I categorical scoring between assessment by 
HCA2/HC10 and EMR8-5 antibodies. P-values ≤0.05 were considered statistically significant.  
 
Results 
HLA class I double staining  
HLA class I expression was evaluated in a TMA of 495 primary rectal tumors either by a combination 
of HCA2/HC10 antibodies or by EMR8-5. It was chosen to analyze one TMA core per patient in order 
to include a high variety of tissue cores in the analysis regarding morphology and HLA class I expression  
 





Figure 1. IHC double staining with subsequent semi-automated image analysis for HLA class I expression in four 
different TMA cores of rectal tumors with HCA2/HC10 or EMR8-5 antibodies. An IHC double staining was set up to 
analyze HLA class I expression in rectal cancer. Stromal tissue, blood vessels, and immune cells were stained brown 
whereas HLA class I expression (HCA2/HC10 antibody mix or EMR8-5) was stained blue. Representative images are 
presented of A. two TMA cores stained with the HCA2/HC10 antibody mix and B. two TMA cores stained with 
EMR8-5 antibodies. The arrows in the high magnification inserts indicate (brown-stained) tumor-infiltrating 
immune cells. The images illustrate the different steps of the semi-automated image analysis of HLA class I 
expression in rectal cancer. Tissue selected in each step of the analysis is indicated in green. First, all tissue in the 
core was selected. Second, tumor epithelium was identified within the tissue selection by subtraction of the brown 
stroma. Third, the percentage of HLA class I-positive epithelium area was scored within the epithelium selection 
as displayed in the upper right corner of each TMA core. Abbreviations: HLA (human leukocyte antigen), IHC 
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as heterogeneity of HLA class I expression among tumors and not within the tumors was subject of 
this study. Due to staining artefacts and loss of tissue cores during the staining procedure, the 
HCA2/HC10 and EMR8-5 staining’s could be evaluated in 284 (57.4%) and 298 tissue cores (60.2%) 
respectively. In total, 280 tissue cores were successfully evaluated for both IHC staining’s. Figure 1 
shows an example of HLA class I IHC staining in TMA cores of rectal tumors as assessed using 
HCA2/HC10 (Figure 1A) and EMR8-5 antibodies (Figure 1B). Please note that no overlap of blue and 
brown chromogens was present on tumor epithelium using this double staining, allowing for clear 
evaluation of HLA class I expression by tumor epithelium. Furthermore, this staining method enabled 
clear visualization of brown-stained tumor-infiltrating immune cells (inserts Figure 1). 
 
Semi-automated scoring of HLA class I expression with HCA2/HC10 antibodies  
HLA class I expression was semi-automatically scored in the tissue cores IHC-stained with HCA2/HC10 
antibodies. Figure 1A shows the sequential steps in the semi-automated image analysis, starting with 
selection of the total tissue area using RGB color settings. Due to deposition of blue chromogen 
outside the tissue area, probably as a result of binding of the antibodies to remnants of the tape that 
was used to transfer the TMA sections onto glass slides, the total tissue area was overestimated in 
approximately 20% of the evaluated TMA cores. These non-tissue containing areas were excluded 
from the semi-automated analysis in the next step in which all non-epithelial tissue was excluded from 
the tissue selection (i.e. negative selection). Please note that brown-stained tumor-infiltrating 
immune cells, together with brown-stained stromal tissue, were excluded from the tumor epithelium 
area selection (Figure 1A). Due to different composition of stromal tissue between tumors, the brown 
staining intensity varied between the tissue cores but this did not affect the image analysis. Finally, 
the area of HLA class I-positive tumor epithelium was selected. Based on blinded manual assessment 
of five randomly selected TMA cores, the threshold for HLA class I-positive staining using semi-
automated image analysis was determined as greyscale level 195. Thus, every pixel present in the 
tumor epithelium selection with a greyscale level between 0-195 was defined as HLA class I-positive, 
while all pixels with a greyscale level between 196-255 were defined as HLA class I negative. Figure 2 
shows a representative area of the TMA stained for HLA class I expression, using the method we 
developed. In total, 9/19 (42.1%) of the TMA cores containing rectal tumor tissue in Figure 2 could not 
be analyzed due to loss of tissue cores during the staining procedure, a phenomenon that is often 
observed when evaluating stained TMA tissue sections. The output from the semi-automated analysis 
for the example cores shown in Figure 2 is summarized in Table 1 and expressed as the number of 
 A method for semi-automated image analysis of HLA class I expression 
117 
 
pixels in the tissue area, tumor epithelium area and HLA class I-positive tumor epithelium area with 
the corresponding percentages. This information can be used to compensate for variation in the 
amount of tissue in different cores in case multiple tumor cores are evaluated per patient. In this 
study, we evaluated a single tumor core per patient and therefore, we did not compensate for 
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An IHC double staining was set up to analyze HLA class I expression in rectal cancer. Stromal tissue, blood vessels, 
and immune cells were stained brown whereas HLA class I expression (EMR8-5) was stained blue. A representative 
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Table 1. Example of the semi-automated image analysis output of TMA cores with rectal tumor tissue stained for 
HLA class I expression with EMR8-5 antibodies. The table summarizes the output of the semi-automated image 
analysis of the TMA cores stained for HLA class I expression shown in figure 2. TMA cores A3, A4, A5, B4, B5, C3 
and D5 were excluded from analyses since <350,000 pixel2 were present in the tissue area (equivalent to <10% 
tissue area of the total core area. C5 contained control placenta tissue and was therefore not analyzed. Finally, D1 
could not be analyzed since the tissue that may be tumor epithelium stained brown. As a result, no discrimination 
could be made in D1 between tumor epithelium and non-epithelial tissue. Abbreviations: HLA (human leukocyte 
antigen), NA (not applicable), TMA (tissue microarray). 
 
 
The mean percentage HLA class-I positive tumor epithelium area scored with the 
HCA2/HC10 antibody mix was 96.7%±5.3 (Table 2). In total, 220/284 (77.5%) of the TMA cores were 
scored with 95-100% HLA class I-positive tumor epithelium (Table 2). Additionally, 56/284 (19.7%) and 
8/284 (2.8%) tissue cores were scored with 80-95% and 60-80% HLA class I-positive tumor epithelium 
respectively (Table 2). No TMA cores were scored with <60% HLA class I-positive tumor epithelium 
(Table 2). These results indicate that the double staining method and subsequent semi-automated 
image analysis can be used to score HLA class I expression in TMA cores of rectal cancer, enabling use 
of objective and consequent scoring criteria. 
 
 Analyzed Tissue area Tumor epithelium area HLA class I-positive tumor area 
TMA 
Core 
y/n Pixel2 % of total 
core area 




% of tumor 
epithelium area 
A1 Y 2493655 71.2% 1561920 62.6% 1107401 70.9% 
A2 Y 2965056 84.7% 1107682 37.4% 1094390 98.8% 
A3 N NA NA NA NA NA NA 
A4 N NA NA NA NA NA NA 
A5 N 152566 4.4% NA NA NA NA 
B1 Y 2399358 68.6% 263289 11,0% 263026 99.9% 
B2 Y 2552283 72.9% 301687 11.8% 299877 99.4% 
B3 Y 2899882 82.9% 1578167 54.4% 1549760 98.2% 
B4 N NA NA NA NA NA NA 
B5 N 173445 5.0% NA NA NA NA 
C1 Y 2803175 80.1% 1328377 47.4% 1253988 94.4% 
C2 Y 2393691 68.4% 1567623 65.5% 1500215 95.7% 
C3 N NA NA NA NA NA NA 
C4 N NA NA NA NA NA NA 
C5 Y 3230220 92.3% 1233284 38.1% 1209852 98.1% 
D1 N 2370722 67.7% NA NA NA NA 
D2 Y 1212719 34.6% 936256 77.2% 870718 93.0% 
D3 Y 2810333 80.3% 690631 24.6% 556649 80.6% 
D4 y 1965909 56.2% 590244 30.0% 526498 89.2% 
D5 N 238838 6.8% NA NA NA NA 
 A method for semi-automated image analysis of HLA class I expression 
119 
 
Semi-automated scoring of HLA class I expression using EMR8-5 antibodies  
Next, we assessed HLA class I expression in TMA cores of rectal cancer with EMR8-5 antibodies using 
the same image analysis workflow as described above. The threshold for HLA class I-positive staining 
was used as determined for the HCA2/HC10 stained TMA cores. Figure 1B shows two representative 
TMA cores stained with EMR8-5 with the sequential steps in the semi-automated image analysis. 
More variation was observed in the percentages of HLA class I-positive tumor epithelium in TMA cores 
with EMR8-5 compared to HCA2/HC10 (Table 2). The mean percentage HLA class-I positive tumor 
epithelium area scored with the EMR8-5 antibodies was 92.9%±9.5 (Table 2). In contrast with the 
HCA2/HC10 antibody mix, almost no deposition of blue chromogen outside the tissue area was 
observed in the EMR8-5 staining, suggesting that EMR8-5 did not bind to remnants of the used tape. 
As a result, the total tissue area was not overestimated using EMR8-5. In conclusion, these results 
indicate that our IHC double staining technique and subsequent semi-automated image analysis can 
be used to score HLA class I expression on tumor epithelium using antibodies that recognize different 
HLA class I epitopes.  
 
 
Table 2. Overview of semi-automated scoring of HLA class I expression in a TMA of rectal cancer using HCA2/HC10 
or EMR8-5 antibodies. Tumor epithelium expression of HLA class I was scored in TMA tumor cores of 284 rectal 
cancer patients with HCA2/HC10 antibodies, and in 298 patients with EMR8-5 antibodies. The mean percentage of 
HLA class I-positive tumor epithelium area is shown in the table. In addition, HLA class I scores were categorized 
as follows: <60%, 60-80%, 80-95%, or 95-100% HLA class I-positive tumor epithelium. Abbreviation: HLA (human 
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Comparison of HCA2/HC10 and EMR8-5 antibodies for the assessment of HLA class I 
expression 
Finally, we compared the percentage of HLA class I-positive tumor epithelium in TMA cores of rectal 
cancer as assessed by HCA2/HC10 and EMR8-5 antibodies, respectively. In total, 280 tissue cores were 
successfully analyzed for both IHC staining’s. Scorings of HLA class I expression on tumor epithelium 
with HCA2/HC10 and EMR8-5 antibodies significantly correlated (ρ=0.136, P=0.022). Hence, tumor 
cores scored with a high area percentage of HLA class-I positive tumor epithelium assessed by 





Figure 3. Comparison of HCA2/HC10 and EMR8-5 antibodies for the evaluation of HLA class I expression in a TMA 
core of rectal cancer. An IHC double staining was set up to analyze HLA class I expression with HCA2/HC10 and 
EMR8-5 antibodies in a TMA of rectal cancer. Stromal tissue, blood vessels, and immune cells were stained brown 
whereas HLA class I expression was stained blue. The percentage of HLA class I-positive tumor epithelium area 
(indicated in the figure) was evaluated using semi-automated image analysis. Tissue selected by the software in 
each step of the analysis is indicated in green. First, all tissue in the TMA cores was selected. Second, tumor 
epithelium was identified within the tissue selection. Third, the percentage of HLA class I-positive epithelium area 
was scored within the epithelium selection. The example shows a TMA core that was observed to be positively 
stained with the HCA2/HC10 antibody mix, while being mostly negative regarding EMR8-5. These tissue cores 
might express non-classical HLA class I molecules such as HLA-E, HLA-F and/or HLA-G that are recognized by the 
HCA2/HC10 antibody mix but not by EMR8-5. Abbreviations: HLA (human leukocyte antigen), IHC 
(immunohistochemistry), TMA (tissue microarray).  
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epithelium using EMR8.5 antibodies and the other way around. However, scoring of HLA class I 
expression in categories did not correlate when assessed with HCA2/HC10 and EMR8-5 antibodies 
(P=0.101). We hypothesized that tumor epithelium would be scored equal or higher for HLA class I 
expression with HCA2/HC10 compared to EMR8-5 antibodies due to known cross reactivity of HCA2 
with non-classical HLA molecules [12,13]. In the majority of the TMA cores (82.5%), the percentage of 
HLA class I-positive tumor epithelium was scored equal (±10%) with HCA2/HC10 and EMR8-5 
antibodies. In a fraction of the tissue cores (4.3%), the percentage of HLA class I-positive epithelium 
was scored >10% higher with EMR8-5 compared to HCA2/HC10. When examined in further detail, the 
scored differences in these tissue cores were due to inaccurate selection of the tumor epithelium as 
a result of tissue damage and a relatively high amount of blue chromogen deposition outside the 
tissue area in the HCA2/HC10 staining. In contrast, 4 times as many tissue cores (13.2%) were 
observed with >10% higher HLA class I-positive percentage tumor epithelium area when assessed by 
HCA2/HC10 antibodies compared to EMR8-5. A representative tumor that was scored >10% higher 
with HCA2/HC10 compared to EMR8-5 is shown in Figure 3. TMA cores with this staining pattern might 
express non-classical HLA class I molecules such as HLA-E, HLA-F and/or HLA-G that are recognized by 
HCA2/HC10 antibodies, but not by EMR8-5. In conclusion, the staining patterns of HCA2/HC10 and 
EMR8-5 antibodies are different, characterized by recognition of additional epitopes by HCA2/HC10, 
most likely non-classical HLA class I molecules.  
 
Discussion 
In order to study the expression of clinical predictive and prognostic biomarkers in tumor tissue using 
IHC, it is essential that scoring is standardized. Here, we presented an IHC double staining and 
subsequent semi-automated image analysis method that can be used to score the tumor epithelium 
expression of HLA class I in rectal cancer. Importantly, our developed technique has a major advantage 
by allowing discrimination between epithelium and non-epithelial tissue, which enabled simple semi-
automated tissue selection based on color. This method therefore enabled quantification of a 
biomarker (i.e. HLA class I) on tumor epithelium, even when also expressed by stromal tissue and/or 
immune cells. Using our relatively simple IHC double staining technique, a straight forward slide 
scanner is sufficient in order to obtain images that can be analyzed at digital platforms that support 
JPEG files and that may be chosen based on availability and/or user experience. With the described 
image analysis method using AxioVision software, it was possible to calculate the percentage of HLA 
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scoring method is relatively fast and simple, it is highly suitable for analysis of biomarker expression 
on tumor tissue in both research and clinical settings. To the best of our knowledge, we are the first 
to describe a double staining method for semi-automated image analysis of biomarkers expressed by 
cancer tissue using a TMA.  
Many different techniques have been reported to evaluate biomarkers on tumor tissue [17-
22]. Some studies, using MATLAB software, could give insights in the relocation of tumor biomarkers 
between a cell’s membrane, cytoplasm and nucleus using RGB unmixing of images of conventional 
IHC-stained sections (DAB and haematoxylin signals) [20,21]. Additionally, MATLAB software 
(MIAQuant code) was recently reported as novel computational method for the quantification of IHC 
stained tissue sections [23,24]. This software is already used in clinical cancer research for 
determination of the expression of microRNAs in melanomas, which might have value in prediction of 
poor immunotherapy outcome [25]. As no discrimination could be made between tumor epithelium 
and non-epithelial tissue, this method is not suitable for quantification of tumor biomarkers that are 
also expressed by non-epithelial cells. Other studies reported that the software platform ImageJ can 
be used to evaluate the expression of biomarkers based on its immunohistochemical staining intensity 
on a TMA in a high throughput manner [17-19]. Using this method, the tumor-epithelium specific 
expression of biomarkers could be analyzed since the biomarker expression signal on epithelium was 
higher compared to non-epithelial tissue. Hence, the threshold for positive staining was set in a way 
that the relatively low signal in stromal tissue was scored as negative. Unfortunately, this method 
cannot be used for tumor epithelium-specific evaluation of biomarkers like HLA class I, that are also 
expressed at high levels on non-tumor cells. Recent studies using digital image analysis software 
QuPath or ImageJ showed that it is in principle possible to score biomarkers such as p53, Ki67, PR, 
HER2, and CD3 on tumor epithelium cells with standard IHC and haematoxylin counterstaining 
without a need for tumor or stromal identification markers [26-28]. However, it should be considered 
that the deep learning algorithms used in these analyses have disadvantages as a large number of 
training samples are required that need to be manually annotated by experts, thereby making it a 
time-consuming method to set up [29,30]. Additionally, deep learning algorithms often require the 
use of expensive microscopes and complicated software. For the future, it is likely that deep-learning 
algorithms in combination with the presented IHC double staining are even better for accurate scoring 
of biomarker expression on tumor epithelium. Importantly, deep learning algorithms might be less 
complicated to set up based on our IHC double staining since we used staining of non-epithelial cells 
instead of morphological features to distinguish tumor cells from other cells.  
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Although our semi-automated image analysis method has many advantages compared to 
other automated image analysis techniques, it also presents with some limitations. For instance, it 
provides information regarding the percentage of HLA class I-positive tumor epithelial area instead of 
percentage of tumor cells. Inclusion of a nuclear stain to the presented IHC staining would be required 
to estimate the latter. For this purpose, it is necessary to discriminate between more than two colors 
on one tissue slide for which the current software like we used is not suitable. Deep learning software, 
for instance in combination with spectral imaging, may solve this problem. Additionally, although 
infiltrating immune cells could be visualized and excluded from the tumor epithelium selection, it was 
not possible to quantify them in TMA tumor cores. This was due to the use of one chromogen for both 
immune cells and other non-epithelial cells, thereby complicating discrimination of these cell types. 
For detailed analyses of infiltrating immune cells, multiplex immunofluorescence is advised [31,32]. 
Furthermore, our IHC double staining does not discriminate between normal epithelium and tumor 
epithelium. This is not an issue when analyzing TMA tumor cores since the location of these tumor 
tissue cores has been annotated and checked by a pathologist. When analyzing whole tissue sections, 
however, it will be necessary to visually verify which areas contain tumor epithelium and should 
therefore be analyzed. Finally, as described in the Materials and Methods section, the presented IHC 
double staining uses species-specific antibodies, meaning that in combination with the rabbit-derived 
ECM/CD45 antibody mix, biomarkers can be evaluated using any non-rabbit-derived antibodies. In 
case only rabbit antibodies are available for the evaluation of a specific biomarker, a new ECM/CD45 
mix has to be prepared with antibodies derived from another species.  
HCA2 and HC10 antibodies are often used to study HLA class I expression in cancer [4-6,15]. 
Importantly, the combination of HCA2 and HC10 antibodies overestimates the total HLA class I 
expression due to the cross reaction of HCA2 with non-classical HLA molecules [12,13] that are known 
to be present in rectal tumors [5,15]. In this study, we showed that some TMA cores of rectal cancer 
positively stained with HCA2/HC10 antibodies while being negative regarding EMR8-5, thereby 
suggesting that EMR8-5 indeed does not cross react with additional non-classical HLA molecules [16]. 
Therefore, in our opinion, EMR8-5 is a better monoclonal antibody to assess the expression of HLA 
class I specifically compared to a mix of HCA2/HC10 antibodies. 
In conclusion, the presented IHC double staining and subsequent semi-automated image 
analysis can be used for the scoring of HLA class I expression on tumor epithelium, thereby acquiring 
quantitative and objective data. This staining method and automated analysis can be expanded to any 
other tissue biomarker and also to different (epithelial) cancer types, and is therefore widely 
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22]. Some studies, using MATLAB software, could give insights in the relocation of tumor biomarkers 
between a cell’s membrane, cytoplasm and nucleus using RGB unmixing of images of conventional 
IHC-stained sections (DAB and haematoxylin signals) [20,21]. Additionally, MATLAB software 
(MIAQuant code) was recently reported as novel computational method for the quantification of IHC 
stained tissue sections [23,24]. This software is already used in clinical cancer research for 
determination of the expression of microRNAs in melanomas, which might have value in prediction of 
poor immunotherapy outcome [25]. As no discrimination could be made between tumor epithelium 
and non-epithelial tissue, this method is not suitable for quantification of tumor biomarkers that are 
also expressed by non-epithelial cells. Other studies reported that the software platform ImageJ can 
be used to evaluate the expression of biomarkers based on its immunohistochemical staining intensity 
on a TMA in a high throughput manner [17-19]. Using this method, the tumor-epithelium specific 
expression of biomarkers could be analyzed since the biomarker expression signal on epithelium was 
higher compared to non-epithelial tissue. Hence, the threshold for positive staining was set in a way 
that the relatively low signal in stromal tissue was scored as negative. Unfortunately, this method 
cannot be used for tumor epithelium-specific evaluation of biomarkers like HLA class I, that are also 
expressed at high levels on non-tumor cells. Recent studies using digital image analysis software 
QuPath or ImageJ showed that it is in principle possible to score biomarkers such as p53, Ki67, PR, 
HER2, and CD3 on tumor epithelium cells with standard IHC and haematoxylin counterstaining 
without a need for tumor or stromal identification markers [26-28]. However, it should be considered 
that the deep learning algorithms used in these analyses have disadvantages as a large number of 
training samples are required that need to be manually annotated by experts, thereby making it a 
time-consuming method to set up [29,30]. Additionally, deep learning algorithms often require the 
use of expensive microscopes and complicated software. For the future, it is likely that deep-learning 
algorithms in combination with the presented IHC double staining are even better for accurate scoring 
of biomarker expression on tumor epithelium. Importantly, deep learning algorithms might be less 
complicated to set up based on our IHC double staining since we used staining of non-epithelial cells 
instead of morphological features to distinguish tumor cells from other cells.  
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Although our semi-automated image analysis method has many advantages compared to 
other automated image analysis techniques, it also presents with some limitations. For instance, it 
provides information regarding the percentage of HLA class I-positive tumor epithelial area instead of 
percentage of tumor cells. Inclusion of a nuclear stain to the presented IHC staining would be required 
to estimate the latter. For this purpose, it is necessary to discriminate between more than two colors 
on one tissue slide for which the current software like we used is not suitable. Deep learning software, 
for instance in combination with spectral imaging, may solve this problem. Additionally, although 
infiltrating immune cells could be visualized and excluded from the tumor epithelium selection, it was 
not possible to quantify them in TMA tumor cores. This was due to the use of one chromogen for both 
immune cells and other non-epithelial cells, thereby complicating discrimination of these cell types. 
For detailed analyses of infiltrating immune cells, multiplex immunofluorescence is advised [31,32]. 
Furthermore, our IHC double staining does not discriminate between normal epithelium and tumor 
epithelium. This is not an issue when analyzing TMA tumor cores since the location of these tumor 
tissue cores has been annotated and checked by a pathologist. When analyzing whole tissue sections, 
however, it will be necessary to visually verify which areas contain tumor epithelium and should 
therefore be analyzed. Finally, as described in the Materials and Methods section, the presented IHC 
double staining uses species-specific antibodies, meaning that in combination with the rabbit-derived 
ECM/CD45 antibody mix, biomarkers can be evaluated using any non-rabbit-derived antibodies. In 
case only rabbit antibodies are available for the evaluation of a specific biomarker, a new ECM/CD45 
mix has to be prepared with antibodies derived from another species.  
HCA2 and HC10 antibodies are often used to study HLA class I expression in cancer [4-6,15]. 
Importantly, the combination of HCA2 and HC10 antibodies overestimates the total HLA class I 
expression due to the cross reaction of HCA2 with non-classical HLA molecules [12,13] that are known 
to be present in rectal tumors [5,15]. In this study, we showed that some TMA cores of rectal cancer 
positively stained with HCA2/HC10 antibodies while being negative regarding EMR8-5, thereby 
suggesting that EMR8-5 indeed does not cross react with additional non-classical HLA molecules [16]. 
Therefore, in our opinion, EMR8-5 is a better monoclonal antibody to assess the expression of HLA 
class I specifically compared to a mix of HCA2/HC10 antibodies. 
In conclusion, the presented IHC double staining and subsequent semi-automated image 
analysis can be used for the scoring of HLA class I expression on tumor epithelium, thereby acquiring 
quantitative and objective data. This staining method and automated analysis can be expanded to any 
other tissue biomarker and also to different (epithelial) cancer types, and is therefore widely 
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Introduction: Natural killer (NK) cells and natural killer T (NKT) cells are implicated in the development 
and progression of colorectal cancer (CRC). Tumor cells express NK cell receptor ligands that modulate 
their function. This study aimed to investigate the expression of such ligands in CRC in relation to the 
phenotype of circulating NK- and NKT cells, and clinical outcome. 
 
Methods: Primary tumor tissues were analyzed for protein expression of NK cell ligands using 
immunohistochemistry with automated image analysis in a cohort of 78 CRC patients. For 24 of the 
78 patients, RNA expression of NK cell ligands was analyzed in primary tumor tissue using RNA 
sequencing. Receptor expression on circulating NK- and NKT cells was previously measured by us in 
71 of the 78 patients using flow cytometry.  
 
Results: High Proliferating Cell Nuclear Antigen (PCNA) protein expression in the primary tumor 
associated with shorter disease-free survival (DFS) of CRC patients (P=0.026). A trend was observed 
towards shorter DFS in CRC patients with above-median galectin-3 protein expression in the primary 
tumor (P=0.055). High protein expression of galectin-3, CD1d, and human leukocyte antigen (HLA) 
class I, and high RNA expression of UL16-binding protein (ULBP)-1, -2, and -5, and HLA-E in the tumor 
tissue correlated with low expression of the corresponding receptors on circulating NK- or NKT cells 
(P<0.05).  
 
Conclusions: Galectin-3 and PCNA expression in the primary tumor may be prognostic biomarkers in 
CRC patients. Furthermore, our results suggest that NK cell receptor ligands expressed by tumor cells 
may modulate the phenotype of circulating NK- and NKT cells, and facilitate immune escape of 








It has become increasingly clear that natural killer (NK) cells and natural killer T (NKT) cells use cell 
surface receptors to regulate their response to abnormal cells, including virus-infected cells and tumor 
cells [1,2]. Different inhibitory and activating receptors play a role in this process to dynamically 
regulate the activation state of NK cells [3], and probably NKT cells as well [4]. The activating receptors 
include natural killer group 2-C (NKG2C), natural killer group 2-D (NKG2D), DNAX accessory molecule-
1 (DNAM-1), CD161, and the natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46. Other 
important activating receptors include the killer cell Immunoglobulin-like receptors (KIRs) 
CD158h/j/l/g/e [5]. CD16 (FcγRIII) on NK cells mediates antibody-dependent cell-mediated 
cytotoxicity (ADCC) [6]. Additionally, NKT cells express an invariant Vα24 T cell receptor (TCR) which 
functions as an activating receptor on these cells [4]. NK- and NKT cells also express a range of 
receptors that provide inhibitory signals upon stimulation, including natural killer group 2-A (NKG2A) 
and KIRs CD158a/b/f/e/k/z, as well as the Ig-like transcript 2 (ILT2) receptor [5,7]. Furthermore, NK 
cells express receptors with both inhibiting and activating functions, depending on the binding motifs 
they attract during downstream signaling. These receptors include signaling lymphocytic activation 
molecule (SLAM)F4, SLAMF6, and SLAMF7 receptors, and the KIR CD158d [5,8]. Important roles have 
been implicated for NK- and NKT cells in tumor development and progression in different cancer 
types, including colorectal cancer (CRC) [4,9,10]. 
We [11] and others [12,13] reported phenotypic dysregulation of NK- and NKT cells in 
peripheral blood of CRC patients as compared to healthy donors, characterized by downregulation of 
the NCRs NKp30, NKp44, and NKp46, and NKG2D. NK cells can be subdivided based on their CD56 
expression: CD56dim NK cells primarily exert cytotoxic functions, while CD56bright NK cells are generally 
associated with immunoregulatory properties and production of pro-inflammatory cytokines [14,15]. 
Our study showed that circulating CD56dim NK cells were phenotypically altered in CRC patients, 
whereas CD56bright NK cells were not [11]. This implicates different roles of CD56dim and CD56bright NK 
cells in cancer progression, thereby emphasizing the need to discriminate between these NK cell 
subsets in future studies. Furthermore, circulating NK cells from CRC patients were observed to show 
impaired interferon (IFN)-γ secretion and degranulation upon activation [13]. This suggests 
impairment of NK cell activity in the circulation of CRC patients, which may facilitate the dissemination 
of tumor cells in the circulation, resulting in outgrowth of distant metastases. Interestingly, we 
showed that expression of NKp44 and NKG2D on circulating NK- and NKT cells increased in CRC 
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tumor and its tumor microenvironment (TME) on NK- and NKT cell phenotype, which is abolished after 
surgical resection of the tumor. Several studies suggested a role for expression of NK cell ligands by 
tumor cells in the modulation of NK- and NKT cell phenotype [17,18].  
The activating receptors expressed by NK- and NKT cells recognize different cell stress-
related ligands that may be expressed and/or secreted by tumor cells. The inhibitory receptors all 
recognize different human leukocyte antigen (HLA) class I molecules. In this study, we focused on 
ligands that bind to activating receptors (NCRs and NKG2D) that were shown to be downregulated on 
circulating NK- and NKT cells in CRC patients as discussed above [11-13]. We focused on the ligands 
galectin-3 and Proliferating Cell Nuclear Antigen (PCNA) as these ligands showed clinical relevance in 
cancer based on literature [19-21]. Galectin-3 may be expressed by tumor cells on their cell surface 
which promotes epithelial-mesenchymal transition (EMT) of tumor cells [22]. Furthermore, tumor 
cells can upregulate expression of PCNA which facilitates and controls DNA replication via DNA 
polymerases [23-25]. Upon binding, galectin-3 and PCNA inhibit the function of the receptors NKp30 
[19] and NKp44 [24], respectively. Upregulation of galectin-3 and PCNA have been shown to result in 
decreased NK cell-mediated lysis of tumor cells [19-21]. Furthermore, we focused on KIR receptors in 
this study, and the TCR on NKT cells specifically, as these receptors play crucial roles in the inhibition 
and activation of NK- and NKT cells [4,26], and therefore have clinical importance in mediating 
immunosurveillance [27,28]. The inhibitory KIRs CD158a and CD158b that were investigated in this 
study both recognize HLA-C molecules and therefore compete for binding [5]. Furthermore, the TCR 
on NKT cells recognizes different glycolipids in the context of the HLA-like molecule CD1d [29]. Co-
stimulation of the CD161 receptor is vital in TCR/CD1d interactions, since its presence is necessary for 
TCR activation [30]. Several studies have now provided evidence that NK receptor-ligand interactions 
are involved in tumor surveillance [31] and have therefore suggested them as new targets for immune 
checkpoint inhibitors [32]. However, the underlying biology of these receptor-ligand interactions and 
their role in immune evasion remains unclear. Therefore, the aim of the present study was to 
investigate protein and RNA expression of NK cell ligands in primary colorectal tumors, and relate this 
expression to the phenotype of circulating CD56dim NK cells, CD56bright NK cells, and NKT cells in the 




 Expression of NK receptor ligands in primary colorectal cancer tissue 
133 
 
Materials and methods 
Study population 
Seventy-eight patients, diagnosed with Tumor Node Metastasis (TNM) stage 0-IV colorectal 
adenocarcinomas between 2001 and 2007 in the Leiden University Medical Center (LUMC, the 
Netherlands), were included in the present study. All patients underwent surgical tumor resection. 
None of the patients received pre-operative chemotherapy or were diagnosed with Lynch syndrome. 
Formalin-fixed paraffin-embedded (FFPE) tumor tissue was obtained from primary CRC tissues of all 
78 included patients. Furthermore, frozen primary tumor tissue for RNA-sequencing was obtained 
from 24 of the 78 patients. Peripheral blood mononuclear cells (PBMCs) were previously collected and 
analyzed by us for 71 of the 78 patients prior to surgery, and for 24 of the 78 patients after surgery as 
described elsewhere [11,16]. Hence, pre- and postoperative PBMC samples were collected and 
analyzed for 24 patients [16]. Clinicopathological data of all patients were available. All blood samples 
were obtained after approval by the Medical Ethical Committee of the LUMC (protocol number 
P000.193). Frozen tumor samples for RNA-sequencing were used following the code of good conduct 
regarding secondary use of human tissue as described in “Human Tissue and Medical Research: Code 
of Conduct for responsible use (2011)” Drawn up by the FEDERA. All procedures performed in this 
study were in accordance with the ethical standards of the Dutch law (“WMO”, medical research 
involving human subjects act), and with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards. All CRC patients included in this study agreed to our use of their PBMCs 
and data for research purposes prior to blood sampling by written informed consent, and agreed to 
anonymous publication of the resulting data. 
 
Public data 
RNASeq data from The Cancer Genome Atlas (TCGA) colon adenocarcinoma (COAD) cohort was 
downloaded using TCGABiolinks [33]. Normalization of RNA-seq data was performed within lanes, 
between lanes, and per quantile using the same package. Subsequently, samples were filtered from 
the dataset using the “ExtractTissueSpecificSamples” function from TCGA Assembler package (v2.03.) 
to select tissue type solid primary tumor (“TP”, N=478) and solid normal tissue (“NT”, N=41) samples. 
 
Antibodies 
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UK), galectin-3 (A3A12, ab2785, Abcam), PCNA (PC10, 13-3900, Invitrogen, Leiden, The Netherlands), 
and CD1d (NOR3.2 (NOR3.2/13.17, ab11076, Abcam) in tumor tissue. Additionally, a mix of rabbit 
polyclonal antibodies targeting collagen I, collagen VI, and elastin (ab34710, ab6588, and ab23747 
respectively, all from AbCam) was used in order to stain extracellular matrix (ECM) and blood vessels 
in tumor stromal tissue. A rabbit monoclonal anti-CD45 antibody (ab40763, AbCam) was included to 




In order to automatically detect and score biomarkers expressed on CRC cells, it is essential that the 
software can discriminate between epithelium and other cell types in the tumor tissue. Therefore, we 
previously set up a double staining protocol wherein a biomarker (HLA class I) was visualized with blue 
chromogen, whereas all non-epithelial tissue, i.e. stromal tissue, blood vessels, and immune cells, was 
colored with brown chromogen [34]. In this previously described staining, no counterstaining was 
included, thereby disabling the possibility to identify cells. In the present study, a hematoxylin 
counterstaining was added to the previously developed staining, and the blue chromogen that was 
used to detect biomarker expression on tumor epithelium was changed to pink. Using this method, 
expression of NK cell ligands was studied on tumor epithelial cells of primary CRC tumors. Briefly, four 
sequential whole tumor tissue sections (4 µm thick) were obtained from the tumors of 78 CRC patients 
and used for HLA class I, galectin-3, PCNA, and CD1d IHC stainings, respectively. The tumor tissue 
sections were deparaffinized and rehydrated followed by heat-mediated antigen retrieval in 
EnvisionTM FLEX target retrieval solution low pH (DAKO, Glostrup, Denmark) using a PT Link module 
(DAKO). Endogenous peroxidase and phosphatase activity were blocked with BloxAll solution (Vector 
Laboratories, Burlingame, CA, USA) for 10 minutes. An antibody mix was prepared in PBS/BSA 1% 
containing mouse (either anti-HLA class I, anti-galectin-3, anti-PCNA, or anti-CD1d) and rabbit 
antibodies (against collagen I, collagen VI, elastin and CD45) in the predetermined optimal dilutions. 
Tissue sections were then incubated overnight. The following day, sections were incubated with AP-
labelled secondary anti-mouse antibodies (MACH-2 Mouse AP-polymer, Biocare Medical, Pacheco, 
CA, USA) and developed with a Vulcan Fast Red chromogen kit (Biocare Medical). Sections were 
subsequently incubated with anti-rabbit HRP-labelled secondary antibodies (Rabbit Envision, DAKO) 
and developed with a DAB substrate kit (DAKO). Tissue sections were then counterstained with 
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hematoxylin (Klinipath, Amsterdam, The Netherlands). Finally, the sections were dehydrated and 
mounted with Ecomount (Biocare Medical).  
 
Automated image analyses  
The VECTRA 3.0 automated quantitative pathology imaging system (Akoya Biosciences, Marlborough 
MA, USA) was used for imaging of the multiplexed-stained slides. The whole tissue sections were 
scanned at a 10x magnification. In consultation with a pathologist, it was assessed whether a tumor 
border could be identified in the tissue sections where tumor epithelium tissue was adjacent to 
normal epithelium and/or other normal tissue. The tumor border was defined as the band of 1 mm at 
the transition between tumor and normal tissue. The tumor center area was defined as the area 
containing tumor epithelium that was not adjacent to any normal tissue within a range of 1 mm. 
PhenoChart software (Akoya Biosciences, 1.0.4.) was used to randomly select 6 multispectral imaging 
(MSI) fields within the tumor center, which were then scanned at a higher resolution (20x). Since PCNA 
expression was expected to be higher at the tumor border due to its cell proliferative function, 5 MSI 
fields were also selected at the tumor border in the tissue sections stained for PCNA. InForm software 
(Akoya Biosciences, 2.2.1) was used to prepare a spectral library of every fluorophore. Spectral 
unmixing was then performed on the multiplexed-stained slides. Thereafter, in order to automatically 
define tumor epithelium, stroma, and areas without tissue, a tissue segmentation algorithm was 
trained using InForm software based on DAB (stroma) and hematoxylin (tumor epithelium and 
stroma) signals within the selected tumor areas. Then, a cell segmentation algorithm was set up based 
on detection of cell nuclei using the hematoxylin signal, followed by detection of the cytoplasm and 
cell membrane of the cells using signals from the pink staining. The cell membrane of tumor epithelial 
cells was then scored as negative, weak positive, or strong positive for either HLA class I, galectin-3, 
PCNA, or CD1d expression using set thresholds. Two independent observers determined the 
thresholds based on blinded assessment of 10 randomly selected MSI fields from PCNA-stained tumor 
tissue sections. The thresholds were slowly increased by 1 level at a time until the independent 
observers indicated that the thresholds resulted in optimal visual separation of negative (no staining), 
weak PCNA positive (weakly stained), and strong PCNA positive (strongly stained) tumor cells. The 
determined thresholds on the PCNA-stained tissue sections were also used to score HLA class I, 
galectin-3, and CD1d expression. Hence, all sections were quantified with image analysis software 
using the same criteria. The percentage of positive cells (the percentage of cells with weak and strong 
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analyses since it also takes the intensity of the staining into account. This H-score was calculated by 
the InForm software using the following formula: [(0 * % of negative cells) + (1 * % of weak positive 
cells) + (2 * % of strong positive cells)].  
 
Flow cytometry  
PBMC samples were isolated and immunophenotyped using multiparameter flow cytometry as 
previously published [11,16]. Briefly, expression of CD16, CD158a, CD158b, NKG2A, NKG2C, CD161, 
CD8, DNAM-1, NKG2D, NKp30, NKp44, and NKp46 were determined on circulating CD56dim NK cells, 
CD56bright NK cells, and NKT cells [11,16]. Where possible, the percentage of positive cells and median 
fluorescence intensity (MFI) of these receptors were determined since both the presence of the 
receptor as the expression level can be biologically relevant.  
 
RNA sequencing 
Fresh frozen tumor samples available from the biobank (Dept. of Surgery, LUMC) were sectioned for 
nucleic acid extraction using a cryostat. Tissue sections flanking the corresponding samples were 
hematoxylin and eosin (H&E) stained to confirm tissue morphology. RNA and DNA were isolated using 
the AllPrep DNA/RNA Mini Kit (Qiagen, Venlo, The Netherlands) automated in the QIAcube, according 
to manufactures protocol. RNA sequencing (HiSeq4000) data was aligned to the human reference 
genome (hg38) using HISAT2 (v2.1.0). Within lane, between lane, and per quantile normalization was 
performed on the raw counts (featureCounts, subreads v1.5.1) with R package EDASeq (v2.12.0). RNA 
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Statistical analyses were performed using SPSS software (IBM SPSS Statistics 24, Chicago, IL, USA). A 
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surgery until first evidence of disease recurrence or until death, whichever came first, or end of follow-
up (censored). Cox regression analysis was used for univariate and multivariate analyses. R package 
“ggplot2” (v3.3.2) was used to plot expression of NK cell ligands in solid primary tumor and normal 
tissue samples from the TCGA-COAD cohort. An unpaired t-test was performed to test difference in 
expression between tissue types. The corresponding statistical significance was plotted in the graph 
using “ggubr” (v.0.2.3). The Pearson correlation test was used to correlate NK ligand protein 
expression in the primary tumor with receptor expression on circulating NK- and NKT cells. R package 
“stats” (R version 3.5.1) was used to calculate Pearson’s r for correlations between log2-transformed, 
quantile-normalized gene expression values for NK cell receptor ligands (RNASeq) and receptor 
expression on circulating NK- and NKT cells. Correlation coefficients between all well-defined NK cell 
ligands and corresponding receptors were visualized in heatmaps using “ComplexHeatmap” (v2.1.2). 




The study cohort consisted of 78 CRC patients diagnosed in the LUMC in the Netherlands. Patient and 
tumor characteristics are shown in Table 1. Due to staining artefacts, protein expression of NK cell 
receptor ligands could be evaluated in 74 of the 78 primary tumors using immunohistochemistry (IHC). 
Furthermore, due to limited sample availability, RNA expression of NK cell receptor ligands was 
studied in primary tumor tissue in a subgroup of the full cohort (N=24) using RNA sequencing. 
Receptor expression on circulating NK- and NKT cells was previously measured by us in a subgroup of 
patients with available PBMC samples (N=71) using flow cytometry [11]. The patient and tumor 
characteristics of these subgroups are summarized in Table 1 and show no significant differences 
compared to the full cohort, thereby indicating that no bias was introduced. The exception was the 
RNA subgroup which was restricted to a group of patients with colon tumors due to limited sample 
availability. Figure 1 shows an overview of the measured NK cell receptor ligands in primary tumor 
tissue in this study, and their associated NK cell receptors expressed on circulating NK- and NKT cells.  
 
Immunohistochemistry and automated image analysis 
Whole tissue sections from the tumors of 74 CRC patients were stained for HLA class I, CD1d, galectin-
3, and PCNA expression using IHC. Varying expression patterns and staining intensities were observed 
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Figure 1. Overview of the studied NK cell receptor ligands in primary tumor tissue, and NK cell receptors on 
circulating NK- and NKT cells in CRC patients. Overview of the studied NK cell receptor ligands in primary tumor 
tissue, and the receptors they bind to on circulating NK- and NKT cells in CRC patients. The activating (+) and/or 
inhibiting (-) effects of the NK cell ligands upon interaction with their receptors is indicated, as well as the 
activating (+) or inhibiting (-) functions of the receptors on NK- and NKT cell activation. All indicated NK cell 
receptor ligands were studied on RNA level using RNA sequencing (N=24). The NK cell ligands indicated by the 
asterisk were also studied on protein level using IHC (N=74). In IHC, HLA-C was studied in combination with HLA-
A and HLA-B (total HLA class I). On NKT cells, CD161 functions as co-stimulatory factor for TCR activation via 
CD1d. Expression of NK- and NKT cell receptors was studied by us on circulating NK- and NKT cells in 71 CRC 
patients using multiparameter flow cytometry as described elsewhere [11]. Abbreviations: BAG6 (BCL2-
associated Athanogene 6), CRC (Colorectal Cancer), CFP (Complement Factor P), CLEC2 (C-type Lectin Domain 
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Family Member 2), DNAM-1 (DNAX Accessory Molecule-1), HLA (Human Leukocyte Antigen), IHC 
(Immunohistochemistry), MIC (MHC class I-related Chain), NK (Natural Killer), NKG2 (Natural Killer Group 2), NKT 
(Natural Killer T), PCNA (Proliferating Cell Nuclear Antigen), PDGFD (Platelet-Derived Growth Factor D), PVR 
(Poliovirus Receptor), TCR (T Cell Receptor), ULBP (UL-16 Binding Protein). 
 
 
HLA class I, CD1d, galectin-3, and PCNA (pink staining) per tumor cell. The expression of these NK cell 
ligands was quantified on the cell membrane of tumor epithelial cells specifically. Hence, only surface 
expression of these proteins was assessed on tumor cells. Figure 3 shows examples of the automated 
image analysis of HLA class I expression on primary colorectal tumors from 3 different patients. The 
output of the image analysis of these 3 tumors is summarized in Table 2 and includes the percentage 
of HLA class I negative, weak positive, and strong positive cells, and the calculated H-score. The image 
analysis pipeline as presented in Figure 3 was applied for all stained tissue sections in this study. 
Protein expression of HLA class I, CD1d, galectin-3, and PCNA was therefore scored in a standardized 
and reproducible way using set thresholds as explained in the Materials and Methods section. For 
further analyses, weak and strong expression of HLA class I, CD1d, galectin-3, and PCNA by tumor cells 
was combined in order to analyse the effect of expression versus no expression of these receptor 
ligands. 
 
Higher expression of PCNA protein in the tumor border compared to the tumor center 
The majority of the studied colorectal tumor cells expressed HLA class I (median 96%, range 54-100), 
and galectin-3 (median 96%, range 55-100). In contrast, expression of CD1d was much more 
heterogeneous (median 82%, range 1-100). Additionally, the staining intensity of HLA class I, galectin-
3, and CD1d was highly heterogeneous, as reflected in a wide range of the H-score (median 106, range 
53-190; median 157, range 76-191; median 85, range 1-165, respectively). A summary of the 
expression data, including the relation between the percentage of positive cells and H-score of HLA 
class I, CD1d, and galectin-3 is presented in Supplementary Figure 1A. Interestingly, the majority of 
the studied tumors expressed low levels of PCNA (median 6.4%, range 0.0-96.0). Since PCNA is 
involved in cell division, we expected to find high expression in tumor cells. When evaluating the 
stained tumor tissue sections, we noted that the staining pattern throughout the tumor (i.e. tumor 
center) was different as compared to the tumor border. Therefore, we decided to compare PCNA 
protein expression in the tumor center and border in 46 CRC patients for which we could evaluate 
both. A summary of the expression data and the relation between the percentage of PCNA+ cells and 
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Figure 2. IHC of NK cell ligands in primary colorectal tumors. An IHC double staining was set up to analyze NK cell 
ligand expression in primary colorectal tumors. Stromal tissue, blood vessels, and immune cells were stained 
brown whereas NK cell ligand expression was stained pink. Cell nuclei were stained blue. For each staining, 
representative images are presented of three primary CRC tumors with negative cell membrane staining (left), 
strong cell membrane staining (right), and moderate cell membrane staining (middle) of A. HLA class I, B. CD1d, 
C. Galectin-3, and D. PCNA. All studied tumors were positive regarding galectin-3 cell membrane expression. The 
left figure therefore represents the weakest staining observed regarding galectin-3. Abbreviations: HLA (Human 
Leukocyte Antigen), IHC (Immunohistochemistry), NK (Natural Killer), PCNA (Proliferating Cell Nuclear Antigen). 
 




Figure 3. IHC double staining with subsequent automated image analysis of HLA class I expression in three primary 
colorectal tumors. An IHC double staining was set up to analyze HLA class I expression in primary colorectal tumors. 
Stromal tissue, blood vessels, and immune cells were stained brown whereas HLA class I expression was stained 
pink. Cell nuclei were stained blue. Representative images are presented of three primary colorectal tumors with 
variable HLA class I expression. The images illustrate the different steps of the automated image analysis of HLA 
class I expression. First, different tissue types were discriminated using a tissue segmentation algorithm (red: 
tumor epithelium; green: stromal tissue; blue: area without tissue). Cell nuclei, cytoplasm, and cell membranes 
were then identified within the tumor epithelium area using a cell segmentation algorithm based on hematoxylin 
staining. Finally, HLA class I expression was scored on the cell membrane of tumor epithelial cells as the percentage 
of HLA class I+ cells. (blue: HLA class I negative; orange: weak HLA class I expression; red: strong HLA class I 
expression). Abbreviations: IHC (Immunohistochemistry), HLA (Human Leukocyte Antigen). 
 
 
illustrates different staining patterns between the tumor center and tumor border in 2 distinct 
colorectal tumors. The percentage of PCNA+ cells (P<0.001) and PCNA H-score (P<0.001) were 
significantly higher in the tumor border compared to the tumor center (Figure 4B). This indicates that 
tumor cells in the center of the tumor only multiply occasionally, as reflected by low expression of 
PCNA, possibly showing limited availability of oxygen and nutrients in the tumor center. In contrast, 
the tumor cells at the tumor border divide much more often, as reflected by high expression of PCNA, 
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Table 2. Scoring of HLA class I expression in three colorectal tumors. An IHC double staining was set up to analyze 
HLA class I expression in primary colorectal tumors using automated image analysis. In this table, the output of 
the scoring algorithm is presented of the three tumors from Figure 3 including the percentage of negative, 
weakly positive, and strongly positive HLA class I tumor epithelial cells. Additionally, the H-score (based on the 
percentage of positive tumor epithelial cells and the staining intensity) was calculated as described in the 
Materials and Methods section. Abbreviations: IHC (Immunohistochemistry), HLA (Human Leukocyte Antigen). 
 Automated image analysis HLA class I Tumor 1 Tumor 2 Tumor 3 
Total number of tumor epithelial cells 1029 1366 1512 
Total number of negative cells  987 2 2 
Negative cells (% of total cells) 95.9% 0.2% 0.1% 
Total number of weak positive cells 42 1291 136 
Weak positive cells (% of total cells) 4.1% 94.5% 9.0% 
Total number of strong positive cells 0 73 1374 
Strong positive cells (% of total cells) 0.0% 5.3% 90.9% 
Average H-score 4 105 191 
 
 
High expression of PCNA and Galectin-3 protein is associated with short DFS 
Next, we investigated the association between the cell surface expression of HLA class I, CD1d, 
galectin-3, and PCNA, as detected by IHC, and tumor characteristics. No associations were observed 
with TNM classification, tumor location, tumor differentiation grade, or tumor-lymph node invasion 
(data not shown). Additionally, the association between HLA class I, CD1d, galectin-3, and PCNA 
expression in the tumor center and clinical outcome was investigated in CRC patients. The patient 
population (N=74) was divided into two groups using the median expression level as cut-off. No 
associations were observed with OS (data not shown). Patients with TNM stage IV tumors were 
excluded from the DFS analyses (N=10) since they already presented with metastatic disease at time 
of diagnosis. No associations were observed between expression of HLA class I and CD1d in the 
primary tumor and DFS (data not shown). Patients with above-median percentage of PCNA+ tumor 
cells in the tumor center showed significantly shorter DFS (P=0.026) compared to patients with below-
median percentage of PCNA+ tumor cells in the tumor center, with a hazard ratio (HR) of 2.3 (95% 
confidence interval (CI) 1.1-4.7, P=0.031) (Figure 5A). Based on these results, we wondered whether 
the percentage of PCNA+ tumor cells in the tumor border was also associated with DFS. In contrast to 
the tumor center, the percentage of PCNA+ tumor cells in the tumor border did not correlate with DFS  




Figure 4. PCNA expression in the tumor center versus tumor border in primary colorectal tumors. An IHC double 
staining was set up to analyze PCNA expression in primary colorectal tumors. Stromal tissue, blood vessels, and 
immune cells were stained brown whereas PCNA expression was stained pink. Cell nuclei were stained blue. PCNA 
expression was then automatically scored in 46 primary colorectal tumors in the tumor center and in the tumor 
border regarding percentage of positive cells and H-score as described in the Materials and Methods section. A. 
Two representative images of higher PCNA expression in the tumor border compared to the tumor center. B. 
Higher percentage of PCNA+ cells and PCNA H-score in the tumor border compared to the tumor center (N=46). 
Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CRC (Colorectal Cancer), IHC 
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(N=40, P=0.512) as visualized in Figure 5B. Furthermore, patients with above-median galectin-3 H-
score showed a trend towards shorter DFS (P=0.055) compared to patients with below-median 
galectin-3 H-score with a HR of 2.0 (95% CI 1.0-4.2, P=0.060) (Figure 5C). A multivariate analysis was 
performed for DFS in CRC patients which revealed that above-median percentage of PCNA+ tumor 
cells in the tumor center (HR 1.4, 95% CI 0.6-3.3, P=0.388) and above-median galectin-3 H-score (HR 
1.5, 95% CI 0.7-3.1, P=0.310) were not independently associated with DFS when corrected for age and 
TNM classification.  
 
 
Figure 5. Relationship between PCNA and galectin-3 expression in primary tumors with DFS of CRC patients. DFS 
curves are shown for TNM stage 0-III CRC patients at risk for development of metastases (N=64). Stratifications 
were based on the median percentage of PCNA+ cells and galectin-3 H-score, respectively. A. Relationship between 
PCNA expression in the tumor center (percentage of PCNA+ cells) and clinical outcome of 64 CRC patients. B. 
Relationship between PCNA expression in the tumor border (percentage of PCNA+ cells) and clinical outcome of 40 
CRC patients. C. Relationship between galectin-3 expression (galectin-3 H-score) and clinical outcome of 64 CRC 
patients. Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CRC (Colorectal Cancer), DFS 
(Disease-Free Survival), PCNA (Proliferating Cell Nuclear Antigen), TNM (Tumor-Node-Metastasis). 
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Association between protein expression of galectin-3, CD1d, and HLA class I in the primary 
tumor and receptor expression on circulating NK- and NKT cells 
Importantly, the immunologic effect of the presence of NK cell receptor ligands on tumor cells is 
dependent on the interaction with their receptors on NK- and NKT cells. Therefore, we studied the 
correlation between protein expression of NK cell ligands in the primary tumor in relation to receptor 
expression on circulating CD56dim NK cells, CD56bright NK cells, and NKT cells in CRC patients. In total, 
protein expression data in the primary tumors and data on receptor expression on circulating NK- and 
NKT cells was available for 67 CRC patients included in our study. The results from the correlation 
analyses are summarized in Supplementary Table 1. The results revealed a significant negative 
correlation between the percentage of galectin-3+ cells (P=0.002) as well as galectin H-score (P=0.026) 
and NKp30 expression level on NKT cells (Figure 6A). Thus, high expression of negative regulator 
galectin-3 was associated with low NKp30 expression on circulating NKT cells. Additionally, the 
percentage of CD1d+ tumor cells (P=0.007) and CD1d H-score (P=0.015) negatively correlated with the 
expression level of TCR co-stimulatory receptor CD161 on circulating NKT cells (Figure 6B). 
Furthermore, the percentage of HLA class I+ cells (P=0.023) but not HLA class I H-score (P=0.128) 
negatively correlated with the percentage of CD158b+ CD56bright NK cells in the circulation of CRC 
patients (Figure 6C). In total, 24 CRC patients in our study had available preoperative as well as 
postoperative PBMC samples. Interestingly, a positive correlation was observed between the 
percentage of galectin-3+ tumor cells and the change in expression level of NKp30 on circulating NKT 
cells after tumor resection (P<0.001, Supplementary Figure 2). Hence, CRC patients with high galectin-
3 tumor expression showed a slight upregulation of the NKp30 receptor on circulating NKT cells after 
surgery whereas CRC patients with relatively low galectin-3 tumor expression showed downregulation 
of the NKp30 receptor after surgery. This suggests a direct modulatory effect of galectin-3 on NKp30 
expression on NKT cells. In summary, expression of some of the studied NK cell ligands in the primary 
tumor associated with expression of receptors on circulating NK- and NKT cells in CRC patients. This 
implies that NK cell ligands expressed by primary tumor cells influence the expression levels of the 
receptors they bind to, thereby possibly influencing the activation of circulating NK- and NKT cells, 







(N=40, P=0.512) as visualized in Figure 5B. Furthermore, patients with above-median galectin-3 H-
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Figure 5. Relationship between PCNA and galectin-3 expression in primary tumors with DFS of CRC patients. DFS 
curves are shown for TNM stage 0-III CRC patients at risk for development of metastases (N=64). Stratifications 
were based on the median percentage of PCNA+ cells and galectin-3 H-score, respectively. A. Relationship between 
PCNA expression in the tumor center (percentage of PCNA+ cells) and clinical outcome of 64 CRC patients. B. 
Relationship between PCNA expression in the tumor border (percentage of PCNA+ cells) and clinical outcome of 40 
CRC patients. C. Relationship between galectin-3 expression (galectin-3 H-score) and clinical outcome of 64 CRC 
patients. Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CRC (Colorectal Cancer), DFS 
(Disease-Free Survival), PCNA (Proliferating Cell Nuclear Antigen), TNM (Tumor-Node-Metastasis). 
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Association between protein expression of galectin-3, CD1d, and HLA class I in the primary 
tumor and receptor expression on circulating NK- and NKT cells 
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cells after tumor resection (P<0.001, Supplementary Figure 2). Hence, CRC patients with high galectin-
3 tumor expression showed a slight upregulation of the NKp30 receptor on circulating NKT cells after 
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of the NKp30 receptor after surgery. This suggests a direct modulatory effect of galectin-3 on NKp30 
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implies that NK cell ligands expressed by primary tumor cells influence the expression levels of the 
receptors they bind to, thereby possibly influencing the activation of circulating NK- and NKT cells, 








Figure 6. Correlation between NK cell receptor ligand expression in tumor tissue (protein) and their associated 
receptors on circulating NK and NKT cells (protein) in CRC patients. Protein expression of NK cell receptor ligands 
was quantified in the primary tumor of CRC patients using IHC and subsequent automated image analysis (x-axis), 
whereas expression of receptors on circulating NK- and NKT cells in peripheral blood of CRC patients was measured 
using multiparameter flow cytometry (y-axis, N=67). A. Correlation between galectin-3 expression in the primary 
tumor and NKp30 expression on circulating NKT cells. B. Correlation between CD1d expression in the primary 
tumor and CD161 expression on circulating NKT cells. C. Correlation between HLA class I expression in the primary 
tumor and the percentage of circulating CD158b+ CD56bright NK cells. Pearson’s r, and corresponding P-values are 
indicated. Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CRC (Colorectal Cancer), 
HLA (Human Leukocyte Antigen), IHC (Immunohistochemistry), NK (Natural Killer), NKT (Natural Killer T). 
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Association between RNA expression of NKG2D ligands in the primary tumor and NKG2D 
expression on circulating NKT cells 
Importantly, the analyses described above are focused on a single ligand and the receptor it binds to. 
However, the activation of NK- and NKT cells is much more complicated than that. Some receptors 
are known to recognize and bind multiple ligands which might all have different effects (either 
activating or inhibiting) as illustrated in Figure 1. Therefore, we further investigated the correlation 
between RNA expression of NK cell ligands in primary tumor tissue in relation to receptor expression 
on circulating CD56dim NK cells, CD56bright NK cells, and NKT cells. Using RNA expression data, it was 
possible to study all well-defined NK cell ligands described in literature. First, to verify expression of 
NK cell ligands in colon cancer (CC) samples as compared to normal tissue, we utilized the publicly 
available data from the TCGA-COAD cohort. Indeed, the expression of NK cell ligands was significantly 
different in primary tumors compared to normal solid tissue for most of the analyzed genes 
(Supplementary Figure 3), suggesting deregulation in CC. We then proceeded to evaluate the relation 
between NK cell ligands and corresponding receptor expression in our cohort. In total, RNA expression 
data in the primary tumors and data on receptor expression on circulating NK- and NKT cells was 
available for 24 CC patients included in this study. For 23 of the 24 CC patients, protein expression 
data of HLA class I, CD1d, galectin-3, and PCNA in the primary tumor was available as described above. 
For the ligands we studied on protein level using IHC, no significant correlation was observed between 
level of protein and corresponding RNA expression (data not shown). We studied the correlation 
between RNA expression of NK cell ligands and receptor expression in peripheral blood as summarized 
in the heatmaps in Supplementary Figure 4. Strong negative correlations were observed between RNA 
expression of the ligands ULBP1 (P=0.017), ULBP2 (P=0.028), and ULBP5 (P=0.011) and the percentage 
of NKG2D+ circulating NKT cells (Figure 7A and 7B). No correlations were observed between 
expression of NK cell ligands and the phenotype of circulating NK cells (Supplementary Figure 4). This 
suggest that for some NK cell ligands, the transcript abundance associated with NKT cell phenotype, 
suggesting modulation of circulating NKT cells by tumor cells. This might be an important mechanism 
though which colon (and rectum) tumors can escape from the immune system, resulting in the 






Figure 6. Correlation between NK cell receptor ligand expression in tumor tissue (protein) and their associated 
receptors on circulating NK and NKT cells (protein) in CRC patients. Protein expression of NK cell receptor ligands 
was quantified in the primary tumor of CRC patients using IHC and subsequent automated image analysis (x-axis), 
whereas expression of receptors on circulating NK- and NKT cells in peripheral blood of CRC patients was measured 
using multiparameter flow cytometry (y-axis, N=67). A. Correlation between galectin-3 expression in the primary 
tumor and NKp30 expression on circulating NKT cells. B. Correlation between CD1d expression in the primary 
tumor and CD161 expression on circulating NKT cells. C. Correlation between HLA class I expression in the primary 
tumor and the percentage of circulating CD158b+ CD56bright NK cells. Pearson’s r, and corresponding P-values are 
indicated. Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CRC (Colorectal Cancer), 
HLA (Human Leukocyte Antigen), IHC (Immunohistochemistry), NK (Natural Killer), NKT (Natural Killer T). 
 Expression of NK receptor ligands in primary colorectal cancer tissue 
149 
 
Association between RNA expression of NKG2D ligands in the primary tumor and NKG2D 
expression on circulating NKT cells 
Importantly, the analyses described above are focused on a single ligand and the receptor it binds to. 
However, the activation of NK- and NKT cells is much more complicated than that. Some receptors 
are known to recognize and bind multiple ligands which might all have different effects (either 
activating or inhibiting) as illustrated in Figure 1. Therefore, we further investigated the correlation 
between RNA expression of NK cell ligands in primary tumor tissue in relation to receptor expression 
on circulating CD56dim NK cells, CD56bright NK cells, and NKT cells. Using RNA expression data, it was 
possible to study all well-defined NK cell ligands described in literature. First, to verify expression of 
NK cell ligands in colon cancer (CC) samples as compared to normal tissue, we utilized the publicly 
available data from the TCGA-COAD cohort. Indeed, the expression of NK cell ligands was significantly 
different in primary tumors compared to normal solid tissue for most of the analyzed genes 
(Supplementary Figure 3), suggesting deregulation in CC. We then proceeded to evaluate the relation 
between NK cell ligands and corresponding receptor expression in our cohort. In total, RNA expression 
data in the primary tumors and data on receptor expression on circulating NK- and NKT cells was 
available for 24 CC patients included in this study. For 23 of the 24 CC patients, protein expression 
data of HLA class I, CD1d, galectin-3, and PCNA in the primary tumor was available as described above. 
For the ligands we studied on protein level using IHC, no significant correlation was observed between 
level of protein and corresponding RNA expression (data not shown). We studied the correlation 
between RNA expression of NK cell ligands and receptor expression in peripheral blood as summarized 
in the heatmaps in Supplementary Figure 4. Strong negative correlations were observed between RNA 
expression of the ligands ULBP1 (P=0.017), ULBP2 (P=0.028), and ULBP5 (P=0.011) and the percentage 
of NKG2D+ circulating NKT cells (Figure 7A and 7B). No correlations were observed between 
expression of NK cell ligands and the phenotype of circulating NK cells (Supplementary Figure 4). This 
suggest that for some NK cell ligands, the transcript abundance associated with NKT cell phenotype, 
suggesting modulation of circulating NKT cells by tumor cells. This might be an important mechanism 
though which colon (and rectum) tumors can escape from the immune system, resulting in the 





Figure 7. Correlation between expression of NK cell receptor ligands in tumor tissue (RNA) and their associated 
receptors on circulating NK- and NKT cells (protein) in CC patients. RNA expression of NK cell receptor ligands was 
analyzed in the primary tumor of CC patients using RNA sequencing whereas expression of receptors on circulating 
NK- and NKT cells in peripheral blood of CC patients was measured using multiparameter flow cytometry (N=24). 
A. Heatmaps of correlations between RNA NK ligand expression in primary colon tumors and receptor expression 
on circulating NK- and NKT cells. B. Scatterplots of log2 transformed, normalized gene expression of NK receptor 
ligands in primary colon tumors (x-axis) and receptor expression on circulating NK- and NKT cells (y-axis). Pearson’s 
r, and corresponding P-values are indicated. Statistically significant P-values (≤0.05) are indicated in A. by the 
asterisk. Abbreviations: CC (Colon Cancer), MIC (MHC class I-related Chain), NK (Natural Killer), NKT (Natural Killer 
T), pct (percentage), ULBP (UL-16 Binding Protein). 
 
Discussion 
In this study, we investigated protein and RNA expression of NK cell receptor ligands in primary 
colorectal tumors in relation to clinical outcome, and the expression of receptors on circulating NK- 
and NKT cells in the peripheral blood.  
We showed that higher PCNA tumor expression in the tumor center was associated with 
shorter DFS in the included CRC patients. In literature, controversial results have been reported 
regarding the potential prognostic implications of PCNA expression. High PCNA expression was 
considered an unfavorable prognostic marker in several CRC studies [35-37], but other studies 
suggested that it had no significance, and even reported an association with favorable outcome 
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[38,39]. A recent meta-analysis concluded that high PCNA expression was associated with poor clinical 
outcome in CRC patients, and suggested that PCNA might be a prognostic biomarker candidate to 
predict clinical outcome [40]. The discrepancies between studies may be explained by the fact that 
PCNA expression shows different staining patterns throughout the tumor. In the present study, we 
showed that PCNA expression in the tumor border was significantly higher compared to the tumor 
center. To our knowledge, this has not been considered previously. Whereas PCNA expression in the 
tumor center was associated with DFS, PCNA expression in the tumor border was not. Thus, the 
location of scoring PCNA in the tumor may influence the results. Furthermore, discrepancies in studies 
could also be explained by the fact that PCNA has different functions in tumor progression depending 
on the cell compartment it resides. When located in the nucleus, PCNA is involved in cell proliferation. 
However, when cancer cells overexpress PCNA and/or interact with NKp44+ NK cells, PCNA relocates 
from the nucleus towards the cell membrane where it may function as a ligand for NK- and NKT cells 
[21,24]. In the present study, we strictly quantified PCNA expression on the cell membrane of tumor 
cells by automated image analysis since we aimed to investigate the immune-modulating functions of 
this protein, whereas other studies investigated combined nucleus, cytoplasmic, and membrane 
expression, thereby studying the different functions of PCNA in tumor progression combined [35,37]. 
A uniform way of scoring IHC images could diminish the discrepancies between studies. Here, 
automated image analysis is crucial for obtaining standardized, robust, objective, and reproducible 
scoring data.  
We observed a trend in this study towards short DFS in patients with high galectin-3 tumor 
expression which is in line with other studies [41-44]. This suggests galectin-3 may have value as a 
prognostic biomarker in CRC. The fact that we did not observe a statistically significant association 
was likely due to the limited sample size of our study cohort.  
We also studied the correlation between protein and RNA expression of NK cell ligands in 
the primary tumor, and expression of their receptors on circulating NK- and NKT cells. Remarkably, no 
significant correlation was observed between level of protein and corresponding RNA expression. This 
may reflect differences in dynamics and kinetics of RNA and protein. However, among RNA profiles of 
NK cell ligands and expression of receptors on circulating NKT cells we did find correlations. Significant 
negative correlations were observed between RNA expression of ULBP1, -2, and -5 and NKG2D 
receptor expression on NKT cells in CRC patients. This may suggest that for some NK cell ligands, the 
level of RNA expression reflects modulation of NKT cell phenotype by tumor cells and/or their soluble 
products. Many studies demonstrated that the NKG2D receptor plays an important role in cancer 




Figure 7. Correlation between expression of NK cell receptor ligands in tumor tissue (RNA) and their associated 
receptors on circulating NK- and NKT cells (protein) in CC patients. RNA expression of NK cell receptor ligands was 
analyzed in the primary tumor of CC patients using RNA sequencing whereas expression of receptors on circulating 
NK- and NKT cells in peripheral blood of CC patients was measured using multiparameter flow cytometry (N=24). 
A. Heatmaps of correlations between RNA NK ligand expression in primary colon tumors and receptor expression 
on circulating NK- and NKT cells. B. Scatterplots of log2 transformed, normalized gene expression of NK receptor 
ligands in primary colon tumors (x-axis) and receptor expression on circulating NK- and NKT cells (y-axis). Pearson’s 
r, and corresponding P-values are indicated. Statistically significant P-values (≤0.05) are indicated in A. by the 
asterisk. Abbreviations: CC (Colon Cancer), MIC (MHC class I-related Chain), NK (Natural Killer), NKT (Natural Killer 
T), pct (percentage), ULBP (UL-16 Binding Protein). 
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level of RNA expression reflects modulation of NKT cell phenotype by tumor cells and/or their soluble 
products. Many studies demonstrated that the NKG2D receptor plays an important role in cancer 




effective anti-tumor immune response in early CRC cancer stages [45-47]. However, sustained NKG2D 
ligand expression, as well as shedding of soluble NKG2D ligands into the circulation, counteracted 
NKG2D-dependent NK cell activity in later stages of CRC via downregulation of the NKG2D receptor 
[47-50], which is in line with our results. Therefore, overexpression of NKG2D ligands by tumor cells, 
and/or shedding of NKG2D ligands in the circulation might be important immune escape strategies 
for tumor cells. Schmiedel et al. argued that shedding of NKG2D ligands has several major advantages 
for cancer cells in terms of immune evasion (even more than NKG2D overexpression by tumor cells) 
[51]. This is because soluble NKG2D ligands are unable to activate NKG2D receptor-bearing immune 
cells while still being capable of binding the NKG2D receptor, thereby causing internalization of the 
receptor [51]. Therefore, antibodies neutralizing soluble NK cell ligands, as well as soluble NKG2D 
receptors to catch away soluble NKG2D ligands from the circulation, are worth pursuing in future 
clinical development. 
In the present study, we also observed a similar pattern regarding protein expression of 
inhibitory ligand galectin-3 by tumor cells and expression of the NKp30 receptor on circulating NKT 
cells. Hence, high expression of galectin-3 by tumor cells correlated with low expression of the NKp30 
receptor on NKT cells. Due to the inhibitory functions of galectin-3, it was proposed that expression 
and secretion of galectin-3 represents a novel pathway to escape NKp30-mediated NK cell 
immunosurveillance [19]. To our knowledge, we are the first to describe that high expression of the 
inhibitory ligand galectin-3 by tumor cells may ultimately result in downregulation of the NKp30 
receptor on NKT cells in peripheral blood, thereby dysregulating NKp30-mediated activation of NKT 
cells. In addition to NKp30, galectin-3 has also been reported to bind the NKG2D binding site of MICA, 
thereby shielding this binding site and severely impairing NKG2D-mediated NK cell activation [52]. 
Besides its suppressive function on NK- and NKT cells, membrane-bound galectin-3 also promotes 
EMT of tumor cells, thereby increasing their invasiveness [22]. Additionally, soluble galectin-3 in the 
TME has been shown to suppress the expansion of tumor-reactive T cells, and polarize macrophages 
toward the immunosuppressive M2 phenotype [53]. Galectin-3 is therefore an interesting target for 
cancer immunotherapy. An important question is whether the immune modulating functions of 
galectin-3 are mediated via its membrane-bound or soluble form. Since direct interaction of galectin-
3 and circulating immune cells is necessary in order for immune modulation to take place, it is most 
likely that soluble galectin-3 in the circulation is responsible for this process. Importantly, different 
NKp30 splice variants have been identified recently with different functions [54]. Whereas the 
NKp30A and NKp30B splice variants are the activating isoforms, NKp30C has been associated with 
immunosuppressive effects on NK cells [20,54]. Although speculative, the immunosuppressive effects 
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of tumor-expressed and/or secreted galectin-3 may be the result of a shift in NKp30A/B splice variants 
towards NKp30C in cancer patients [20]. In our study, it was not possible to distinguish between 
expression of different NKp30 isoforms on circulating NK- and NKT cells (protein level) due to lack of 
specific antibodies. Galectin-3 and its complex immune-modulating effects are an interesting topic of 
research and should be explored further in future studies.  
We observed a negative correlation between CD1d protein expression on tumor cells and 
expression of the co-stimulatory molecule CD161 on circulating NKT cells in CRC patients. CD161 is 
crucial for activation of the TCR on NKT cells in a CD1d-dependent manner [30]. To our knowledge, no 
previous study has investigated the relation between CD1d protein expression in the primary tumor 
and CD161 expression on circulating NKT cells in cancer patients. The observed negative correlation 
in our study may implicate impairment of TCR-mediated activation of NKT cells in CD1d-expressing 
tumors, and therefore immune escape from NKT cells. Future studies should focus on the underlying 
biology of impairment of TCR-mediated activation of NKT cells and whether this can be restored. 
Furthermore, we observed a negative correlation between the percentage HLA class I+ tumor cells on 
protein level and the percentage of CD158b+ CD56bright NK cells in the circulation of CRC patients. 
Interaction between HLA class I and CD158b results in inhibition of NK cells. Our results indicate that 
especially patients with a high percentage of HLA class I+ tumor cells show relatively low expression 
of the CD158b receptor on NK cells. In these patients, HLA class I might induce less inhibitory signals 
towards NK cells compared to patients with moderate HLA class I expression and relatively higher 
CD158b expression. In line with this hypothesis, a study by Ewen et al. reported that human NK cells 
are unleashed from KIR/HLA class I inhibition via downregulation of KIRs, resulting in enhanced killing 
of tumor cells [55]. The fact that the CD158b receptor is downregulated in patients with HLA class I+ 
tumors suggests enhanced killing of tumor cells instead of immune escape. Further research is needed 
to explain this. 
Our results suggest that NK cell ligands galectin-3, CD1d, HLA class I, and ULBPs modulate 
the expression of their receptors (NKp30, CD1d, CD158b, and NKG2D, respectively) on circulating NK- 
and NKT cells. This may influence their function, including their ability to directly kill tumor cells, as 
well as their ability to produce and secrete large amounts of cytokines in order to activate other 
immune cells. As a result, circulating tumor cells might escape immune recognition in the peripheral 
blood and form distant metastases. These observations show that the primary tumor, including its 
expression and secretion of immune-modulating NK cell ligands, highly influences the tumor-immune 
response in the circulation of patients. This emphasizes the importance of a system-based biology 
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CD158b expression. In line with this hypothesis, a study by Ewen et al. reported that human NK cells 
are unleashed from KIR/HLA class I inhibition via downregulation of KIRs, resulting in enhanced killing 
of tumor cells [55]. The fact that the CD158b receptor is downregulated in patients with HLA class I+ 
tumors suggests enhanced killing of tumor cells instead of immune escape. Further research is needed 
to explain this. 
Our results suggest that NK cell ligands galectin-3, CD1d, HLA class I, and ULBPs modulate 
the expression of their receptors (NKp30, CD1d, CD158b, and NKG2D, respectively) on circulating NK- 
and NKT cells. This may influence their function, including their ability to directly kill tumor cells, as 
well as their ability to produce and secrete large amounts of cytokines in order to activate other 
immune cells. As a result, circulating tumor cells might escape immune recognition in the peripheral 
blood and form distant metastases. These observations show that the primary tumor, including its 
expression and secretion of immune-modulating NK cell ligands, highly influences the tumor-immune 
response in the circulation of patients. This emphasizes the importance of a system-based biology 




single patient, including the primary tumor, the circulation, and, for instance, the metastatic site as 
well [56]. This enables us to acquire an overall picture of the immune system in relation to disease 
progression which will help us to better understand the underlying biology of tumor-immune 
interactions. 
Importantly, the correlations between expression of NK cell ligands in primary tumors and 
receptor expression on circulating immune cells that we observed in the present study were largely 
restricted to NKT cells. This emphasizes the important role for NKT cells in tumor progression and 
implicates the involvement of these cell types in immune escape. Furthermore, in line with our 
recently published review on the role of NKT cells in cancer [4], our results suggest that chronic 
stimulation of NKT cells via ligand-receptor interactions is associated with downregulation of their 
corresponding receptors, irrespective of the fact whether the ligand-receptor interaction activates or 
inhibits their cellular function. Although speculative, this might imply the presence of a highly complex 
protective feedback mechanism in NK- and NKT cells that prevents both overstimulation and 
overinhibition of these cell types. Interestingly, we showed that downregulation of the NKp30 
expression on circulating NKT cells in CRC patients was not permanent as this receptor was 
upregulated after removing the putative source of galectin-3 expression (i.e. the primary tumor) via 
tumor resection.  
The strength of our study is the fact that we investigated the tumor-immune response in 
CRC patients on different levels. The design of these types of studies is difficult since unique and 
consequent sample collection is crucial, including concomitant collection of FFPE and frozen tumor 
tissue, as well as PBMCs from the same patients. As a result of these difficulties, the sample size of 
our study is relatively small which could be considered a limitation. Despite this small sample size, we 
observed significant correlations, suggesting that NK cell receptor ligands are involved in modulation 
of the phenotype of circulating NK- and NKT cells and are therefore interesting to study further. In the 
future, it is relevant to perform functional assays to study the consequences of the phenotypical 
modulations we observed, as well as studying other NK cell receptor ligands.  
In conclusion, we have shown that galectin-3 and PCNA protein expression in the primary 
tumor are potential prognostic biomarkers in CRC patients. Furthermore, we have shown associations 
between expression of different NK cell receptor ligands in the primary tumor and receptor expression 
on circulating NK- and NKT cells. This suggests that NK cell ligands expressed by tumor cells modulate 
the phenotype of circulating NK- and NKT cells, thereby possibly influencing their function. As a result, 
circulating tumor cells might escape immune recognition in peripheral blood, resulting in the 
formation of distant metastases. With this study, we gained more knowledge concerning tumor-
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immune interactions, not only involving the primary tumor, but also the circulation of CRC patients. 
In the future, this new knowledge may lead to the discovery of new immune-related biomarkers, and 
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The macrophage-associated molecule CD163 has been reported as prognostic biomarker in different 
cancer types, but its role in colorectal cancer (CRC) is unclear. We studied CD163 in the tumor 
microenvironment and circulation of patients with CRC in relation to clinicopathological parameters. 
An enzyme-linked immunosorbent assay (ELISA) was used to measure the serum sCD163 levels and 
multiparameter flow cytometry was used to study the peripheral blood monocytes and their CD163 
expression in CRC patients (N=78) and healthy donors (N=50). The distribution of tumor-associated 
macrophages (TAMs) was studied in primary colorectal tumors with multiplex immunofluorescence. 
We showed that CRC patients with above-median sCD163 level had a shorter overall survival (OS, 
P=0.035) as well as disease-free survival (DFS, P=0.005). The above-median sCD163 remained 
significantly associated with a shorter DFS in the multivariate analysis (P=0.049). Moreover, a shorter 
OS was observed in CRC patients with an above-median total monocyte percentage (P=0.007). The 
number and phenotype of the stromal and intraepithelial TAMs in colorectal tumors were not 
associated with clinical outcome. In conclusion, sCD163 and monocytes in the circulation may be 
potential prognostic biomarkers in CRC patients, whereas TAMs in the tumor showed no association 
with clinical outcome. Thus, our results emphasize the importance of the innate systemic immune 








Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide [1]. 
Approximately 25% of CRC patients have distant metastases at diagnosis [2]. Additionally, up to 25% 
of the patients diagnosed in the early stages eventually relapse or develop distant metastases 
following radical surgery and adjuvant chemotherapy [2,3]. In order to optimize treatment strategies, 
it is crucial that biomarkers are identified that associate with clinical outcome. Due to its critical role 
in combating tumor development and progression, the immune system has become an important 
focus in biomarker research. Studies have indicated important roles for monocytes and macrophages 
in CRC development and progression [4]. 
Monocytes can be divided into subsets based on their CD14 and CD16 expression levels. 
Classical monocytes (CD14++CD16-) develop in the bone marrow from myeloid progenitor cells and 
enter the circulation where they may differentiate into intermediate monocytes (CD14++CD16+) and, 
subsequently, to nonclassical monocytes (CD14+CD16++) [5]. Classical monocytes are the most 
prevalent subset in peripheral blood and are important phagocytes [6]. Intermediate monocytes are 
potent producers of pro-inflammatory cytokines, whereas nonclassical monocytes produce anti-
inflammatory cytokines [6]. Recent meta-analyses have shown that, considering peripheral blood 
leukocytes, a high lymphocyte-to-monocyte ratio was a significant predictor of better overall survival 
(OS), disease-free survival (DFS) and cancer-specific survival in CRC patients [7,8]. However, circulating 
monocyte subsets and the monocyte–macrophage marker CD163 have not been widely investigated 
in CRC patients. 
CD163 is a 130-kDa transmembrane scavenger receptor solely expressed by monocytes and 
macrophages mediating the endocytic uptake of haptoglobin–hemoglobin (Hp-Hb) complexes that 
form upon intravascular hemolysis [9]. Upon internalization, Hp-Hb complexes are degraded in 
lysosomes thereby producing anti-inflammatory heme metabolites [9] that dampen the inflammatory 
response of monocytes and macrophages [10]. CD163 can be cleaved from the cell membrane of 
monocytes and macrophages by the protease ADAM17/TACE upon activation by pro-inflammatory 
stimuli [11]. Soluble CD163 (sCD163) is an important biomarker in various inflammatory diseases 
including sepsis, liver disease, and macrophage activation syndrome [12]. In addition, high sCD163 
levels have been associated with disease progression and clinical outcome in different cancer types 
[13–17]. When monocytes leave the circulation and migrate into tissue, they differentiate into 
macrophages. Uncommitted M0 macrophages have been described to polarize into pro-inflammatory 
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inflammatory cytokines [6]. Recent meta-analyses have shown that, considering peripheral blood 
leukocytes, a high lymphocyte-to-monocyte ratio was a significant predictor of better overall survival 
(OS), disease-free survival (DFS) and cancer-specific survival in CRC patients [7,8]. However, circulating 
monocyte subsets and the monocyte–macrophage marker CD163 have not been widely investigated 
in CRC patients. 
CD163 is a 130-kDa transmembrane scavenger receptor solely expressed by monocytes and 
macrophages mediating the endocytic uptake of haptoglobin–hemoglobin (Hp-Hb) complexes that 
form upon intravascular hemolysis [9]. Upon internalization, Hp-Hb complexes are degraded in 
lysosomes thereby producing anti-inflammatory heme metabolites [9] that dampen the inflammatory 
response of monocytes and macrophages [10]. CD163 can be cleaved from the cell membrane of 
monocytes and macrophages by the protease ADAM17/TACE upon activation by pro-inflammatory 
stimuli [11]. Soluble CD163 (sCD163) is an important biomarker in various inflammatory diseases 
including sepsis, liver disease, and macrophage activation syndrome [12]. In addition, high sCD163 
levels have been associated with disease progression and clinical outcome in different cancer types 
[13–17]. When monocytes leave the circulation and migrate into tissue, they differentiate into 
macrophages. Uncommitted M0 macrophages have been described to polarize into pro-inflammatory 
macrophages (the so-called M1 phenotype) with a high inducible nitric oxide synthase (iNOS) 
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expression, or into macrophages associated with wound healing and anti-inflammatory functions (the 
so-called M2 phenotype) with a high CD163 expression [18,19]. Tumor-associated macrophages 
(TAMs) have been reported to express high levels of CD163 (i.e., M2 phenotype) and the density of 
these TAMs is associated with unfavorable clinical outcome in numerous human cancers [20–22]. 
Additionally, M3 TAMs have also been described with an M1/M2 or M2/M1 switch phenotype, both 
in mice [23] and humans [24,25]. 
Although CD163 has been reported a prognostic biomarker in different cancer types, its role 
in CRC is still unclear and requires further investigation. For instance, a high CD163+ TAM density has 
been reported to associate with both unfavorable [26–28] and favorable clinical outcome [24,25,29–
31] in CRC. Therefore, we decided to study CD163 in a broader context, comprising both the tumor 
microenvironment and circulation of CRC patients. We investigated CD163 expressed by circulating 
monocytes and TAMs, and the sCD163 in the blood in relation to clinicopathological parameters 
in CRC. 
 
Materials and methods 
Study Population and Patient-Derived Material 
Seventy-eight patients diagnosed with tumor node metastasis (TNM) stage 0-IV CRC between 2001 
and 2007 at Leiden University Medical Center (LUMC, the Netherlands) were included in the present 
study, and all underwent surgical resection. None of the patients received pre-operative 
chemotherapy nor were they diagnosed with Lynch syndrome. The pre-operative sera and peripheral 
blood mononuclear cells (PBMCs) were collected within a month prior to surgery. The post-operative 
serum samples were collected during routine checks in the outpatient clinic (mean 6.2 months after 
surgery, range 2-14). The post-operative samples obtained ≤2 months after surgery, or ≤5 months 
after the final therapy date in case a patient started adjuvant chemotherapy, were excluded as 
treatment may have influenced the peripheral blood immune system. Forty serum samples from 
healthy spouses of cancer patients and 10 PBMC samples from healthy blood donors were included 
as controls in this study. For the collection of serum samples, the peripheral blood of CRC patients 
was obtained (Dept. of Surgery, LUMC, The Netherlands) in BD Vacutainer serum separation transport 
tubes (BD Biosciences, Breda, The Netherlands). The tubes were centrifuged for 12 min at 1000xg 
after which the serum (supernatant) was frozen at -80°C. The PBMCs were isolated and cryopreserved 
as described previously [39]. Formalin-fixed paraffin-embedded (FFPE) tumor tissue was obtained 
from primary CRC tissues (Dept. of Pathology, LUMC, The Netherlands). The clinicopathological data 
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of all patients and healthy donors were available. All materials were obtained after approval by the 
Medical Ethical Committee of LUMC (protocol number P000.193). Written informed consent was 
obtained from all CRC patients and healthy donors included in the study. 
 
Enzyme-Linked Immunosorbent Assay for the Detection of the sCD163 Levels in Serum 
Serum samples were thawed and the sCD163 concentrations in serum were measured by an enzyme-
linked immunosorbent assay (ELISA) using a BEP-2000 ELISA-analyzer (Dade Behring, Siemens, 
Erlangen, Germany) essentially as previously described [53]. Briefly, 96-wells plates were coated with 
polyclonal rabbit anti-CD163 IgG [9] diluted in a carbonate buffer (20 mM, pH 9.6). The wells were 
then washed three times in PBS, and 100 µL serum (diluted 1:101 in PBS/0.2% bovine serum albumin 
(BSA, Sigma-Aldrich, St. Louis, MO, USA)) supplemented with 0.25% Tween20 (Merck, Søborg, 
Denmark) was added and incubated for 90 min. After washing the wells, monoclonal anti-CD163 
(clone GHI/61, BD Biosciences, Franklin Lakes, NJ, USA) was added and incubated for 60 min. After 
washing, peroxidase-labelled antibodies (goat anti-mouse immunoglobulins, DAKO, Glostrup, 
Denmark) were added and incubated for 60 min. The wells were washed and TMB ONE (Kem-En-Tec 
Nordic, Taastrup, Denmark) was added and incubated for 3 min. Finally, H3PO4 (1 M in water) was 
added to the wells and the plate was read on a BEP-2000 ELISA-analyzer. The internal control samples 
and serum standards were included in each run. 
 
Multiparameter Flow Cytometry for the Detection of CD163 on Circulating Monocyte 
Subsets 
The PBMC samples were thawed and cells were counted using a NucleoCounter NC-250 
(Chemometec, Allerod, Denmark). The cell concentration was adjusted to 10 million/mL and the 
PBMCs were blocked for 15-30 min at room temperature (RT) with 50 µg/mL human IgG (CSL Behring, 
Bern, Switzerland) to prevent nonspecific antibody binding [54]. The PBMCs were then incubated with 
mouse anti-human antibodies against T cell and monocyte markers including CD3, CD4, CD8, CD14, 
CD16, CD25, CD45, CD127 and CD163 (for details see Table S2) as described previously [39]. Only one 
batch of each antibody type was used. Immediately after staining, the samples were analyzed on the 
LSRFortessa (BD Biosciences) flow cytometer running FACSDivaTM software version 8.0 (BD 
Biosciences). FlowJo software version 10.1 (Tree Star Inc., Ashland, OR, USA) was used to analyze the 
data. In order to identify any inter-experimental variation, a buffy coat from a healthy donor obtained 
from Aarhus University Hospital, Denmark, was used as an internal control (PBMC reference sample). 
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of all patients and healthy donors were available. All materials were obtained after approval by the 
Medical Ethical Committee of LUMC (protocol number P000.193). Written informed consent was 
obtained from all CRC patients and healthy donors included in the study. 
 
Enzyme-Linked Immunosorbent Assay for the Detection of the sCD163 Levels in Serum 
Serum samples were thawed and the sCD163 concentrations in serum were measured by an enzyme-
linked immunosorbent assay (ELISA) using a BEP-2000 ELISA-analyzer (Dade Behring, Siemens, 
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(BSA, Sigma-Aldrich, St. Louis, MO, USA)) supplemented with 0.25% Tween20 (Merck, Søborg, 
Denmark) was added and incubated for 90 min. After washing the wells, monoclonal anti-CD163 
(clone GHI/61, BD Biosciences, Franklin Lakes, NJ, USA) was added and incubated for 60 min. After 
washing, peroxidase-labelled antibodies (goat anti-mouse immunoglobulins, DAKO, Glostrup, 
Denmark) were added and incubated for 60 min. The wells were washed and TMB ONE (Kem-En-Tec 
Nordic, Taastrup, Denmark) was added and incubated for 3 min. Finally, H3PO4 (1 M in water) was 
added to the wells and the plate was read on a BEP-2000 ELISA-analyzer. The internal control samples 
and serum standards were included in each run. 
 
Multiparameter Flow Cytometry for the Detection of CD163 on Circulating Monocyte 
Subsets 
The PBMC samples were thawed and cells were counted using a NucleoCounter NC-250 
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Bern, Switzerland) to prevent nonspecific antibody binding [54]. The PBMCs were then incubated with 
mouse anti-human antibodies against T cell and monocyte markers including CD3, CD4, CD8, CD14, 
CD16, CD25, CD45, CD127 and CD163 (for details see Table S2) as described previously [39]. Only one 
batch of each antibody type was used. Immediately after staining, the samples were analyzed on the 
LSRFortessa (BD Biosciences) flow cytometer running FACSDivaTM software version 8.0 (BD 
Biosciences). FlowJo software version 10.1 (Tree Star Inc., Ashland, OR, USA) was used to analyze the 
data. In order to identify any inter-experimental variation, a buffy coat from a healthy donor obtained 
from Aarhus University Hospital, Denmark, was used as an internal control (PBMC reference sample). 
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The threshold for positive staining was determined using unstained or fluorescence minus one (FMO) 
controls. In the present study, we used an FMO control for CD16. A standardized gating strategy based 
on the measurements of the PBMC reference sample was used to identify monocyte subpopulations 
(Figure S1). The expression of CD163 was then determined by the median fluorescence intensity (MFI) 
of the total monocyte population, as well as for the classical (CD14++CD16-), intermediate 
(CD14++CD16+), and nonclassical (CD14+CD16++) monocyte subsets separately. Additionally, regulatory 
T cells (Tregs, CD127lowCD25+) were identified as described previously [39]. 
 
Multiplex Immunofluorescence for the Detection of TAMs 
In total, 4 µm FFPE whole tumor tissue sections were cut and stained with macrophage-related 
markers using the Akoya Biosciences tyrosine amplification (TSA) method for multiplex 
immunofluorescence. Briefly, FFPE tissue sections were deparaffinized and rehydrated, and fixed with 
PBS/1% formaldehyde (Klinipath, Breda, The Netherlands) for 5 min at RT. Thereafter, the endogenous 
peroxidase activity was blocked by an incubation with 0.3% H2O2 (Millipore BV, The Netherlands) 
followed by a heat-induced antigen retrieval using a PT link module (DAKO). The tissue sections then 
underwent four staining cycles. Briefly, during every staining cycle, the sections were incubated with 
one type of primary antibody, anti-CD68 (KP1, DAKO), anti-iNOS (ab3523, AbCam, Cambridge, UK), 
anti-CD163 (NCL-L-CD163, DAKO), and finally anti-cytokeratin (EA1/EA3, DAKO). After each incubation 
round with primary antibodies, sections were incubated with horseradish peroxidase (HRP)-
conjugated secondary antibodies (anti-mouse Envision, DAKO or anti-rabbit Envision, DAKO, 
depending on the species of which the primary antibodies were derived). The sections were then 
developed using Opal 570, Opal 690, Opal 520, or Opal 620 fluorophores (all from Akoya Biosciences) 
dissolved in 1x amplification buffer (Akoya Biosciences). After this visualization step, the sections were 
microwaved in AR6 buffer (Akoya Biosciences) to strip the antibody complexes from the sections and 
to perform antigen retrieval for the next staining cycle. The staining procedure described above was 
repeated three more times until all the epitopes of interest were targeted. Next, all sections were 
counterstained with DAPI (Sigma-Aldrich) and mounted with ProLong Gold Antifade Mountant 
(Thermo Fisher Scientific, Bleiswijk, The Netherlands). 
 
Automated Image Analyses 
The VECTRA 3.0 automated quantitative pathology imaging system (Akoya Biosciences) was used for 
imaging of the multiplexed-stained slides. The whole tissue sections were scanned at a 10x 
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magnification. PhenoChart software (Akoya Biosciences, 1.0.4.) was used to randomly select 6 
multispectral imaging (MSI) fields within the tumor regions, defined as areas containing at least 30% 
tumor epithelium based on the anti-cytokeratin staining and DAPI signal, which were then scanned at 
a higher resolution (20x). InForm software (Akoya Biosciences, 2.2.1) was used to prepare a spectral 
library of every fluorophore. Spectral unmixing was then performed on the multiplexed-stained slides 
and the background signals were extracted using InForm software. Thereafter, a tissue segmentation 
algorithm was trained using InForm software in order to automatically define tumor epithelium, 
stroma, and areas without tissue based on anti-cytokeratin antibodies and DAPI signals. A cell 
segmentation algorithm was set up based on the detection of cell nuclei using the DAPI signal. A 
phenotyping algorithm was trained to distinguish macrophages (CD68+) from non-macrophages 
(CD68-) within the tumor epithelium and stromal compartments separately. Finally, the iNOS and 
CD163 expression were scored on the identified TAMs using a set threshold to identify M0 (iNOS-
CD163-), M1 (iNOS+CD163-), M2 (iNOS-CD163+), and M3 (iNOS+CD163+) TAMs. Subsequently, the cell 




Statistical analyses were performed using SPSS software (IBM SPSS Statistics 22, Chicago, IL, USA). 
Independent samples T tests and Mann-Whitney U tests were used in order to compare the markers 
between CRC patients and healthy donors. Dependent samples T tests were used to study the change 
in sCD163 concentrations between pre-operative and post-operative serum samples. Independent 
samples T tests, Mann-Whitney U tests, Kruskal–Wallis tests, ANOVA, and the Spearman’s rho 
correlation test were used to relate monocytes, sCD163, and macrophages with tumor characteristics. 
The Spearman’s rho test was used to study the correlation between the serum sCD163 levels and the 
CD163 expression on monocytes and TAMs. In addition, Kaplan-Meier analyses and log-rank tests 
were used to correlate monocytes, sCD163, and macrophages with patients’ OS and DFS. The OS was 
defined as the time from surgery until death, or the end of follow-up (censored). The DFS was defined 
as the time from surgery until the first sign of disease recurrence or until death, whichever came first, 
or the end of the follow-up (censored). A Cox regression analysis was used for the univariate and 
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We investigated CD163 expressed by circulating monocytes and TAMs, and its soluble circulating form 
(sCD163) in relation to the clinicopathological parameters in CRC. In total, 78 CRC patients were 
included in the study. Due to a limited sample availability, sCD163, monocytes, and TAMs were studied 
in subgroups of this cohort, as visualized in Figure 1. As controls, sCD163 was studied in the serum of 
40 healthy donors. Additionally, the CD163 expression on circulating monocytes was studied in 10 
healthy donors. The clinicopathological characteristics of the 78 CRC patients and healthy donors are 
summarized in Table 1. No differences were observed between the distribution of age or sex between 
the 78 CRC patients and the 40 healthy serum donors. The age of the healthy PBMC donors was 
significantly lower than the CRC patients (P=0.028). This was due to the limited PBMC sample 
availability from elderly healthy donors. No differences were found regarding the distribution of sex 





Figure 1. Sample availability for the measurement of monocytes, sCD163 and TAMs in CRC patients and healthy 
donors. Monocytes, sCD163 and TAMs were studied in 78 CRC patients. TAMs and monocytes were studied in 72 
and 47 CRC patients, respectively. Additionally, sCD163 levels were studied in 64 pre-operative and 44 post-
operative patients. Finally, monocytes were studied in 10 healthy donors whereas sCD163 levels were studied in 
40 healthy donors. The numbers in the figure indicate the number of patients in each subgroup with overlapping 
samples. Abbreviations: CRC (colorectal cancer), ELISA (enzyme-linked immunosorbent assay), PBMC (peripheral 
blood mononuclear cells), sCD163 (soluble CD163), TAM (tumor-associated macrophages).  
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Table 1. Clinicopathological characteristics of patients with CRC and healthy donors in the study. Statistically 
significant P-values (≤0.05) are indicated in bold. Abbreviations: CRC (colorectal cancer), PBMC (peripheral blood 
mononuclear cells), TNM (Tumor Node Metastasis).  
  CRC patients Healthy serum donors Healthy PBMC donors 
  (N=78) (N=40) P-value (N=10) P-value 
Age*     0.392   0.028 
Mean (years) 65.9 63.8  48.8  
Range (years) 25-85 26-82   22-78   
Sex     0.597   0.951 
Female  35 (44.9%) 20 (50.0%)  5 (50.0%)  
Male 34 (55.1%) 20 (50.0%)   5 (50.0%)   
Tumor location           
Colon 64 (82.1%)     
Rectum 14 (17.9%)         
TNM classification           
Stage 0 4 (5.1%)     
Stage I 12 (15.4%)     
Stage II 26 (33.3%)     
Stage III 26 (33.3%)     
Stage IV 10 (12.8%)         
Tumor differentiation           
Well/moderate 62 (79.5%)     
Poor 13 (16.7%)     
Unknown 3 (3.8%)         
Tumor-positive lymph nodes           
No 45 (57.7%)     
Yes 32 (41.0%)     
Unknown 1 (1.3%)         
Neoadjuvant radiotherapy           
No 69 (88.5%)     
Yes 9 (11.5%)         
Adjuvant chemotherapy           
No 49 (62.8%)     
Yes 29 (37.2%)         
*Age at time of surgery was used for patients and time of serum/ PBMC donation for healthy donors 
 
 
Trend towards Increased sCD163 Levels in CRC Patients with a Higher TNM Classification  
We studied the levels of sCD163 in the pre-operative (N=64) and post-operative serum samples (N=44) 
derived from CRC patients and in 40 healthy donors. The majority of the measured sCD163 levels from 
healthy donors and CRC patients were within the reference range (0.7-3.9 mg/L) with no difference in 
the sCD163 levels between the two groups (Figure 2A, P=0.267). In the 39 patients with pre-operative 
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the sCD163 levels between the two groups (Figure 2A, P=0.267). In the 39 patients with pre-operative 
and post-operative serum samples available, we observed that sCD163 levels did not change after 
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resection of the tumor (P=0.723, Figure 2A). We also investigated the association between sCD163 
levels and tumor characteristics (Table S1A). Although no correlation was observed between the 
sCD163 levels and TNM stage in a Spearman’s rho correlation test (P=0.141), an intergroup analysis 
revealed that patients with TNM stage IV tumors showed a trend towards higher sCD163 levels 
compared to TNM stage 0/I patients (P=0.052, Figure 2B). No association was observed between the 




Figure 2. sCD163 levels in serum of CRC patients and healthy donors as measured by ELISA in relation to 
clinicopathological parameters. A. Comparison of sCD163 serum levels in healthy donors (N=40) and pre-operative 
CRC patients (N=64), and the change in sCD163 levels in CRC patients after surgery (N=39). B. Association between 
the sCD163 levels in CRC patients and TNM stage (stage 0/I, N=15; stage II/III, N=43; stage IV, N=6). C. Association 
between the sCD163 levels and clinical outcome in CRC patients. Kaplan-Meier curves for the OS are shown for 
TNM stage 0-IV CRC patients (N=64) and Kaplan-Meier curves for DFS are shown for the TNM stage 0-III CRC 
patients (N=58). Stratifications were based on the median sCD163 level (2.0 mg/l). The bars (A, left figure; B) show 
the median sCD163 level with a 95% CI whereas the dotted lines show the reference sCD163 levels (0.7-3.9 mg/l). 
Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CI (confidence interval), CRC 
(colorectal cancer), DFS (disease-free survival), HD (healthy donor), OS (overall survival), post-op (post-operative), 
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High sCD163 Levels Are Associated with a Shorter OS and DFS in CRC Patients 
Next, the association between the sCD163 levels and clinical outcome was investigated in CRC 
patients. The patient population (N=64) was divided into two groups using the median concentration 
of sCD163 (2.0 mg/L) as a cutoff. We observed that above-median sCD163 levels in CRC patients were 
associated with a shorter OS (P=0.035), with a hazard ratio (HR) of 2.2 (95% confidence interval (CI) 
1.0-4.6, P=0.040). Patients with TNM stage IV tumors were excluded from the DFS analyses (N=6) since 
they already presented metastatic disease at the time of blood sampling. Patients with above-median 
sCD163 levels showed a significantly shorter DFS (P=0.005) compared to patients with below-median 
sCD163 levels, with a hazard ratio (HR) of 3.1 (CI 1.4-7.1, P=0.007) (Figure 2C). A multivariate analysis 
was performed for DFS and OS in CRC patients which revealed that above-median sCD163 levels (HR 
2.4, 95% CI 1.0–5.7, P=0.049) remained significantly associated with a shorter DFS when corrected for 
age (category ≤70 or >70 years) and TNM classification (Table 2), but not with the OS (HR 1.5, 95% CI 
0.7-3.3, P=0.291, Table 3). 
 
 
Table 2. Univariate and multivariate analyses of sCD163 serum levels for the DFS of CRC patients. Univariate and 
multivariate analyses for DFS were generated for stage 0-III CRC patients (N=58). The median sCD163 level (2.0 
mg/l) was used as a cutoff. Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CI 
(confidence interval), CRC (colorectal cancer), DFS (disease-free survival), HR (hazard ratio), sCD163 (soluble 
CD163), TNM (Tumor Node Metastasis). 
 Univariate analysis for DFS Multivariate analysis* for DFS 
Parameter HR 95% CI P-value HR 95% CI P-value 
Age (continuous) 1.0 1.0-1.1 0.340       
Age              
≤70 years 1.0      
>70 years 2.0 0.9-4.3 0.072       
Sex             
Female  1.0      
Male 1.4 0.7-3.1 0.358       
TNM classification             
Stage 0/I 1.0      
Stage II 2.0 0.5-7.6 0.299    
Stage III 5.9 1.7-20.4 0.005       
Tumor location             
Colon 1.0      
Rectum 1.9 0.8-4.5 0.117       
Tumor differentiation grade             
Well/moderate 1.0      
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Sex             
Female  1.0      
Male 1.4 0.7-3.1 0.358       
TNM classification             
Stage 0/I 1.0      
Stage II 2.0 0.5-7.6 0.299    
Stage III 5.9 1.7-20.4 0.005       
Tumor location             
Colon 1.0      
Rectum 1.9 0.8-4.5 0.117       
Tumor differentiation grade             
Well/moderate 1.0      




Table 2. Continued 
 Univariate analysis for DFS Multivariate analysis* for DFS 
Parameter HR 95% CI P-value HR 95% CI P-value 
sCD163 (continuous) 1.1 0.8-1.6 0.446 1.0 0.7-1.4 0.903 
sCD163             
Below median 1.0   1.0   
Above median 3.1 1.4-7.1 0.007 2.4 1.0-5.7 0.049 
* Corrected for age (categorized as ≤70 or >70 years age) and TNM classification 
 
 
Table 3. Univariate and multivariate analyses of sCD163 serum levels for the OS of CRC patients. Univariate and 
multivariate analyses for OS were generated for stage 0-IV CRC patients (N=64). The median sCD163 level (2.0 
mg/l) was used as a cutoff. Statistically significant P-values (≤0.05) are indicated in bold. Abbreviations: CI 
(confidence interval), CRC (colorectal cancer), HR (hazard ratio), OS (overall survival), sCD163 (soluble CD163), TNM 
(Tumor Node Metastasis). 
 Univariate analysis for OS Multivariate analysis* for OS 
Parameter HR 95% CI P-value HR 95% CI P-value 
Age (continuous) 1.0 1.0-1.1 0.039       
Age              
≤70 years 1.0      
>70 years 2.9 1.4-6.1 0.005       
Sex             
Female  1.0      
Male 1.9 0.9-4.1 0.101       
TNM classification             
Stage 0/I 1.0      
Stage II 1.7 0.4-6.4 0.459    
Stage III 4.5 1.3-15.8 0.018    
Stage IV 30.7 6.6-143.0 <0.001       
Tumor location             
Colon 1.0      
Rectum 1.5 0.7-3.4 0.314       
Tumor differentiation grade             
Well/moderate 1.0      
Poor 1.5 0.6-3.4 0.393       
sCD163 (continuous) 1.2 0.9-1.6 0.303 1.0 0.7-1.4 0.960 
sCD163             
Below median 1.0   1.0   
Above median 2.2 1.0-4.6 0.040 1.5 0.7-3.3 0.291 
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Expression of Membrane-Bound CD163 on Circulating Classical Monocytes Is Decreased in 
CRC Patients Compared to Healthy Donors 
We studied the presence of circulating CD14+ and/or CD163+ monocytes in pre-operative PBMC 
samples from CRC patients (N=47) and healthy donors (N=10) with multiparameter flow cytometry 
using a standardized gating strategy (Figure S1). The total monocyte percentage (% of CD45+ PBMCs) 
was comparable between CRC patients and healthy donors (P=0.425, Figure 3A). The monocyte 
population was further divided into classical (CD14++CD16-), intermediate (CD14++CD16+) and 
nonclassical (CD14+CD16++) monocyte subsets. No statistically significant differences were observed 
in the percentage (of total monocytes) of classical (P=0.975), intermediate (P=0.536), or nonclassical 
(P=0.116) monocytes when CRC patients were compared to healthy donors (Figure 3A). Interestingly, 
CD163 was expressed to a lower extent in the total monocyte population in CRC patients compared 
to healthy donors (P=0.007, Figure 3A). The decreased expression of CD163 was observed only in 
classical monocytes (P=0.006), and not in intermediate (P=0.522) or nonclassical monocytes (P=0.193, 
Figure 3A). Interestingly, the percentage of total monocytes positively correlated with the percentage 
of total Tregs (P=0.019, Figure S2). No association was observed between the CD163 expression on 
monocytes and the percentage of Tregs in the peripheral blood of CRC patients (P=0.745). 
Additionally, no significant correlation was observed between the CD163 expression on monocytes 
and serum sCD163 levels in CRC patients (P=0.482, Figure S3). 
 
Increased Monocyte Percentage in More Advanced Tumors 
Next, we examined the association between the total monocyte percentage and monocyte subsets 
(Table S1B) and their level of CD163 expression (Table S1C) with tumor characteristics. A positive 
correlation was observed between the total percentage of monocytes and TNM stage in CRC patients 
(P=0.004). An intergroup analysis revealed that patients with TNM stage IV tumors (N=8) showed a 
significantly higher total monocyte percentage compared to patients with TNM stage 0/I tumors 
(N=14, P=0.016, Figure 3B). Additionally, patients with poorly differentiated tumors (N=11) showed a 
trend towards a higher percentage of circulating monocytes compared to patients with well or 
moderately differentiated tumors (N=34, P=0.055, Figure 3B). This was restricted to the classical 
monocytes (P=0.039, Figure 3C). Furthermore, the percentage of total monocytes was higher in 
patients with tumor-positive lymph nodes (N=17) compared to patients without tumor-positive lymph 
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Expression of Membrane-Bound CD163 on Circulating Classical Monocytes Is Decreased in 
CRC Patients Compared to Healthy Donors 
We studied the presence of circulating CD14+ and/or CD163+ monocytes in pre-operative PBMC 
samples from CRC patients (N=47) and healthy donors (N=10) with multiparameter flow cytometry 
using a standardized gating strategy (Figure S1). The total monocyte percentage (% of CD45+ PBMCs) 
was comparable between CRC patients and healthy donors (P=0.425, Figure 3A). The monocyte 
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nonclassical (CD14+CD16++) monocyte subsets. No statistically significant differences were observed 
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Figure 3. Distribution of monocyte subsets and their level of CD163 expression in the peripheral blood of CRC 
patients and healthy donors as measured by flow cytometry in relation to clinicopathological parameters. A. 
Comparison of the total monocyte percentage, monocyte subset distribution (CD14++CD16- classical, CD14++CD16+ 
intermediate and CD14+CD16++ nonclassical monocytes), and CD163 expression level on these monocyte subsets 
between healthy donors (N=10) and CRC patients (N=47). B. Association between the total monocyte percentage 
and TNM stage (stage 0/I, N=14; stage II/III, N=25; stage IV, N=8), differentiation grade (well/moderate, N=34; 
poor, N=11) and tumor-positive lymph nodes (no, N=30; yes, N=17) in CRC patients. C. Association between the 
percentage of classical monocytes and differentiation grade (well/moderate, N=34; poor, N=11) in CRC patients. 
D. Association between the total monocyte percentage and clinical outcome in CRC patients. Kaplan-Meier curves 
for the OS are shown for TNM stage 0-IV CRC patients (N=47) and Kaplan-Meier curves for the DFS are shown for 
stage 0-III CRC patients (N=39). Stratifications were based on the median total monocyte percentage (24.9%). The 
bars in figure (A-C) show the median with a 95% CI. Statistically significant P-values (≤0.05) are indicated in bold. 
Abbreviations: CI (confidence interval), Class. (classical), CRC (colorectal cancer), DFS (disease-free survival), HD 
(healthy donor), Int. (Intermediate), OS (overall survival), MFI (median fluorescence intensity), Nonclass. 
(Nonclassical), PBMCs (peripheral blood mononuclear cells), TNM (Tumor, Node, Metastasis), yrs (years). 
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characteristics, the percentage of intermediate or nonclassical monocytes, or CD163 expression 
(Table S2B,C). 
 
Association between Total Monocyte Percentage and Clinical Outcome in CRC Patients 
We subsequently investigated if the total monocyte percentage in CRC patients was associated with 
clinical outcome. Kaplan-Meier plots and log-rank tests revealed a shorter OS in CRC patients with an 
above-median (≥24.9%) total monocyte percentage (N=24) compared to CRC patients with a below-
median percentage (N=23, P=0.007, Figure 3D) with a HR of 3.0 (95% CI 3.1-7.1, P=0.010). Patients 
with TNM stage IV tumors were excluded from the DFS analyses (N=8). No association was observed 
between the percentage of total monocytes and DFS (P=0.153, Figure 3D) with a HR of 1.9 (95% CI 
0.8-4.8, P=0.161). A multivariate analysis showed that the above-median percentage of circulating 
monocytes was not independently associated with a shorter OS when corrected for age and TNM 
classification. The percentage of classical, intermediate, and nonclassical monocytes, and the CD163 
expression level on monocytes, were not associated with clinical outcome (data not shown). 
 
TAMs in the Stromal Compartment of Primary Colorectal Tumors Have an M2-Polarized 
(iNOS-CD163+) Phenotype whereas in the Epithelium M0- (iNOS-CD163-) and M1-Polarized 
(iNOS+CD163-) Phenotypes Are Predominant 
Multiplex immunofluorescent imaging was used to identify the presence of stromal TAM (sTAM) and 
intraepithelial TAM (ieTAM) subsets in the primary tumors of CRC patients (N=72). The sTAMs were 
successfully quantified in all 72 included primary colorectal tumors. Due to the occasional expression 
of CD68 in tumor epithelium cells, the total number of ieTAMs was sometimes overestimated. In total, 
four patients were identified as outliers with an overestimated cell density of the total ieTAMs and 
were therefore excluded from the analyses. M0 (iNOS-CD163-), M1 (iNOS+CD163-), M2 (iNOS-CD163+), 
and M3 (iNOS+CD163+) TAMs could be identified in primary colorectal tumors as illustrated in Figure 
4A. Although the majority of TAMs were identified in the stromal compartment, TAMs were also 
observed to infiltrate the tumor epithelium compartment of some tumors. Figure 4B shows 
representative examples of colorectal tumors with high numbers of sTAMs and ieTAMs, respectively. 
In the majority of the studied tumors, the cell density of sTAMs was higher compared to ieTAMs 
(Figure 5A). In both stromal and epithelial tissue compartments, the TAM subsets were not equally 
distributed (P<0.001, Figure 5A). The majority of sTAMs showed a M2-polarized phenotype (63%±17), 
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successfully quantified in all 72 included primary colorectal tumors. Due to the occasional expression 
of CD68 in tumor epithelium cells, the total number of ieTAMs was sometimes overestimated. In total, 
four patients were identified as outliers with an overestimated cell density of the total ieTAMs and 
were therefore excluded from the analyses. M0 (iNOS-CD163-), M1 (iNOS+CD163-), M2 (iNOS-CD163+), 
and M3 (iNOS+CD163+) TAMs could be identified in primary colorectal tumors as illustrated in Figure 
4A. Although the majority of TAMs were identified in the stromal compartment, TAMs were also 
observed to infiltrate the tumor epithelium compartment of some tumors. Figure 4B shows 
representative examples of colorectal tumors with high numbers of sTAMs and ieTAMs, respectively. 
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(Figure 5A). In both stromal and epithelial tissue compartments, the TAM subsets were not equally 
distributed (P<0.001, Figure 5A). The majority of sTAMs showed a M2-polarized phenotype (63%±17), 





Figure 4: TAM subsets in primary colorectal tumors as visualized by multiplex immunofluorescence. A. Image of M0 
(CD68+iNOS-CD163-), M1 (CD68+iNOS+CD163-), M2 (CD68+iNOS-CD163+) and M3 (CD68+iNOS+CD163+) TAMs. B. 
Representative images of colorectal tumors with high numbers of sTAMs and ieTAMs (white: DAPI; red: 
cytokeratin+ tumor epithelium; blue: CD68+ TAMs). The white arrows indicate examples of TAMs with indicated 
phenotypes (A) or localization (B). Abbreviations: CRC (colorectal cancer), iNOS (inducible nitric oxide synthase), 
ieTAM (intraepithelial TAM), sTAM (stromal TAM), TAM (tumor-associated macrophage).  
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Interestingly, the distribution of ieTAMs showed a different pattern with relatively high numbers of 
M0 (37%±20) and M1 (36%±19) ieTAMs compared to low numbers of M2 (15%±10) and M3 (12%±12) 
ieTAMs (Figure 5A). Hence, sTAMs primarily showed an immunosuppressive (M2) phenotype whereas 
the majority of ieTAMs showed a naïve (M0) or inflammatory (M1) phenotype. 
 
 
Figure 5. Distribution of the TAM subsets in the stromal and intraepithelial compartments of primary colorectal 
tumors as measured by multiplex immunofluorescence in relation to clinicopathological parameters. A. 
Distribution of sTAM and ieTAM subsets (CD68+iNOS-CD163- M0, CD68+iNOS+CD163- M1, CD68+iNOS-CD163+ M2 
and CD68+iNOS+CD163+ M3 TAMs) in primary colorectal tumors (N=72 and N=68, respectively). B. Associations 
between the percentage of M2 ieTAMs and TNM stage (stage 0/I, N=14; stage II/III, N=46; stage IV, N=8), and 
between the percentage of M2 ieTAMs and M2 ieTAM density and tumor differentiation grade (well/moderate, 
N=55; poor, N=12) in primary colorectal tumors. The bars show the median with a 95% CI. Statistically significant 
P-values (≤0.05) are indicated in bold. Abbreviations: CI (confidence interval), CRC (colorectal cancer), iNOS 
(inducible nitric oxide synthase), ieTAM (intraepithelial TAM), sTAM (stromal TAM), TAM (tumor-associated 
macrophage), TNM (Tumor, Node, Metastasis). 
 
 
Increased M2 TAM Percentage in the Epithelial Compartment of Advanced Tumors 
Next, the association between the cell density and distribution of different TAM subsets in the stromal 
(Table S1D,E) and epithelial (Table S1F,G) compartments of colorectal tumors and tumor 
characteristics was studied. The cell density and subset distribution of sTAMs were not associated 
with tumor characteristics (Table S1D and S1E, respectively). Although no correlation was observed 
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Increased M2 TAM Percentage in the Epithelial Compartment of Advanced Tumors 
Next, the association between the cell density and distribution of different TAM subsets in the stromal 
(Table S1D,E) and epithelial (Table S1F,G) compartments of colorectal tumors and tumor 
characteristics was studied. The cell density and subset distribution of sTAMs were not associated 
with tumor characteristics (Table S1D and S1E, respectively). Although no correlation was observed 
between the percentage of M2 ieTAMs and the TNM stage (P=0.205), an intergroup analysis revealed 
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that patients with TNM stage IV tumors showed a higher percentage of M2 ieTAMs compared to TNM 
stage 0/I patients (P=0.029) and TNM stage II/III patients (P=0.028, Figure 5B). Furthermore, the 
percentage of M2 ieTAMs as well as the M2 ieTAM density were observed to be higher in patients 
with poorly differentiated tumors (N=12) compared to patients with well or moderately differentiated 
tumors (N=55, P=0.004 and P=0.003, respectively, Figure 5B). The cell density and subset distribution 
of the sTAMs and ieTAMs were not correlated with clinical outcome (data not shown). Interestingly, 
a trend was observed towards a positive correlation between the cell density of M2 sTAMs and the 
total percentage of circulating Tregs (P=0.077), as well as for the cell density of M2 ieTAMs and Tregs 
(P=0.103, Figure S4). No significant correlation was observed between the M2 sTAM or ieTAM density 
and serum sCD163 levels in CRC patients (P=0.989 and P=0.498, respectively, Figure S5). 
 
Discussion 
Innate immune cells in the circulation and tumor microenvironment participate in several stages of 
cancer progression [32]. The macrophage-associated molecule CD163 has been reported to be a 
prognostic biomarker in different cancer types [13-17,20-22], but its role in CRC is still unclear. We 
decided to study CD163 in a broader context, comprising both the tumor microenvironment and 
circulation of CRC patients. We investigated the CD163 expressed by circulating monocytes and TAMs, 
and its soluble circulating form (sCD163) in relation to clinicopathological parameters in CRC. 
We evaluated the levels of sCD163 in serum and observed no differences between healthy 
donors and CRC patients, which is in agreement with studies on ovarian cancer [13], melanoma [14], 
and multiple myeloma [17], but in contrast with a study on hepatocellular carcinoma [15] and another 
study in CRC patients by Ding et al. [16]. The latter showed increased sCD163 levels in the total CRC 
patient population compared to healthy donors [16]. However, subset analyses revealed that early 
stage CRC patients showed comparable sCD163 levels with healthy donors [16]. This is in line with our 
results that showed increased sCD163 levels in CRC patients with advanced cancer stages. The total 
study population by Ding et al. contained relatively more patients with advanced cancer stages 
compared to our cohort, which may explain the discrepancy. Additionally, although the majority of 
our healthy donors had sCD163 levels within the reference range (0.7-3.9 mg/L), four healthy donors 
showed elevated levels. The healthy serum donors included in our study were spouses from cancer 
patients which may have been less healthy (i.e., relatively higher sCD163 levels) compared to the 
healthy donors included in the study by Ding et al. Excluding the healthy donor outliers from analysis 
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did not affect the results of our analyses. In the present study, we observed no change in the sCD163 
level of CRC patients after tumor resection. The post-operative serum samples were obtained within 
a range of 2-14 months after surgery, suggesting that resection of the primary tumor did not influence 
sCD163 levels or, alternatively, that it takes longer than the studied interval to detect a change in 
sCD163 levels after surgical resection of the tumor. In line with studies on other cancers [13-15,17] 
and a study on CRC specifically [16], a high sCD163 level was an independent predictor of DFS in our 
CRC cohort. Therefore, sCD163 levels may be used in a clinical setting as a prognostic biomarker. 
Additional research in a prospective setting is required to further investigate the potential use of 
sCD163 as prognostic biomarker in CRC. 
We also observed comparable monocyte percentages and distribution of circulating 
monocyte subsets between CRC patients and healthy donors. Within the patient population, patients 
with the highest total monocyte frequency had more advanced tumors, represented by a high TNM 
classification, poor differentiation grade, and tumor-positive lymph nodes. This is in agreement with 
the meta-analysis by Tan et al. that reported an association between decreased lymphocyte-to-
monocyte ratios and high tumor invasion depths and larger tumor sizes [7]. Additionally, in line with 
other studies [7,8], we observed a trend towards a shorter OS in CRC patients with a high percentage 
of total circulating monocytes. Such an association was not observed in our study for DFS. This may 
be due to the limited number of patients in our study cohort, but may also suggest that the monocyte 
percentages are associated with comorbidities instead of cancer-specific deaths. This has also been 
suggested by other studies that showed an association between high monocyte percentages and 
cardiovascular disease [33] and infectious diseases [34]. Furthermore, we showed in this study that 
the percentage of circulating monocytes positively correlated with the percentage of circulating Tregs. 
This is in line with other studies that suggested a positive feedback loop between these cell types 
[35,36]. Among others, monocytes can produce CCL5 and express the TIE2 receptor that recruits and 
expands immunosuppressive Tregs, respectively [37,38]. Additionally, Tregs produce IL-4, IL-10, and 
IL-13 that direct the differentiation of classical monocytes into M2 TAMs with further 
immunosuppressive functions [35,36]. In line with these studies, we observed a trend towards a 
positive correlation between the cell density of M2 TAMs and total percentage of circulating Tregs in 
CRC patients. Furthermore, we [39] and others [40-42] reported an association between a high 
percentage of circulating Tregs and poor clinical outcome in CRC patients. This suggests that 
monocytes/TAMs and Tregs closely interact and, additionally, play important roles in cancer 
development and progression. 
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that patients with TNM stage IV tumors showed a higher percentage of M2 ieTAMs compared to TNM 
stage 0/I patients (P=0.029) and TNM stage II/III patients (P=0.028, Figure 5B). Furthermore, the 
percentage of M2 ieTAMs as well as the M2 ieTAM density were observed to be higher in patients 
with poorly differentiated tumors (N=12) compared to patients with well or moderately differentiated 
tumors (N=55, P=0.004 and P=0.003, respectively, Figure 5B). The cell density and subset distribution 
of the sTAMs and ieTAMs were not correlated with clinical outcome (data not shown). Interestingly, 
a trend was observed towards a positive correlation between the cell density of M2 sTAMs and the 
total percentage of circulating Tregs (P=0.077), as well as for the cell density of M2 ieTAMs and Tregs 
(P=0.103, Figure S4). No significant correlation was observed between the M2 sTAM or ieTAM density 
and serum sCD163 levels in CRC patients (P=0.989 and P=0.498, respectively, Figure S5). 
 
Discussion 
Innate immune cells in the circulation and tumor microenvironment participate in several stages of 
cancer progression [32]. The macrophage-associated molecule CD163 has been reported to be a 
prognostic biomarker in different cancer types [13-17,20-22], but its role in CRC is still unclear. We 
decided to study CD163 in a broader context, comprising both the tumor microenvironment and 
circulation of CRC patients. We investigated the CD163 expressed by circulating monocytes and TAMs, 
and its soluble circulating form (sCD163) in relation to clinicopathological parameters in CRC. 
We evaluated the levels of sCD163 in serum and observed no differences between healthy 
donors and CRC patients, which is in agreement with studies on ovarian cancer [13], melanoma [14], 
and multiple myeloma [17], but in contrast with a study on hepatocellular carcinoma [15] and another 
study in CRC patients by Ding et al. [16]. The latter showed increased sCD163 levels in the total CRC 
patient population compared to healthy donors [16]. However, subset analyses revealed that early 
stage CRC patients showed comparable sCD163 levels with healthy donors [16]. This is in line with our 
results that showed increased sCD163 levels in CRC patients with advanced cancer stages. The total 
study population by Ding et al. contained relatively more patients with advanced cancer stages 
compared to our cohort, which may explain the discrepancy. Additionally, although the majority of 
our healthy donors had sCD163 levels within the reference range (0.7-3.9 mg/L), four healthy donors 
showed elevated levels. The healthy serum donors included in our study were spouses from cancer 
patients which may have been less healthy (i.e., relatively higher sCD163 levels) compared to the 
healthy donors included in the study by Ding et al. Excluding the healthy donor outliers from analysis 
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did not affect the results of our analyses. In the present study, we observed no change in the sCD163 
level of CRC patients after tumor resection. The post-operative serum samples were obtained within 
a range of 2-14 months after surgery, suggesting that resection of the primary tumor did not influence 
sCD163 levels or, alternatively, that it takes longer than the studied interval to detect a change in 
sCD163 levels after surgical resection of the tumor. In line with studies on other cancers [13-15,17] 
and a study on CRC specifically [16], a high sCD163 level was an independent predictor of DFS in our 
CRC cohort. Therefore, sCD163 levels may be used in a clinical setting as a prognostic biomarker. 
Additional research in a prospective setting is required to further investigate the potential use of 
sCD163 as prognostic biomarker in CRC. 
We also observed comparable monocyte percentages and distribution of circulating 
monocyte subsets between CRC patients and healthy donors. Within the patient population, patients 
with the highest total monocyte frequency had more advanced tumors, represented by a high TNM 
classification, poor differentiation grade, and tumor-positive lymph nodes. This is in agreement with 
the meta-analysis by Tan et al. that reported an association between decreased lymphocyte-to-
monocyte ratios and high tumor invasion depths and larger tumor sizes [7]. Additionally, in line with 
other studies [7,8], we observed a trend towards a shorter OS in CRC patients with a high percentage 
of total circulating monocytes. Such an association was not observed in our study for DFS. This may 
be due to the limited number of patients in our study cohort, but may also suggest that the monocyte 
percentages are associated with comorbidities instead of cancer-specific deaths. This has also been 
suggested by other studies that showed an association between high monocyte percentages and 
cardiovascular disease [33] and infectious diseases [34]. Furthermore, we showed in this study that 
the percentage of circulating monocytes positively correlated with the percentage of circulating Tregs. 
This is in line with other studies that suggested a positive feedback loop between these cell types 
[35,36]. Among others, monocytes can produce CCL5 and express the TIE2 receptor that recruits and 
expands immunosuppressive Tregs, respectively [37,38]. Additionally, Tregs produce IL-4, IL-10, and 
IL-13 that direct the differentiation of classical monocytes into M2 TAMs with further 
immunosuppressive functions [35,36]. In line with these studies, we observed a trend towards a 
positive correlation between the cell density of M2 TAMs and total percentage of circulating Tregs in 
CRC patients. Furthermore, we [39] and others [40-42] reported an association between a high 
percentage of circulating Tregs and poor clinical outcome in CRC patients. This suggests that 
monocytes/TAMs and Tregs closely interact and, additionally, play important roles in cancer 
development and progression. 
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The CD163 expression level was significantly lower on monocytes from CRC patients 
compared to healthy donors, suggesting that colorectal tumors influence the phenotype of 
monocytes. The mechanism behind the phenotypic regulation of monocytes, and other circulating 
innate immune cells, such as natural killer and natural killer T cells, are not fully understood, but 
immunosuppressive cytokines are thought to play a major role, along with the hypoxic conditions 
generated in the tumor microenvironment [39,43,44]. In our study, a decreased expression of CD163 
on monocytes in CRC patients, compared to healthy donors, was not accompanied by elevated sCD163 
levels. Additionally, there was no correlation between the CD163 expression on monocytes and 
sCD163 levels. This is in contrast with other studies that reported an inverse relation between the 
sCD163 and monocytic membrane expression of CD163 [11,45]. However, it is also argued that most 
sCD163 does not come from monocytes but from tissue macrophages [12,46], and thus, an increased 
shedding of CD163 from monocytes might not significantly increase the total sCD163. This hypothesis 
was further supported by Sugaya et al. who reported an association between the high infiltration of 
CD163+ cells in the skin and high sCD163 levels in patients with cutaneous T cell lymphoma [47]. These 
observations were not confirmed in our study. Importantly, other factors should also be considered 
when studying the shedding of the CD163 receptor from macrophages and monocytes, such as the 
presence and function of the ADAM17/TACE protease which mediates the cleavage of the CD163 
receptor [11]. In the present study, the CD163 expression on circulating monocytes was not associated 
with tumor characteristics and clinical outcome. 
We also characterized TAM subsets in primary colorectal tumors with an automated image 
analysis. Although the markers used in this study are often used to identify total (CD68), M1 (iNOS) 
and M2 (CD163) TAMs, we have to consider that TAMs show a remarkable functional plasticity and 
often express markers characteristic of both activation states [48]. Hence, the vast majority of 
macrophages have a functional phenotype on a scale in which M1 and M2 macrophages represent 
the extremes [49]. This makes subdividing TAMs into different subsets based on any type of cell 
surface markers with immunofluorescence difficult. In the present study, we observed that M2 TAMs 
were predominant in stromal tissue of colorectal tumors as also reported by others [27,50]. 
Additionally, Edin et al. reported more M2 compared to M1 TAMs at the invasive front of colorectal 
tumors [25]. This suggests that most sTAMs have an M2-polarized phenotype associated with 
immunosuppression. In contrast, Koelzer et al. reported that 40% of the total TAM population in 
colorectal tumors showed a M2 phenotype, whereas 60% presented an M1 phenotype [31]. A case-
by-case analysis showed a positive correlation between the stromal CD68 counts and total tumor 
CD163 counts, but not with the total tumor iNOS counts [31]. Although not further studied, these 
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results suggested that the majority of sTAMs had an M2-polarized phenotype. Since the total TAM 
population showed higher percentages of M1 TAMs compared to M2 TAMs, this might suggest that 
many ieTAMs with M1-polarized phenotypes were present in the colorectal tumors included in the 
study of Koelzer et al. In agreement with this observation, we reported an M0- and M1-biased TAM 
phenotype in the epithelial compartment of colorectal tumors in the present study. This observation 
is also supported by Kim et al. who reported low densities of M2 ieTAMs compared to total ieTAMs, 
suggesting that most ieTAMs had a phenotype other than M2, most likely M1 [50]. In summary, we 
and others showed that, in contrast to sTAMs, primary ieTAMs have an M1 phenotype that are 
associated with pro-inflammatory functions. As the function of TAMs might be dependent on their 
spatial distribution, it seems crucial to characterize TAMs in tumor epithelium and stroma separately 
in future studies. 
To our knowledge, we are the first to study the presence of TAMs with M3 characteristics 
in human tissue. M3 TAMs have already been described in mice, also known as TAMs with an M1/M2 
or M2/M1 switch phenotype, and thus are positive for both M1 (Ly6C) and M2 (CXCR1) markers [23]. 
Additionally, TAMs have also been reported to express both M1 and M2 markers in humans [24,25], 
although they have never been quantified and related to clinical parameters until now. In our study, 
we used a combination of the human M1 (iNOS) and M2 (CD163) markers to identify M3 macrophages 
(iNOS+CD163+). M3 TAMs are reported to have anti-tumor activities in an Ehrlich ascites [51] and a 
prostate cancer mouse model [52]. In our cohort, we did not observe an association between M3 TAM 
densities in the stroma or epithelium from primary colorectal tumors and tumor characteristics or 
clinical outcome. Therefore, the function of M3 TAMs in CRC remains unclear. In the present study, 
the percentage of M2 ieTAMs positively correlated with the TNM stage and differentiation grade. 
Hence, M2 ieTAMs were more present in colorectal tumors with advanced stages. Two other studies 
reported the correlation between ieTAMs and tumor characteristics [31,50]. Whereas Koelzer et al. 
did not show any correlation between the total ieTAM counts and TNM stage or differentiation grade 
[31], Kim et al. showed higher total ieTAM counts in tumors with higher TNM stages [50]. In contrast, 
the M2 ieTAM counts were not associated with the TNM stage [50]. Additionally, we did not observe 
any correlations between the sTAM or ieTAM densities or subset distributions and clinical outcome of 
CRC patients in the present study. Koelzer et al. reported that, independent from TAM localization, 
high CD68 counts were associated with a longer OS [31]. In contrast, Kim et al. reported an association 
between a high intraepithelial CD68 density and worse outcome, but not for a high stromal CD68 
density [50]. In summary, many contradictory findings have been reported on the association of TAMs 
in colorectal tumors with tumor characteristics and clinical outcome. Therefore, the role of TAMs in 
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results suggested that the majority of sTAMs had an M2-polarized phenotype. Since the total TAM 
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is also supported by Kim et al. who reported low densities of M2 ieTAMs compared to total ieTAMs, 
suggesting that most ieTAMs had a phenotype other than M2, most likely M1 [50]. In summary, we 
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in colorectal tumors with tumor characteristics and clinical outcome. Therefore, the role of TAMs in 
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CRC remains elusive. Major issues in TAM research include the differences in used markers, 
techniques, and analyzing methods, which makes it difficult to compare studies, calling for more 
standardized assays. Based on our findings and others, it seems crucial to take the spatial distribution 
of TAMs in CRC into account. This should be investigated and validated in future studies. 
In conclusion, we have shown that monocytes and sCD163 in the circulation are potential 
prognostic biomarkers to predict disease progression in CRC patients, whereas the TAM densities and 
phenotypes in the primary tumor are not, thereby emphasizing the importance of the innate systemic 
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Summary and discussion 
Over the past years, major progress has been made in the treatment of colorectal cancer (CRC) 
patients including introduction of new (neo)-adjuvant treatment strategies and surgical techniques. 
These developments have resulted in improvement of survival of CRC patients [1], but there is still 
considerable potential. Due to the crucial role of tumor-immune interactions in development and 
progression of CRC, immune-related biomarkers have become an important focus of research. 
Research aims at better identification of CRC patients with a high risk for disease progression, and 
selection of patients who would benefit most from immunotherapeutic strategies. This thesis focused 
on systemic immune-related biomarkers in CRC with as ultimate goal to better understand the 
underlying biology of tumor-immune interactions in the circulation of CRC patients. The primary focus 
was on natural killer (NK) cells and natural killer T (NKT) cells since these cell types are able to 
recognize and kill tumor cells with downregulated human leukocyte antigen (HLA) class I expression, 
a feature that is often observed in CRC.  
 
Circulating NK- and NKT cells 
NKT cells constitute a unique subset of T cells at the interface between the innate and adaptive 
immune system displaying features of both NK- and T cells. NKT cells possess cytotoxic capabilities, 
but are primarily considered to have a regulatory function via the secretion of large amounts of pro- 
or anti-inflammatory cytokines upon activation, thereby resulting in amplification or dampening of 
the immune response [2]. In Chapter 2, we argued that, because of their major modulating effects on 
immune responses, NKT cells might be important mediators of tumor immunosurveillance. Therefore, 
NKT cells are interesting targets for immunotherapy. Over the past years, multiple clinical trials have 
been performed aimed at activation of NKT cells in cancer patients using the synthetic compound α-
GalCer. However, up till now, the beneficial clinical responses in patients are limited [3-5]. In Chapter 
2 we argued that this is because the contribution of functionally altered NKT cells to the failure of NKT 
cell-based immunotherapies has been largely ignored. During tumor progression, NKT cells may 
become overstimulated which results in deletion of a part of the NKT cell population in cancer patients 
via activation-induced cell death. Additionally, the remaining NKT cells may become hyporesponsive 
(i.e. anergic), or start secreting immunosuppressive cytokines, thereby facilitating tumor progression 
and immune escape. Therefore, we concluded that there should be three important focuses of NKT 
cell research in cancer patients: (1) expansion of the NKT cell population, (2) prevention and/or 
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breaking of NKT cell anergy, and (3) skewing of NKT cells towards subsets with potent antitumor 
activity.  
 
In order to gain more insights in the role and function of circulating immune cell subsets in tumor 
progression, including NKT cells, we studied the peripheral blood immune profile of CRC patients 
before and after tumor resection as described in Chapter 3 and 4, respectively. In these studies, we 
observed downregulation of activating receptors on circulating NK- and NKT cells in CRC patients 
before tumor resection, thereby implying impaired function. CRC patients therefore seem to have an 
immunocompromised state of their circulating NK- and NKT cells, which might contribute to immune 
escape and disease progression. These findings are consistent with previous studies that showed low 
numbers of peripheral blood NK cells expressing activating receptors in preoperative CRC patients 
[6,7]. Interestingly, we showed in Chapter 4 that expression of several activating receptors was 
upregulated on circulating NK- and NKT cells in CRC patients after surgical removal of the primary 
tumor, whereas inhibitory receptors were downregulated. Hence, the immunosuppressive state of 
NK- and NKT cells in preoperative CRC patients was not observed anymore after surgery. In line with 
our results, others [8-10] also reported higher numbers of cytotoxic immune cell subsets in cancer 
patients after surgery, including NK cells, NKT cells, and CD8+ T cells. These observations imply that 
the altered phenotype, and possibly function, of circulating immune cells might be induced by the 
primary tumor. Thus, tumors may have a suppressive effect on the systemic immune system which 
possibly leads to escape of tumor cells from recognition and elimination in the circulation, thereby 
resulting in the formation of distant metastasis.  
 
We showed in Chapter 3 that a high percentage of CD16+ circulating NKT cells was associated with 
short disease-free survival (DFS) in CRC patients, independent from TNM classification and age. Thus, 
it seems that the CD16 receptor, which is involved in antibody-dependent cell-mediated cytotoxicity, 
is upregulated on NKT cells during the course of tumor cell dissemination in CRC patients. The 
biological function of CD16 on NKT cells is, however, still unclear. Of course, we have to keep in mind 
that the immune system is highly complex and expression of one specific receptor on one distinct 
immune cell subset might not be causally related to disease progression and, therefore, clinical 
outcome. It is essential to understand the underlying biology of tumor-immune responses if we want 
to use systemic immune-related biomarkers for clinical purposes in the future. This should be an 
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breaking of NKT cell anergy, and (3) skewing of NKT cells towards subsets with potent antitumor 
activity.  
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We showed in Chapter 3 that a high percentage of CD16+ circulating NKT cells was associated with 
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it seems that the CD16 receptor, which is involved in antibody-dependent cell-mediated cytotoxicity, 
is upregulated on NKT cells during the course of tumor cell dissemination in CRC patients. The 
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We showed in Chapter 4 that the immunosuppressive state of NK- and NKT cell receptors was not 
altered after tumor resection in CRC patients that received adjuvant therapy, even months after 
therapy completion, which is in line with results from a study on breast cancer [11]. Although adjuvant 
therapy is administered to patients in order to kill residual tumor cells and to decrease the risk of 
recurrence or distant metastasis, it has to be considered that at the same time, adjuvant therapy 
compromises the immune system for a long period of time. In this period, the immune system is 
probably not able to induce an effective tumor-immune response against any residual tumor cells. In 
the future, patients might be treated with a combination of adjuvant chemotherapy and 
immunotherapy in order to counteract the immunosuppressive effects of chemotherapy, thereby 
diminishing the risk to develop metastases. Rocca et al. reported that a combination of IL-2 and IL-15 
could upregulate the expression of activating receptors on CRC patient-derived dysregulated 
circulating NK cells ex vivo [12]. Although these results seem promising, this approach to activate 
patient-derived NK cells into potent tumor-killing cells closely resembles the lymphokine-activated 
killer (LAK) cell therapy strategy introduced over 30 years ago [13]. Patient-derived lymphocytes were 
obtained using lymphocytapheresis, and cultured in the presence of IL-2 in order to activate immune 
cells (mostly NK cells) to heighten their cytotoxicity towards malignant cells [14]. These activated 
immune cells, also called LAK cells, were then re-administered to the patient in conjunction with high-
dose IL-2. Although some patients with metastatic renal cancer and melanoma showed prolonged 
remission [15], the effects were limited, while the procedure was highly time-consuming and 
logistically complex. In addition, many toxic effects were reported, mainly related to increased 
vascular permeability induced by IL-2. This strongly suggests that upregulation of activating receptors 
on patient-derived NK cells ex vivo using cytokines is not useful in the clinic as cancer immunotherapy. 
Instead, it might be more promising to develop immunotherapies that target specific receptors on NK- 
and NKT cells in order to enhance the function of these cells in cancer patients. In this way, major 
toxic side effects (as observed after systemic IL-2 treatment) may be prevented. Additionally, targeted 
immunotherapy does not require ex vivo culturing of patient NK- and NKT cells, thereby making it a 
feasible treatment strategy for daily use in the clinic. In order to design these types of 
immunotherapies, it is crucial to understand the underlying biology of tumor-induced 
immunosuppression of NK cells, since we need to know which receptors to target, what the effect of 
this would be, and how to target these receptors. 
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NK- and NKT cell ligands in primary tumors 
In Chapter 5 and 6, we studied the underlying biology of tumor-induced immunosuppression of 
circulating NK- and NKT cells in CRC patients. Several studies suggested a role for expression of NK- 
and NKT cell ligands by tumor cells [16,17], as well as production of soluble NK- and NKT cell ligands 
by the tumor [18]. The activating receptors expressed by NK- and NKT cells recognize different stress-
related soluble and membrane-bound ligands that may be secreted and/or expressed by tumor cells 
whereas the inhibitory receptors all recognize different HLA class I molecules. In Chapter 5, a semi-
automated image analysis method was demonstrated which enabled scoring of biomarkers on tumor 
epithelium specifically, even when also expressed by stromal tissue and/or immune cells, as is the 
case for NK- and NKT cell ligands. Using this method, HLA class I expression could be quantified in 
tumor epithelium in a robust, reproducible, and objective manner. This method was further 
developed using deep learning software and used in Chapter 6 to quantify expression of different NK- 
and NKT cell ligands in primary CRC tumors. In this chapter, we showed correlations between ligand 
expression in the primary tumor (both on protein and on RNA level) and receptor expression on 
circulating NK- and NKT cells. For instance, we observed a negative correlation between expression of 
the natural killer group 2D (NKG2D) ligands UL-16 binding protein (ULBP)-1, -2, and -5 in the primary 
tumor, and expression of the NKG2D receptor on circulating NKT cells. This implies that NK cell ligands 
expressed by the primary tumor indeed have immune-modulating effects on the peripheral blood 
immune profile which might result in immune escape. This hypothesis is supported by the study of 
Gharagozloo et al. which reported a decrease in circulating NKG2D+ NK cells in CRC patients with 
metastatic disease as compared to patients with early stage cancer [19]. Furthermore, studies showed 
that sustained NKG2D ligand expression, as well as shedding of soluble NKG2D ligands into the 
circulation, counteracted NKG2D-dependent NK cell activity in later stages of CRC via downregulation 
of the NKG2D receptor [20-23], which is in line with our results. Therefore, overexpression of NKG2D 
ligands by tumor cells, and/or shedding of NKG2D ligands in the circulation might be important 
immune escape strategies for tumor cells. Schmiedel et al. argued that shedding of NKG2D ligands has 
several major advantages for cancer cells in terms of immune evasion (even more than NKG2D 
overexpression by tumor cells) since soluble NKG2D ligands are unable to activate NKG2D receptor-
bearing immune cells while still being capable of binding the NKG2D receptor, thereby causing 
internalization of the receptor [24]. In line with this hypothesis, multiple studies reported poor clinical 
outcome in cancer patients with high levels of soluble NKG2D ligands [25,26]. As also mentioned in 
Chapter 2, overstimulation of NKT cells (and NK cells as well) via their receptors might induce an 
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anergic and hyporesponsive state of these immune cell subsets, thereby rendering them useless in 
the defense against tumor growth. By preventing overstimulation of NK- and NKT cell receptors, the 
antitumor function of NK- and NKT cells might be restored. Ligand-receptor interactions on NK- and 
NKT cells can therefore be considered as immune checkpoints in tumor-immune interactions, thereby 
making them important new targets for inhibitors. 
 
At the moment, NK cell-based clinical trials are mostly based on blocking the interaction between NK 
cell inhibitory receptors and their ligands using monoclonal antibodies [27,28]. This includes blocking 
the NKG2A/HLA-E axis using monalizumab, and the KIR ligand-receptor axis with lirilumab. Currently, 
several monalizumab-based clinical trials are ongoing [29], including a basket trial with advanced solid 
malignancies (NCT02671435). Interestingly, this trial reported durable partial responses in 
microsatellite-stable CRC patients treated with combinations of FOLFOX chemotherapy and VEGF, PD-
L1, and NKG2A blocking antibodies [30]. Based on these promising results, a larger phase II trial is 
currently set up for high-risk microsatellite-stable CRC patients that underwent surgical resection of 
their primary tumor (NCT04145193). Different adjuvant treatment strategies will be tested in this trial 
based on FOLFOX chemotherapy in combination with NKG2A and PD-L1 blocking antibodies 
(monalizumab and durvalumab, respectively). Lirilumab therapy in patients with different cancer 
types has been proven to be safe, however, limited anti-tumor efficacy was observed [31,32]. 
Furthermore, pre-clinical studies also focus on blocking the ILT/HLA-G signaling pathway, as well as 
the interaction between TIGIT and its ligands CD155 and nectin-2. As our data clearly demonstrated, 
activating NK cell receptors are also potential targets for immune checkpoint inhibitors. Importantly, 
it is the integration of multiple activating and inhibitory signals that determines whether NK- and NKT 
cells become activated or not. Therefore, it seems crucial to target these cell types at multiple levels 
using immunotherapy, for instance by combining multiple immune checkpoint inhibitors that target 
inhibitory as well as activating receptors in order to skew NK- and NKT cells towards activation. 
Additionally, studies suggested that CD16-mediated antibody-dependent cellular cytotoxicity (ADCC) 
plays an important role in mediating anti-tumor effects of monoclonal antibody therapies by binding 
the Fc part of the therapeutic antibody, which in turn is bound to tumor-associated antigens on the 
tumor surface [33]. In line with this hypothesis, cetuximab was shown to restore the lytic capacity of 
dysregulated NK cells from CRC patients [12]. Furthermore, studies in different cancer types, including 
CRC, demonstrated clinical benefit of treatment with rituximab, trastuzumab, and cetuximab via 
enhancement of CD16-mediated ADCC by NK cells [34-36]. With this in mind, it seems beneficial to 
develop antibody-based immune checkpoint inhibitors that block receptor-ligand interactions on the 
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tumor cell-site, in order to benefit from CD16-mediated ADCC by NK cells. Up till now, it is unclear 
whether the CD16 receptor expressed by NKT cells has a similar role in mediating anti-tumor effects 
of monoclonal antibody therapies as compared to NK cells. As addressed in Chapter 2, NKT cells in 
cancer patients seem to be hyporesponsive (i.e. anergic), or start secreting immunosuppressive 
cytokines upon stimulation. Therefore, stimulating the CD16 receptor on NKT cells might, in contrast 
to NK cells, facilitate tumor progression and immune escape. This hypothesis is further supported by 
the results from Chapter 3 in which we showed that CRC patients with high numbers of CD16+ 
circulating NKT cells have poor clinical outcome. As thoroughly discussed in Chapter 2, it is crucial for 
future research to focus on prevention and/or breaking of NKT cell anergy and to skew these cells 
towards proinflammatory cytokine producing subsets with potent antitumor activity. Finally, 
antibodies neutralizing soluble NK cell ligands in the circulation are worth pursuing in future clinical 
development. 
 
Monocytes and macrophages 
Finally, we also studied CD163 as biomarker in CRC in Chapter 7, comprising both the circulation and 
tumor microenvironment. CD163 is expressed by circulating monocytes and M2-polarized tissue 
macrophages, that dampens the inflammatory response of these cell types [37]. CD163 is also present 
as a soluble molecule (sCD163) in the circulation when cleaved from the cell membrane of monocytes 
and macrophages by the protease ADAM17 [38]. In Chapter 7, it was shown that a high sCD163 level 
was an independent predictor of DFS in our CRC cohort, which is in line with studies in other cancers 
[39-42] and a study in CRC specifically [43]. Thus, it seems that patients with the highest 
immunosuppressive state, based on sCD163 levels, had the worst clinical outcome in our CRC cohort. 
This is in contradiction to what we showed in Chapter 3 where patients with a relatively active immune 
system, based on the presence of high expression of activating receptors on NK- and NKT cells, were 
observed to have poor clinical outcome in the same study population. This emphasizes the fact that 
different cell types have distinct functions during tumor progression that are yet poorly understood.  
 
Additionally, Chapter 7 showed shorter overall survival (OS) in CRC patients with a high percentage of 
circulating monocytes (% of total CD45+ cells). This was also reported by two meta-analyses that, in 
addition, also showed a correlation between a high percentage of circulating monocytes and DFS 
[44,45]. In contrast to sCD163 and monocytes in the circulation, (CD163+) M2 tumor-associated 
macrophages (TAMs) in the primary tumor were not associated with clinical outcome in CRC patients 
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in our study. Other studies reported contradictory findings, in which high M2 TAM density has been 
reported to associate with both unfavorable [46-48], and favorable clinical outcome [49-53] in CRC. 
Importantly, the majority of these studies did not take the spatial distribution of TAMs in the primary 
tumor into account. In Chapter 7, we showed that the percentage of intraepithelial M2 TAMs 
positively correlated with TNM stage and differentiation grade whereas stromal M2 TAMs did not. In 
line with our results, Kim et al. showed higher intraepithelial TAM counts, but not stromal TAMs in 
colorectal tumors with higher TNM stages [54]. Furthermore, this study reported an association 
between high intraepithelial TAM counts and worse clinical outcome, but not for high stromal TAM 
counts [54]. These findings suggest a different role for stromal TAMs and intraepithelial TAMs in CRC 
progression. Therefore, based on our findings and others, it seems crucial to keep the spatial 
distribution of TAMs in CRC into account. This should be further investigated and validated in future 
studies.  
 
In summary, Chapter 7 showed that circulating monocyte markers may have prognostic value in CRC 
patients whereas TAMs in the primary tumor have not. Furthermore, we showed in Chapter 3 that a 
high percentage of CD16+ circulating NKT cells was associated with short disease-free survival (DFS) in 
CRC patients, independent from TNM classification and age. This illustrates that the peripheral blood 
immune profile is an important pool of potential biomarkers that may provide insight in the dynamic 
process of metastases development since they can be monitored over time. Most biomarker studies 
primarily focus on primary tumor-associated biomarkers, including the immunoscore as defined by 
Galon et al. [55]. This scoring system is based on quantification of infiltrated T cells in primary CRC 
tumors and showed that high density of CD3+ and CD8+ tumor-infiltrating T cells is strongly correlated 
with better clinical outcome [55-57]. As we have shown in Chapter 3 and 4, tumor-immune 
interactions are much more complex than the interaction between primary tumor cells and tumor-
infiltrated immune cells only. The tumor-immune response consists of multiple different levels that 
are all intertwined. In order to estimate the state of the tumor-immune response in cancer patients, 
it is important to not only study tumor-immune interactions in the primary tumor, but in the 
circulation, and maybe the (pre)-metastatic niche [58] as well. Based on our findings, it might be 
interesting to expand the immunoscore with circulating biomarkers such as NK- and/or NKT cell 
markers, and/or monocyte-related markers in order to estimate the state of the immune system in 
the entire patient and thus, better predict clinical outcome of CRC patients.  
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Link between the primary tumor and circulating immune cells 
Based on the data presented in this thesis, there are two important questions that require further 
attention. First of all, the question remains whether the primary tumor actively suppresses the 
peripheral blood immune profile in cancer patients in order to stimulate immune escape of circulating 
tumor cells in peripheral blood. In other words: is active immunoediting going on in the primary tumor 
that results in outgrowth of tumor cell clones that are most effective in suppressing the systemic 
immune system for survival benefit during dissemination of the disease? The answer to this question 
seems to be: “no”. Since there is no continuous interaction between the primary tumor and circulating 
immune cells, it seems highly unlikely for immunoediting to have taken place due to lack of direct 
feedback. Primary tumor cells that are able to suppress the systemic immune system may have 
survival benefit when they enter the circulation. However, these cells do not necessarily have any 
survival benefit as long as they are located in the primary tumor, and, therefore, do not selectively 
grow out in the primary tumor. Instead, suppression of the peripheral blood immune system might 
merely be a bystander effect of tumor development, for instance via cytokine release, tumor 
metabolites, exosomes, and soluble NK cell receptor ligands that are produced by the tumor and 
released into the circulation. Based on our results, it seems this effect is induced during early tumor 
progression since the peripheral blood immune profile was equally suppressed in CRC patients with 
early and late cancer stages.  
 
The next logical question is whether immunoediting takes place in the circulation of cancer patients. 
When tumor cells enter the circulation, they interact with circulating immune cells. The immune 
insensitive tumor cells are not recognized and, therefore, escape immune recognition in the 
peripheral blood. Although these tumor cell clones do not selectively grow out in peripheral blood, 
they do selectively survive, thereby resembling immunoediting. Whether a specific circulating tumor 
cell is able to successfully grow out into metastasis may depend on the immunoediting process taking 
place at the metastatic site. As the immune composition differs between organs, different 
immunoediting processes will take place, resulting in outgrowth of different tumor clones in different 
organs. In summary, immunoediting takes place in the primary tumor, next in the circulation, and 
finally at the metastatic site. This is a dynamic complex process in which different conditions apply for 
each compartment. Future research should focus on further unraveling the complexity of 
immunoediting, including the link between tumor-immune interactions in the primary tumor, the 
circulation, and the metastatic site.  
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interesting to expand the immunoscore with circulating biomarkers such as NK- and/or NKT cell 
markers, and/or monocyte-related markers in order to estimate the state of the immune system in 
the entire patient and thus, better predict clinical outcome of CRC patients.  
 
 General discussion and future perspectives 
197 
 
Link between the primary tumor and circulating immune cells 
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tumor cells in peripheral blood. In other words: is active immunoediting going on in the primary tumor 
that results in outgrowth of tumor cell clones that are most effective in suppressing the systemic 
immune system for survival benefit during dissemination of the disease? The answer to this question 
seems to be: “no”. Since there is no continuous interaction between the primary tumor and circulating 
immune cells, it seems highly unlikely for immunoediting to have taken place due to lack of direct 
feedback. Primary tumor cells that are able to suppress the systemic immune system may have 
survival benefit when they enter the circulation. However, these cells do not necessarily have any 
survival benefit as long as they are located in the primary tumor, and, therefore, do not selectively 
grow out in the primary tumor. Instead, suppression of the peripheral blood immune system might 
merely be a bystander effect of tumor development, for instance via cytokine release, tumor 
metabolites, exosomes, and soluble NK cell receptor ligands that are produced by the tumor and 
released into the circulation. Based on our results, it seems this effect is induced during early tumor 
progression since the peripheral blood immune profile was equally suppressed in CRC patients with 
early and late cancer stages.  
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organs. In summary, immunoediting takes place in the primary tumor, next in the circulation, and 
finally at the metastatic site. This is a dynamic complex process in which different conditions apply for 
each compartment. Future research should focus on further unraveling the complexity of 
immunoediting, including the link between tumor-immune interactions in the primary tumor, the 
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an important pool of biomarkers in cancer. Up till now, most studies have primarily focused on tumor-
immune interactions in the primary tumor, the most well-known being the immunoscore as defined 
by Galon et al. [55]. In this thesis, we illustrated that the tumor-immune response is much more 
complex and consists of multiple different levels that are all intertwined. In particular, we showed that 
the systemic tumor-immune response plays an important role during tumor progression and is 
therefore an interesting pool of biomarkers in cancer in addition to primary tumor-derived 
biomarkers. As is clear from this thesis, and from other studies as well [58-60], the immune system is 
a closely connected complex network. Therefore, in our opinion, it should be studied as one process 
in a patient, instead of as single stand-alone components as has been the standard in the past years. 
Hence, future research should focus on a system-based biology approach wherein the patient is 
studied in toto. Technical innovation is essential to establish this shift in research. Developments in 
multiparameter flow cytometry, mass cytometry, multiplex immunofluorescence, and software based 
on artificial intelligence have already accelerated research over the past decade. Whereas only a 
limited number of biomarkers could simultaneously be used to study different immune cell subsets 
and their phenotypes in tissues and peripheral blood in the past, nowadays this has already increased 
to simultaneous imaging and data processing of over 40 biomarkers by mass cytometry and multiplex 
immunofluorescence [61,62]. These new techniques enable us to acquire an overall picture of the 
immune system in relation to disease progression which will help us to better understand the 
underlying biology of tumor-immune interactions. In the future, this new knowledge may lead to the 
discovery of new immune-related biomarkers and new targets for immunotherapies. Early diagnosis 
of distant metastases, in combination with development of new treatment strategies, will get us 
closer in developing personalized medicine which will further improve the clinical prognosis of CRC 
patients in the future.  
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In de afgelopen jaren is de duur van de overleving van patiënten met dikkedarmkanker, en het aantal 
patiënten dat overleeft, aanzienlijk verbeterd. Dit wordt verklaard door de effectiviteit van nieuwe 
behandelingen, die zowel voor (neo-adjuvant) als na (adjuvant) het operatief verwijderen van de 
primaire (oorspronkelijke) tumor toegepast worden [1]. Hoewel de overleving van patiënten is 
verbeterd, is er echter nog veel winst te behalen. Per jaar overlijden er namelijk wereldwijd nog altijd 
een half miljoen patiënten aan de gevolgen van dikkedarmkanker [2]. Ongeveer 25% van deze 
patiënten heeft op het moment dat de diagnose gesteld wordt al uitzaaiingen in andere organen, vaak 
in de lever, wat resulteert in een relatief kortere overleving van deze patiënten. Daarnaast ontwikkelt 
ongeveer 30% van de patiënten in een vroeg stadium alsnog uitzaaiingen na een succesvolle operatie 
[3]. De ontwikkeling van een “gepersonaliseerde behandeling”, waarbij aan iedere patiënt een 
therapie op maat aangeboden kan worden, is veelbelovend voor het vergroten van de 
overlevingskansen van patiënten met dikkedarmkanker. Het is hiervoor belangrijk dat de patiënten 
met een hoog risico op uitzaaiingen kunnen worden geïdentificeerd, aangezien deze patiënten in 
potentie het meeste baat zullen hebben bij adjuvante therapie. Daarnaast is het van belang dat er 
wordt onderzocht hoe patiënten die het best zullen reageren op een therapie geïdentificeerd kunnen 
worden. Ziekteprogressie (voortgang van de ziekte) en het aanslaan van de behandeling kunnen 
worden voorspeld door middel van zogenoemde “biomarkers”. Biomarkers zijn bijvoorbeeld 
specifieke moleculen of cellen die gemeten kunnen worden in de tumor of het bloed van patiënten. 
Recente ontwikkelingen in het kankeronderzoek hebben laten zien dat het immuunsysteem een 
belangrijke rol speelt in de ontwikkeling en groei van tumoren. Daarom zijn immuun-gerelateerde 
biomarkers een belangrijk onderwerp van onderzoek geworden.  
 
De rol van het immuunsysteem in de primaire tumor 
Tumorcellen ontstaan als gevolg van ontregeling van o.a. de normale controlemechanismen voor 
celgroei en celdeling. Dit vaak in samenhang met beschadigingen van het erfelijke materiaal van de 
cel (het DNA). Deze beschadigingen worden ook wel mutaties genoemd en kunnen verschillende 
oorzaken hebben. Ze kunnen bijvoorbeeld het resultaat zijn uv-straling, sigarettenrook, en asbest, die 
daarom ‘kankerverwekkend’ worden genoemd, maar ook van spontane fouten die optreden tijdens 
de celdeling. Tot slot zijn er ook erfelijke mutaties die van ouder op kind kunnen worden overgedragen 
en ervoor zorgen dat iemand een sterk verhoogd risico heeft op het ontwikkelen van bepaalde types 
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kanker. Op het moment dat er verschillende mutaties optreden die gerelateerd zijn aan processen die 
belangrijk zijn voor bijvoorbeeld de celdeling, kan een cel ongecontroleerd gaan delen en zich dus 
ontwikkelen tot een tumorcel. Tijdens de ongecontroleerde celdeling van de tumorcel zullen er nóg 
meer mutaties ontstaan waardoor de tumorcel er anders uit gaat zien dan normale cellen. Het 
immuunsysteem controleert voortdurend of lichaamscellen nog normaal functioneren. Daarvoor 
laten lichaamscellen aan cellen van het immuunsysteem op ieder moment een soort “paspoort” zien. 
Op hun celoppervlak steken bepaalde eiwitten uit (HLA-moleculen) die als presenteerblaadjes kleine 
fragmenten van willekeurige eiwitten uit de cel laten zien. Cellen van ons immuunsysteem (T-cellen) 
zijn voortdurend bezig om deze fragmenten te controleren en zodra ze iets onregelmatigs bespeuren, 
dus de aanwezigheid van een fragment afkomstig van een abnormaal eiwit als gevolg van een mutatie 
in het DNA, slaan ze alarm en wordt de betreffende cel vernietigd. Helaas kunnen tumorcellen ook 
DNA-mutaties verkrijgen waardoor ze eiwitten gaan maken die ervoor zorgen dat het immuunsysteem 
ze niet herkent en opruimt. Deze tumorcellen, die niet opgeruimd worden door het immuunsysteem, 
kunnen vervolgens verder groeien terwijl de tumorcellen die deze eiwitten niet hebben wél worden 
opgeruimd. Door de selectie van welke tumorcellen worden opgeruimd en welke blijven leven zal 
uiteindelijk een groot deel van de tumor bestaan uit cellen die niet herkend worden door het 
immuunsysteem. Dit proces noemen we “immuno editing” en leidt er uiteindelijk toe dat de tumor 
ontsnapt aan het immuunsysteem waardoor deze ongeremd verder kan groeien. De aanwezigheid 
van eiwitten die de reactie van het immuunsysteem (‘de immuunrespons’) tegen de tumorcellen 
onderdrukken, evenals de aanwezigheid van verschillende typen immuuncellen die de tumorcellen 
kunnen herkennen, zijn interessante biomarkers om de ziekteprogressie van patiënten te voorspellen. 
De “immunoscore”, zoals gedefinieerd door de onderzoeksgroep van de Franse onderzoeker Galon 
[4-7], laat bijvoorbeeld zien dat patiënten met darmkanker een betere overleving hebben als er veel 
T-cellen in hun tumor zitten. Er was echter ook een deel van de patiënten met relatief veel T-cellen in 
de tumor dat juist een slechte prognose had [4,5,7]. Deze tumoren hebben waarschijnlijk de HLA-
moleculen uitgeschakeld waardoor de fragmenten van abnormale eiwitten in de tumorcellen niet 
meer gecontroleerd kunnen worden door T-cellen. Tumorcellen zonder HLA-moleculen ontsnappen 
dus aan de herkenning van T-cellen. Precies deze tumoren zijn potentiële aangrijpingspunten voor NK-
cellen (Natural Killer) en NKT-cellen (Natural Killer T) die tumorcellen kunnen herkennen en opruimen 
zonder HLA-moleculen [8-10]. Echter zijn deze celtypes erg schaars in darmtumoren en lijken daarom 
geen grote rol te spelen in de immuunrespons gericht tegen de primaire tumor [11-14]. Samenvattend 
speelt het immuunsysteem dus een belangrijke rol in het opruimen van tumorcellen. Met name T-
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De rol van het immuunsysteem in de primaire tumor 
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kanker. Op het moment dat er verschillende mutaties optreden die gerelateerd zijn aan processen die 
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meer gecontroleerd kunnen worden door T-cellen. Tumorcellen zonder HLA-moleculen ontsnappen 
dus aan de herkenning van T-cellen. Precies deze tumoren zijn potentiële aangrijpingspunten voor NK-
cellen (Natural Killer) en NKT-cellen (Natural Killer T) die tumorcellen kunnen herkennen en opruimen 
zonder HLA-moleculen [8-10]. Echter zijn deze celtypes erg schaars in darmtumoren en lijken daarom 
geen grote rol te spelen in de immuunrespons gericht tegen de primaire tumor [11-14]. Samenvattend 
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cellen spelen een grote rol in de immuunrespons gericht tegen de primaire tumor door het herkennen 
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en opruimen van tumorcellen via HLA-moleculen. Ontsnapping aan T-cellen is daarom een belangrijk 
proces voor tumorcellen in de primaire tumor van darmkankerpatiënten.   
 
De rol van het immuunsysteem in de bloedbaan 
Op een gegeven moment, gedurende ziekteprogressie, kunnen tumorcellen loslaten van de primaire 
tumor waarna deze in de bloedbaan (circulatie) terecht komen. Via deze weg kunnen tumorcellen 
uitzaaien naar lymfeklieren en andere organen. Of een circulerende tumorcel uiteindelijk leidt tot 
uitzaaiingen in lymfeklieren en/of andere organen hangt af van het feit of de betreffende tumorcel 
kan ontsnappen aan immuuncellen in de bloedbaan. NK-cellen en NKT-cellen zijn in relatief grote 
aantallen aanwezig in de bloedbaan, in tegenstelling tot in de primaire tumor [9], en zijn heel goed in 
staat om tumorcellen te doden. Waar ontsnapping aan T-cellen dus belangrijk is voor tumorcellen in 
de primaire tumor, is ontsnapping aan NK-cellen en NKT-cellen een belangrijk proces voor tumorcellen 
in de bloedbaan. De mate van aanwezigheid en activiteit van deze celtypes in het bloed worden 
daarom genoemd als potentiële biomarkers voor het voorspellen van het risico op uitzaaiingen in 
patiënten met darmkanker. In tegenstelling tot biomarkers ín de primaire tumor, die op één gefixeerd 
tijdstip bepaald worden (namelijk in het tumorweefsel dat verwijderd wordt tijdens de operatie), 
kunnen biomarkers in het bloed op meerdere tijdstippen worden bepaald door een simpele 
bloedafname. Hierdoor kan eventuele ziekteprogressie van patiënten worden gemonitord gedurende 
een lange periode.  
 
Doel van dit proefschrift 
Samenvattend kunnen verschillende interacties tussen tumorcellen en het immuunsysteem (tumor-
immuun interacties) worden geïdentificeerd in patiënten met dikkedarmkanker, onder andere in de 
primaire tumor en in de bloedbaan, welke ieder een unieke rol spelen in ziekteprogressie [15]. Met 
name tumor-immuun interacties in de bloedbaan zijn een interessante focus van onderzoek 
aangezien de uitkomst hiervan bepaalt of tumorcellen in het bloed worden herkend en opgeruimd, of 
juist ontsnappen aan het immuunsysteem en vervolgens uitzaaien naar andere organen. Het doel van 
dit proefschrift was om meer te weten te komen over de onderliggende biologie van tumor-immuun 
interacties in het bloed van patiënten met dikkedarmkanker, en om een link te leggen tussen tumor-
immuun interacties in de primaire tumor en in de bloedbaan.  
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NK-cellen en NKT-cellen in de bloedbaan 
Hoofdstuk 2 behandelt alle huidige kennis over de recent ontdekte NKT-cellen en hun mogelijke rol 
in de ziekteprogressie van kankerpatiënten. NKT-cellen kunnen tumorcellen herkennen en opruimen, 
maar zijn vooral belangrijk voor het reguleren van de immuunrespons [16]. Na activatie produceren 
NKT-cellen grote hoeveelheden signaalmoleculen waardoor andere immuuncellen geactiveerd ofwel 
geremd worden. Mede door deze regulerende eigenschappen zijn NKT-cellen interessante 
aangrijpingspunten voor immuuntherapie. De laatste jaren zijn er verschillende klinische studies 
uitgevoerd in kankerpatiënten gericht op de activatie van NKT-cellen. Helaas hebben tot nu toe maar 
weinig patiënten baat bij deze behandeling [17-19]. In Hoofdstuk 2 beargumenteren we dat dit 
mogelijk komt door de veranderde functie van NKT-cellen in kankerpatiënten. NKT-cellen kunnen 
overprikkeld worden in kankerpatiënten door te veel stimulatie door de tumor waardoor deze NKT-
cellen doodgaan, niet meer reageren op activatie, of signaalmoleculen produceren die juist zorgen 
voor onderdrukking van het immuunsysteem. Hierdoor kunnen tumorcellen ontsnappen aan het 
immuunsysteem waardoor ziekteprogressie bevorderd wordt. Op basis van de besproken literatuur 
concludeerden we dat er drie belangrijke punten opgelost moeten worden voordat immuuntherapie 
op basis van NKT-cellen effectief kan zijn in de behandeling van kankerpatiënten: 1) het aantal NKT-
cellen moet worden verhoogd in patiënten, 2) activatie van NKT-cellen moet worden hersteld, en 3) 
er moet gezorgd worden dat NKT-cellen signaalmoleculen produceren die zorgen voor activatie van 
andere immuuncellen, waardoor de immuunrespons tegen de tumorcellen een boost krijgt.  
 
Om meer inzicht te krijgen in de rol van immuuncellen in het bloed in ziekteprogressie, inclusief NKT-
cellen, hebben we het immuunprofiel in de bloedbaan (perifeer bloed immuunprofiel) nader 
bestudeerd in patiënten met dikkedarmkanker, zowel voor als na operatieve verwijdering van de 
tumor. Dit immuunprofiel bevat onder andere informatie over de aanwezigheid van verschillende 
subtypes immuuncellen in het bloed, maar ook informatie over de aanwezigheid van receptoren op 
deze cellen. Een receptor is een eiwit dat signalen doorgeeft aan de cel als er een specifiek molecuul 
aan bindt en kan ofwel zorgen voor remming of activatie van de cel. De aanwezigheid van remmende 
en activerende receptoren op immuuncellen geeft dus indirect informatie over hun activiteit en 
functie [20]. In Hoofdstuk 3 laten we zien dat NK-cellen en NKT-cellen in het bloed van patiënten met 
dikkedarmkanker, voordat ze geopereerd worden, minder activerende receptoren hebben dan 
gezonde individuen. Dit suggereert dat NK-cellen en NKT-cellen minder functioneel zijn in deze 
patiënten, wat kan bijdragen aan de ontsnapping van tumorcellen aan het immuunsysteem en 
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en opruimen van tumorcellen via HLA-moleculen. Ontsnapping aan T-cellen is daarom een belangrijk 
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gezonde individuen. Dit suggereert dat NK-cellen en NKT-cellen minder functioneel zijn in deze 
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daarmee ziekteprogressie. In Hoofdstuk 4 laten we zien dat de aanwezigheid van activerende 
receptoren op NK-cellen en NKT-cellen toeneemt in darmkankerpatiënten na de operatie wanneer zij 
géén adjuvante therapie (therapie na de operatie) hebben gekregen, terwijl de aanwezigheid van 
remmende receptoren op deze cellen afneemt. Dit suggereert dat de onderdrukte functie van NK-
cellen en NKT-cellen hersteld wordt in patiënten na het weghalen van de primaire tumor. Gebaseerd 
op deze bevindingen concludeerden we dat darmtumoren in staat zijn om immuuncellen in het bloed 
te onderdrukken, wat zou kunnen leiden tot ontsnapping van tumorcellen in de bloedbaan aan het 
immuunsysteem en vervolgens tot de vorming van uitzaaiingen in andere organen.    
 
Daarnaast laten we in Hoofdstuk 4 zien dat de aanwezigheid van activerende receptoren op NK-cellen 
en NKT-cellen in het bloed nog steeds verlaagd was na de operatie in darmkankerpatiënten die wél 
behandeld werden met adjuvante therapie. Dit effect was zelfs nog aantoonbaar maanden nadat de 
therapie was afgerond. Adjuvante therapie, zoals chemotherapie, wordt vaak aan patiënten gegeven 
om overgebleven tumorcellen na de operatie op te ruimen, en daarmee het risico op het terugkomen 
van de tumor en het risico op het ontwikkelen van uitzaaiingen te verkleinen. Echter, chemotherapie 
heeft langdurige onderdrukkende effecten op het immuunsysteem waardoor het immuunsysteem in 
deze periode waarschijnlijk ook geen effectieve immuunrespons opbouwt tegen overgebleven 
tumorcellen na de operatie. In de toekomst is het wellicht een optie om patiënten te behandelen met 
een combinatie van adjuvante chemotherapie en immuuntherapie om de immuun-onderdrukkende 
effecten van chemotherapie te neutraliseren, waardoor de kans op uitzaaiingen na de operatie kleiner 
wordt. 
 
NK-cel liganden in de primaire tumor 
In Hoofdstuk 5 en 6 bestuderen we hoe een darmtumor NK-cellen en NKT-cellen in het bloed zou 
kunnen beïnvloeden. De receptoren op NK-cellen en NKT-cellen, zoals beschreven in voorgaande 
hoofdstukken, zorgen voor remming of activatie van deze celtypes op het moment dat ze binden aan 
specifieke eiwitten. De activerende receptoren op NK-cellen en NKT-cellen herkennen verschillende 
celstress-gerelateerde eiwitten, ook wel liganden genoemd, die door tumorcellen gemaakt kunnen 
worden. De remmende receptoren herkennen verschillende HLA-moleculen. De activatie van NK-
cellen en NKT-cellen is dus afhankelijk van de interactie tussen de receptoren op deze cellen, en 
liganden die aanwezig kunnen zijn op tumorcellen. Verschillende studies hebben daarom 
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gesuggereerd dat de aanwezigheid van liganden op tumorcellen de activatie van NK-cellen en NKT-
cellen zou kunnen beïnvloeden [21,22]. Dit hebben we daarom nader onderzocht.   
 
Hoofdstuk 5 demonstreert een methode waarin we met behulp van een semiautomatisch algoritme 
de aanwezigheid van biomarkers, zoals liganden voor NK-cellen en NKT-cellen, kunnen bepalen in 
tumorweefsel. Hiervoor worden dunne plakjes tumorweefsel gesneden waarop specifieke eiwitten 
worden aangekleurd. Deze labtechniek noemen we “immunohistochemie”. De hoeveelheid 
aankleuring is een maatstaf voor de hoeveelheid eiwit dat aanwezig is in de tumor. Deze aankleuring 
op tumorcellen wordt meestal met het oog (door middel van een microscoop) beoordeeld op aan- of 
afwezigheid, maar ook op intensiteit van de kleuring. Deze methode is echter erg gevoelig voor 
misinterpretatie aangezien het lastig is om op het oog tumorweefsels met dezelfde criteria te scoren. 
Dit is met name omdat er grote verschillen tussen patiënten kunnen zijn hoe het tumorweefsel er uit 
ziet. Daarnaast is het soms lastig om de aanwezigheid van biomarkers specifiek op tumorcellen te 
beoordelen aangezien deze ook regelmatig voorkomen op andere type cellen in de tumor, zoals 
bindweefsel, immuuncellen, zenuwen, en bloedvaten. Bovendien is het op het oog bijvoorbeeld niet 
mogelijk om voldoende nauwkeurig een percentage positieve tumorcellen te scoren. Deze limitaties 
hebben we opgelost in de methode zoals gepresenteerd in Hoofdstuk 5. Allereerst hebben we een 
immunohistochemiemethode met twee kleuren opgezet waarin we al het weefsel, behalve de 
tumorcellen, bruin hebben aangekleurd, en de biomarker van interesse op de tumorcel (in dit geval 
HLA-moleculen) blauw. In plaats van beoordeling met het oog door een microscoop hebben we de 
aangekleurde tumorweefsels gescand en vervolgens digitaal, met specifieke software, op een 
semiautomatische manier gescoord. Met semiautomatisch bedoelen we dat het grootste gedeelte 
van het algoritme automatisch werkte, maar nog enige handmatige instellingen en controlestappen 
vereiste. Door het excluderen van al het bruin aangekleurde weefsel was het mogelijk om de 
tumorcellen te selecteren waarop we vervolgens de aanwezigheid van HLA-moleculen door de 
software konden laten scoren volgens standaardcriteria. Met deze methode hebben we laten zien dat 
de aanwezigheid van HLA-moleculen in de tumor bepaald kon worden op een reproductieve, 
robuuste, en objectieve manier.  
 
In Hoofstuk 6 hebben we vervolgens deze analysemethode verder geoptimaliseerd met behulp van 
kunstmatige intelligentie en zogenaamde “deep-learning” (zelflerende) software. Vervolgens hebben 
we deze techniek gebruikt om de aanwezigheid van verschillende NK-cel en NKT-cel liganden te 
bepalen in darmtumoren. In deze studie laten we onder andere zien dat er een sterke negatieve 
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daarmee ziekteprogressie. In Hoofdstuk 4 laten we zien dat de aanwezigheid van activerende 
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gesuggereerd dat de aanwezigheid van liganden op tumorcellen de activatie van NK-cellen en NKT-
cellen zou kunnen beïnvloeden [21,22]. Dit hebben we daarom nader onderzocht.   
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correlatie is tussen de mate van aanwezigheid van het ligand galectin-3 in de tumor, en mate van 
aanwezigheid van de bijbehorende receptor NKp30 op NKT-cellen in het bloed. Met andere woorden: 
hoe hoger de aanwezigheid van galectin-3 in de tumor, des te lager de aanwezigheid van de NKp30 
receptor op NKT-cellen waardoor activatie in verminderde mate plaats kan vinden. Dit impliceert dat 
NK-cel en NKT-cel liganden het immuunprofiel in de bloedbaan kunnen beïnvloeden/onderdrukken 
wat ertoe kan leiden dat tumorcellen in de bloedbaan ontsnappen aan het immuunsysteem. 
Daarnaast ondersteunt dit resultaat de hypothese zoals gepresenteerd in Hoofdstuk 2: overprikkeling 
van NKT-cellen gedurende ziekteprogressie leidt tot verminderde functie waardoor ze waarschijnlijk 
tumorcellen niet meer effectief kunnen herkennen en opruimen. Door het voorkomen van 
overprikkeling van NK-cellen en NKT-cellen, bijvoorbeeld door het blokkeren van de interacties tussen 
specifieke receptoren en hun liganden, kan de anti-tumor functie van NK-cellen en NKT-cellen worden 
hersteld. Receptor-ligand interacties op NK-cellen en NKT-cellen zijn daarom potentiële nieuwe 
aangrijpingspunten voor immuuntherapie.  
 
Biomarkers in de bloedbaan van darmkankerpatiënten  
Tot slot beschrijven we in Hoofdstuk 7 het onderzoek waarin we ons hebben gericht op monocyten 
en macrofagen. Deze immuuncellen spelen, net als NK-cellen en NKT-cellen, een grote rol in de 
immuunrespons gericht tegen de tumor. Monocyten en macrofagen breken dode cellen af, en 
produceren signaalmoleculen waardoor andere immuuncellen ofwel geactiveerd of geremd worden. 
Monocyten bevinden zich in het bloed en ontwikkelen zich tot macrofagen op het moment dat ze een 
weefsel binnendringen. CD163 is een molecuul dat aanwezig kan zijn op monocyten en macrofagen. 
Het zorgt ervoor dat deze celtypes signaalmoleculen produceren die een immuunrespons 
onderdrukken [23]. CD163 kan daarnaast ook van monocyten en macrofagen geknipt worden, waarna 
het als oplosbare vorm (sCD163) in de bloedbaan terecht komt [24]. In het bloed kan sCD163 de 
functie van diverse immuuncellen onderdrukken. In Hoofdstuk 7 laten we zien dat hoge sCD163 
concentraties in de circulatie van darmkankerpatiënten geassocieerd is met een kortere ziektevrije 
overleving (de tijd gedurende welke de patiënt overleeft zonder tekenen van kanker). Dit is in 
overeenstemming met andere studies in verschillende kankertypes en suggereert dat sCD163 
concentraties gebruikt zouden kunnen worden als biomarker voor het voorspellen van ziektevrije 
overleving in patiënten [25-27]. Grote aantallen monocyten in het bloed waren geassocieerd met 
slechte overleving van patiënten. Aantallen en subtypes macrofagen in de tumor waren daarentegen 
niet geassocieerd met klinische uitkomst in darmkankerpatiënten. Samenvattend hebben we in deze 
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studie laten zien dat monocyten en sCD163 in het bloed wél biomarkerpotentie hebben voor het 
voorspellen van ziektevrije overleving van patiënten met darmkanker, en macrofagen ín de tumor 
niet. Daarnaast hebben we in Hoofdstuk 3 laten zien dat aanwezigheid van specifieke receptoren op 
NKT-cellen in het bloed van invloed was op de overleving van patiënten met darmkanker: een hoog 
percentage CD16+ NKT-cellen in het bloed was geassocieerd met slechte ziektevrije overleving. Over 
de biologische functie van de CD16 receptor op NKT-cellen is echter nog weinig bekend en moet nader 
bestudeerd worden. De bevindingen uit Hoofdstuk 3 en 7 illustreren dat het immuunprofiel in de 
bloedbaan een belangrijke bron is van potentiële biomarkers om inzicht te geven in welke patiënten 
een hoog risico hebben op het ontwikkelen van uitzaaiingen na de operatie. Het is dus van belang om 
in gedachte te houden dat de immuunrespons tegen de tumor ingewikkelder is dan alleen de 
interactie tussen tumorcellen en immuuncellen in de primaire tumor. Om preciezer te zijn, de 
immuunrespons tegen de tumor bestaat uit verschillende niveaus welke allemaal samenhangen. Om 
een overzicht te krijgen hoe de staat is van een immuunrespons tegen de tumor moet daarom niet 
alleen naar de primaire tumor gekeken worden, maar ook naar wat er in de bloedbaan van deze 
patiënten aan de hand is. Gebaseerd op deze resultaten is het interessant om biomarkers afkomstig 
uit de bloedbaan, zoals NK-cellen, NKT-cellen, en/of monocyten, toe te voegen aan de “immunoscore” 
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Het immuunsysteem speelt een cruciale rol in ziekteprogressie van darmkankerpatiënten en is 
daarom een belangrijke bron van mogelijke biomarkers om het risico op uitzaaiingen te kunnen 
voorspellen. Tot nu toe richtten de meeste studies zich op tumor-immuun interacties ín de primaire 
tumor, waarvan de meest bekende de “immunoscore” is zoals gedefinieerd door de onderzoeksgroep 
van Galon [6]. In dit proefschrift hebben we geïllustreerd dat de tumor-immuunrespons veel 
complexer is dan alleen de interactie tussen tumorcellen en immuuncellen in de primaire tumor: ook 
interacties elders in het lichaam zijn bepalend voor het ziekteverloop. De immuunrespons tegen de 
tumor is een complex netwerk dat bestaat uit verschillende niveaus die allemaal nauw samenhangen. 
Naar onze mening zou het daarom als één geheel bestudeerd moeten worden in een patiënt in plaats 
van in losse op zichzelf staande onderdelen. Toekomstig onderzoek moet zich daarom focussen op 
een zogenoemde “system-based biology” benadering waarin de patiënt als geheel wordt bestudeerd 
en er zowel naar de primaire tumor als naar het bloed van patiënten gekeken wordt en wellicht in de 
toekomst ook naar uitzaaiingen. Technische innovatie is essentieel voor focusverschuiving binnen 
kankeronderzoek. Onder andere ontwikkelingen in laboratoriumtechnieken en artificiële intelligentie 
hebben ertoe geleid dat we al meer dan 40 biomarkers tegelijkertijd in patiënten kunnen meten en 
verwerken [28,29]. Deze nieuwe technieken zorgen ervoor dat we overzicht krijgen hoe de staat is 
van de totale tumor-immuunrespons in een patiënt in relatie tot ziekteprogressie. Dit helpt ons om 
de interactie tussen de tumor en het immuunsysteem beter te begrijpen. In de toekomst kan deze 
kennis leiden tot de ontdekking van nieuwe biomarkers en nieuwe aangrijpingspunten voor 
immunotherapieën. Het beter voorspellen van het risico op het krijgen van uitzaaiingen, in combinatie 
met het ontwikkelen van nieuwe therapieën, brengt ons een stap dichterbij gepersonaliseerde 
behandeling. Deze vooruitgang zal de overleving van darmkankerpatiënten aanzienlijk verbeteren in 
de toekomst.  
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hebben ertoe geleid dat we al meer dan 40 biomarkers tegelijkertijd in patiënten kunnen meten en 
verwerken [28,29]. Deze nieuwe technieken zorgen ervoor dat we overzicht krijgen hoe de staat is 
van de totale tumor-immuunrespons in een patiënt in relatie tot ziekteprogressie. Dit helpt ons om 
de interactie tussen de tumor en het immuunsysteem beter te begrijpen. In de toekomst kan deze 
kennis leiden tot de ontdekking van nieuwe biomarkers en nieuwe aangrijpingspunten voor 
immunotherapieën. Het beter voorspellen van het risico op het krijgen van uitzaaiingen, in combinatie 
met het ontwikkelen van nieuwe therapieën, brengt ons een stap dichterbij gepersonaliseerde 
behandeling. Deze vooruitgang zal de overleving van darmkankerpatiënten aanzienlijk verbeteren in 
de toekomst.  
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